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The IgLONs are an immunoglobulin subfamily of
glycosylphosphatidylinositol-anchored cell adhesion molecules, comprising four
members: OPCML, HNT, LSAMP and NEGRI. They have been mainly studied in
the brain of rat and chick, where they affect cell adhesion and cell-cell recognition.
Both homophilic and heterophilic interactions are thought to be important in
facilitating IgLON functions.
Human OPCML has been proposed as a novel tumour suppressor gene (TSG)
in sporadic epithelial ovarian cancer (EOC). EOC, the leading cause of death from
gynaecological malignancy, arises in the monolayer of cells overlying the ovary
called the ovarian surface epithelium. OPCML is normally expressed in these cells,
but is epigenetically silenced in EOC. Moreover, it has functional features typical of
a TSG: suppression of cell growth in vitro and suppression of tumourigenicity in
vivo.
The deficiency in our knowledge of the functions of OPCML beyond the
locality of the brain renders the understanding of its connexion to ovarian cancer
insufficient. The relevance of the other IgLON family members in this type of cancer
has not been investigated, even though there is much speculation about their
interactions. Addressing these two key issues has been the main objective in the
work that is presented in this thesis.
In order to study the functions ofOPCML, two transfected cell line resources
were used: an over-expression system based on SKOV-3 ovarian cancer cells and an
inducible expression system based on HeLa cervical cancer cells. Upon induction
with doxycycline, selected HeLa inducible clones were shown to demonstrate
regulated expression of OPCML, both at the RNA and protein levels; however,
low-level uninduced expression was also detected, a feature commonly associated
with this type of system.
iv
Expression studies of OPCML and the other IgLON family members were
undertaken in cancer cell lines, as well as normal mouse and human tissues.
Expression analysis of the IgLONs in the two OPCML-transfected cell line systems
identified a transcriptional effect of OPCML on two other IgLONs in SKOV-3 cells
only: expression of OPCML reduces the expression of both LSAMP and NEGRI at
the RNA level. In the mouse and human, the expression profile of the family was
established in panels of multiple-tissue cDNAs, where similarities but also
differences among different IgLONs were highlighted. Immunohistochemical studies
of OPCML were used to profile expression developmentally and in adult tissues. A
comparison between IgLON RNA levels in human normal ovaries and a panel of
ovarian tumours has pointed to significantly reduced levels of OPCML, LSAMP and
NEGRI in specific histological subtypes of ovarian cancer; HNT expression, on the
other hand, was significantly elevated. This study has revealed the importance of the
IgLON family as a whole in EOC.
Various assays were undertaken in the two transfected cell line systems in
order to suggest potential functions of OPCML. In SKOV-3 cells, OPCML was
shown to significantly decrease chemotactic migration and increase adhesion to
fibronectin and vitronectin. Moreover, OPCML was found to promote cell-to-cell
adhesion. The growth suppression effect ofOPCML in vitro was reproduced, and the
underlying mechanism was investigated. This effect is not accounted for by a
difference in proliferation; on the contrary, OPCML was shown to significantly
increase apoptosis. Expression of OPCML in the non-ovarian HeLa inducible cells
did not recapitulate the phenotypic features identified in the ovarian SKOV-3 cells,
indicating the importance of context specificity.
In summary, IgLON expression profiling has yielded valuable observations;
most significantly, it demonstrated a link between the family as a whole and EOC.
One of the family's members, OPCML, has functional features that fit the role of a
TSG in SKOV-3 cells, in particular a pro-apoptotic role. In the future, a SKOV-3
inducible system will offer a refined method to further study its functions and
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1.1 The IgLON family
The term 'TgLON" was coined in 1995 by Levitt and colleagues to describe a
group of three neural glycoproteins that had features characteristic of the cell
adhesion molecules of the immunoglobulin superfamily1. These three proteins,
namely LAMP, OBCAM and Neurotrimin, have three immunoglobulin domains and
a glycosylphosphaditylinositol (GPI) anchor. To date, the family has expanded and
now includes a fourth member, originally known as KILON. The nomenclature of
the family is shown in Table 1.1. The following sections will provide an in-depth
introduction to the biology of the IgLON family, firstly focusing on individual


















Table 1.1 IgLON nomenclature




The protein known as OPCML or OBCAM was originally purified from rat
2 •brain as a p opioid-specific receptor by Cho and colleagues". The majority of the
initial work on OPCML centred on its characterisation as an opioid receptor,
although it had been hinted from the beginning that such a function would be
• 3
unusual, as most opioid receptors are seven-transmembrane domain receptors a
feature not met in OPCML. Thus, early papers reported that antibodies against
OPCML, as well as antisense transfection of the gene, inhibit opioid binding4,5.
When OPCML-transfected NG108-15 cells (a neuroblastoma/glioma hybrid cell line)
were treated with opioid agonists, which reduce levels of opioid receptors, OPCML
immunoreactivity was decreased6; conversely, when CHO (Chinese hamster ovary)
cells were transfected with an opioid receptor they exhibited high surface OPCML
immunoreactivity7. Eventually, it was realised that OPCML did not fit the criteria of
an opioid receptor; for example, PI-PLC treatment of brain membranes, which
should result in the cleavage of GPI anchors, did not have an effect on opioid
binding8.
The OPCML coding sequence was firstly cloned in the rat and was found to
encode a protein of 345 amino acids, with evidence for a GPI linkage9. OPCML was
subsequently cloned in the human: it was positioned on chromosome 11 and
contained a putative open reading frame of 1038 bp10. The human OPCML sequence
was found to be 93% identical to the rat sequence at the nucleotide level and 98% at
the amino acid level. In the chick, two OPCML cDNAs have been cloned, both
encoding the same mature protein, but differing in the coding of the N-terminal
signal peptide with respect to its length".
Although the predicted molecular weight of the OPCML protein is 36 kDa,
its apparent weight is approximately 58 kDa and it is commonly detected as a
o
doublet by immunoblotting . The increase in the molecular weight, as well as the
presence of two bands, has been accounted for by N-linked glycosylation. In
addition, the protein is entirely extracellular and is tethered to the cell membrane by a
GPI anchor. This has been demonstrated with the use of the enzyme PI-PLC, which
o 12 13cleaves GPI anchors ' ' . Moreover, the OPCML protein is detected in the
Triton-insoluble fraction of cell membrane preparations14, a fraction that is
3
associated with lipid rafts. Lipid rafts can be described as membrane subdomains,
enriched in cholesterol and glycosphingolipids, which exist in a liquid-ordered
phase"'16. They are thought to facilitate signal transduction, by bringing in close
proximity signalling components and favouring specificity and sensitivity in their
interactions17.
As an IgLON, OPCML is typically expressed in the brain, and its expression
patterns have been widely studied in this locality. In bovine brain, OPCML is
o
strongly detected in the striatum and cerebral cortex . In the rat brain, OPCML is
detected in almost all of the grey matter, with very restricted expression in the white
matter, only found in the corpus callosum and the deep part of the dorsal funiculus18.
Its expression is at its peak in the cerebral cortex and the hippocampus, moderate in
the olfactory bulb and the diencephalon and weaker in the cerebellum, medulla
oblongata and spinal cord14. OPCML has been described as a dendrite-speciflc cell
adhesion molecule, as it has been reported to localise in the dendrites of fully
polarised cortical and hippocampal neurones19 20. More specifically, Opcml is mainly
expressed at post-synaptic sites of cortical and hippocampal synapses14. Within
dendrites, OPCML localises in vasopressin-positive neurosecretory granules. In the
chick, OPCML is widely expressed in the CNS, where studies have particularly
focused on its expression in the retina, and neurones of the dorsal root and
sympathetic ganglia". Outside the CNS, OPCML expression has been reported in the
spleen, heart, placenta, liver, kidney, pancreas, testis, colon and the epithelial
component of the ovary8'1 ' .
In all the aforementioned species, OPCML expression in the brain is known
to rise in development. In the rat, its expression starts being detectable at E16 and has
been reported to peak either around the second post-natal week or between P28 and
P5614'22. Early in development, Opcml is expressed on all post-mitotic neurones and
strongly in fibre tracts containing expanding neurones, whilst in the adult it is
principally expressed in the grey matter. In the developing chick retina, the
expression of OPCML rises from E7 to E2011.
After the opioid receptor notion was disproved, a number of studies tried to
identify the functions of OPCML in the brain. One concept that emerged is that
OPCML can bind homophilically, but also heterophilically with other members of
4
1114the IgLON fanily ' . Although originally thought to influence axon guidance by
modulating neurite growth, there is more recent evidence that it might be primarily
involved in cell-cell adhesion and cell recognition" . DRG (dorsal root ganglia)
neurones and sympathetic neurones to a lesser extent adhered to a substrate of
OPCML-Fc chimaeras presented on protein A, but did not extend neurites. In
addition, OPCML has been implicated in visual cortex plasticity due to the finding
that it is highly expressed in the visual cortex of kittens but only mininally of older
cats24,25. Further support for this hypothesis comes from the observation that the
number of OPCML-expressing neurones is higher in the visual cortex of older cats
that have been dark-reared in comparison to normal-reared ones. Finally, there is
indirect evidence of a potential role in the inflammatory response, as in a model of
rheumatoid arthritis, OPCML was found to be four times down-regulated following
IL-1P stimulation of chondrocytes .
Additional information on the human OPCML gene and the protein it encodes
is shown in Figure 1.1; this is not based on published data, but on analysis























Figure 1.1 i OPCML at a glance
Gene structure (A) and mature mRNA structure (B) of human OPCML based on
NCBI 11q25 sequence and NM_002545 (not to scale). IVS = intron; Ex = exon; UTR
= untranslated region; CD = coding region; AAA = poly(A) track.
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Figure 1.1 ii OPCML at a glance
Human OPCML proprotein sequence (NCBI NP_002536) annotated with features
(C) and its percentage identity with orthologues and homologous sequences across
species (D). Note that for homologous sequences there is not always a one-to-one
match for a specific IgLON between species.
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1.1.2 HNT
Neurotrimin (HNT) was originally isolated from rat brain as a GPI-anchored
97
protein, together with OPCML" . The cDNA was cloned and positioned on the
proximal end of mouse chromosome 9. The chick orthologue, usually termed
98
CEPU-1, was identified subsequently . In the chick, neurotrimin alternative
isoforms have been well documented11'29. The prototype CEPU-1 protein can be
described as a CEPU-1. There is also (3 CEPU-1, which has an additional C-terminal
insert. Both these can have a longer (1) or a shorter signal peptide (2); for example,
al and a2 CEPU-1. Finally, there is another form, termed CEPU-Se, which differs to
CEPU-1 at the C terminus, missing the GPI attachment sequence, and hence is
thought to be secreted. In the human, HNT has been recently cloned30. The gene is
reported to contain an open reading frame of 1032 bp, encoding a protein of 344
amino acids with a predicted molecular weight of 37 kDa. The HNT gene is located
on chromosome llq25, approximately 80 kb away from the OPCML gene, but it is
transcribed at the opposite orientation. Some evidence of alternative isoforms exists
in the human, with multiple transcripts detected by northern blotting. Human HNT is
87% identical to the rat nucleotide sequence and 97% to the rat peptide sequence.
In the rat nervous system. Hnt has a wide expression pattern, being expressed
in neurones of the thalamus, subplate, lower cortical laminae, pontine nucleus,
cerebellar granule cells, Purkinje cells, olfactory bulb, retina, dorsal root ganglia,
97
spinal cord, basal ganglia and hippocampus . In the chick cerebellum, HNT
expression has been described in granule cells, but there are conflicting reports on its
90 JQ
expression in Purkinje cells ' . In the human, its highest expression was found in
the cerebellum; it is also the only species where expression outside the CNS has been
documented, namely in the heart and lung"0.
Developmentally, like OPCML, HNT expression rises with age. In the
developing chick brain, the timing of HNT expression has been linked with the
growth of the dendritic tree28. Moreover, there is evidence of alternative isoforms
being expressed differentially in development11. This is not true for the secreted
29
isoform, though, which is co-expressed with CEPU-1 at all stages examined" . More
detailed neurodevelopmental studies in the chick have indicated that early in
development, HNT has a broad expression pattern, which is subsequently restricted
8
to a ring-shaped domain in the midbrain-hindbrain boundary, co-localising with
31*WNTl expression in the isthmus, as well as migrating neural crest cells . Later still,
HNT expression is switched on in other parts of the brain, for example sensory
ganglia and ventral aspects. In the human brain, adult expression has been shown to
TA
be higher than foetal expression .
What are the functions of HNT? Cross-linking studies of transfected CHO
cells have demonstrated that HNT forms dimers and multimers in cis and mediates
homophilic adhesion . HNT can bind to and promote neurite outgrowth in neurones
that express it (e.g. from DRG) but not those that do not (e.g. sympathetic neurones).
Interestingly, the secreted form ofHNT does not have this effect, although it can act
as a soluble ligand when it is dimerised29. HNT has been also shown to bind
heterophilically with OPCML and LSAMP11. As with OPCML, a subsequent report
raised concerns on the ability of HNT to modulate neurite growth and highlighted a
AT
more favourable role in cell-cell adhesion and cell recognition" . This hypothesis is
supported by the finding that HNT promotes cell-cell aggregation30.
Additional information on the human HNT gene and the protein it encodes is
shown in Figure 1.2; this is not based on published data, but on analysis undertaken
























Figure 1.2i HNT at a glance
Gene structure (A) and mature mRNA structure (B) of human HNT based on NCBI
11 q25 sequence and NM_016522 (not to scale). IVS = intron; Ex = exon; UTR =
untranslated region; CD = coding region; AAA = poly(A) track.
10
1 mgvcgylflp wkclvvvslr llflvptgvp vrsgdj|®c amdn|vtvrqg esatlrctid
■rvtrvawln! rstilyagnd kwcldprvvl lsntqtqysi eiqnvdvyde gpytcsvqtd
nhpktsrvhl 1v(j pk1ve j.ssd1s1neg nnllsltciat grpeptvtwr hispkavgfv
sedeyleiqg itreqsgdye csasndvaap vvrrvkvtvn yppyiseakg tgvpvgqkgt
lqceasavps aefqwykddk rliegkkgvk venrpflskl iffn|vsehdy gnytcvasnk
30l lghtn|asiml fgpgavsevs ngtsrragcv wllpllvlhlmm
signal peptide | Ig domains glycosylation sites
| GPI attachment site | cleaved in mature peptide
D






Figure 1.2ii HNTata glance
Human HNT proprotein sequence (NCBI NP_057606) annotated with features (C),
and its percentage identity with orthologues and homologous sequences across
species (D). Note that for homologous sequences there is not always a one-to-one
match for a specific IgLON between species.
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1.1.3 LSAMP
LSAMP, also known as LAMP, was first discovered using a monoclonal
antibody that stained cortical and subcortical regions of the limbic system in rat
-5 ->
brain . Since then, it probably constitutes the most studied member of the IgLON
family. LSAMP was initially cloned in the rat and shortly afterwards in the human1'34.
The human LSAMP sequence contains an ORF of 1014 bp, and encodes a 338 aa
protein with 3 immonoglobulin domains, an N-terminal signal peptide, a C-terminal
GPI attachment site and 8 N-linked glycosylation sites. Human and rat sequences are
reported to be 94% identical at the nucleotide level and 99% identical at the amino
acid level. The chick LSAMP gene has been also cloned and is 91% identical to the
rat nucleotide sequence . Physically, human LSAMP has been mapped to
chromosome 3q, whereas mouse Lsamp to chromosome 16, at a region of conserved
-j/-
#
synteny with the human . Three transcripts have been identified in the human and
chick, two in the rat and multiple in the mouse11' 1. These isoforms differ mainly
either in the signal peptide coding sequence or the C-terminal one.
The LSAMP protein was originally purified from rat and bovine
hippocampus'8. It was found to be an extracellular protein of 64-68 kDa, modified by
N-linked glycosylation and tethered to the membrane by a GPI anchor.
The expression of LSAMP has been tightly linked with the limbic system
since its discovery. In the adult rat brain, it localises post-synaptically on neuronal
-> o
somata and dendrites, but not axons . Generally, Lsamp is expressed heavily in areas
of the forebrain and diencephalon that are considered limbic and only sparsely in
non-limbic midbrain and hindbrain regions''9. When the distribution of LSAMP was
studied in the amygdaloid complex and the hippocampus of cynomolgus monkeys, it
was found that staining of limbic structures is highly heterogeneous, and probably
confined to very specific functional domains40. In the chick nervous system, LSAMP
expression has been shown in the forebrain, cerebellum, tecta, retina and spinal
cord41. It mostly localises in areas of interneuronal contact, such as the molecular
layer in the cerebellum and the inner and outer plexiform layers in the retina.
Furthermore, the distribution of LSAMP in the pigeon brain has been elucidated and
found to be very similar to that in mammals42. Outside the CNS, the only organ
where expression of LSAMP has been reported to date is the kidney43.
12
It is known that LSAMP is expressed in neurones early in foetal development,
as early as El3, and its pattern of temporal expression correlates with the formation
of limbic pathways44'45. Interestingly, although in the adult LSAMP is present in
post-synaptic sites, in development it is more widespread, being expressed on
TO
growing axons both pre- and post-synaptically . Transplantation experiments,
involving taking precursors of either perirhinal or sensorimotor cortex prior or just
after the onset of Lsamp expression and placing them either homo- or
heterotopically, have elegantly demonstrated that there is an initial developmental
window during which cells are still "pluripotent" (until El2 in the rat) before they
become committed to a limbic fate46. In the developing chick neural tube, LSAMP is
expressed in the anterior midbrain and by most neural crest cells47. In the chick, there
is some evidence of differential expression of LSAMP alternative transcripts in
development35.
With regard to its functions, the ability of LSAMP to affect neurite outgrowth
has been studied extensively. More specifically, LSAMP is thought to play a
bifunctional role: it facilitates neurite outgrowth of neurones that express it, such as
limbic neurones, and it inhibits neurite outgrowth from neurones that do not express
it1,48,49. LSAMP is thought to induce neurite outgrowth by modulating intracellular
Ca2+ levels50. It has been demonstrated that the first Ig domain within the LSAMP
protein is necessary and sufficient for its neurite-promoting acitivity in hippocampal
neurones; this is also the domain that can interact homophilically51. The inhibition of
neurite outgrowth from non-expressing neurones is mediated by heterophilic
interactions and requires full length LSAMP, although is mostly dependent on the
second Ig domain, furthermore, administration of anti-LSAMP antibody to rats
results in an abnormal growth of the mossy fibre projections from developing
granule neurones of the dentate gyrus of the hippocampus1. Moreover, evidence for
the involvement of LSAMP in both homo- and heterophilic adhesion and interactions
is well documented11'23'35,49'52. The functional significance of the finding that Lsamp
is up-regulated in rats with reduced exploratory activity remains to be clarified53.
Additional information on the human LSAMP gene and the protein it encodes
is shown in figure 1.3; this is not based on published data, but on analysis
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Figure 1.3i LSAMP at a glance
Gene structure (A) and mature mRNA structure (B) of human LSAMP based on
NCBI 3q13.2-q21 sequence and NM_002338 (not to scale). IVS = intron; Ex = exon;
UTR = untranslated region; CD = coding region; AAA = poly(A) track.
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Species Accession number % identity
M.musculus BAE34618 88
G.gallus CAB08115 80
X.laevis AAH 74296 82
D.rerio AAH81685 52
D.melanogaster AAY55132 31
Figure 1.3ii LSAMP at a glance
Human LSAMP proprotein sequence (NP_002329) annotated with features (C), and
its percentage identity with orthologues and homologous sequences across species
(D). Note that for homologous sequences there is not always a one-to-one match for
a specific IgLON between species.
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1.1.4 NEGRI
The last member to be added in the IgLON family, NEGRI, most widely
known as KILON, was originally isolated and cloned from a rat brain raft fraction
after PI-PLC solubilisation54. It has also been independently cloned by a second
group55. Like the rest of the IgLONs, it has three Ig domains and is subjected to
post-translational glycosylation due to its 6 N-linked glycosylation sites, which
results in an increase in the apparent molecular weight to 46 kDa relative to the
predicted one of 36 kDa. The rat NEGRI peptide sequence is 56% identical to the rat
LSAMP sequence, 49% to OPCML and 48% to HNT54. The chick orthologue has
also been identified and is commonly known as neurotractin . Two isoforms have
been described, a long (L) 50 kDa protein and a short (S) 37 kDa protein. The latter
lacks the third Ig domain. Recently, mouse Negri has been cloned56.
In the rat, expression of Negri has been documented in the cerebral cortex,
hippocampus, diencephalon and cerebellum, with lower expression in the medulla
oblongata and very low in the spinal cord14'54. More specifically, NEGRI
immunoreactivity has been demonstrated in magnocellular neurones of the
supraoptic and paraventricular nuclei in the rat hypothalamus, where NEGRI mainly
localises in the dendrites of vasopressin-secreting neurones and to a lesser extent of
oxytocin-secreting neurones14'19. NEGRI is mainly found at post-synaptic sites in the
adult rat cerebral cortex and hippocampus, co-localising with the vesicle-associated
membrane protein 2 (VAMP-2), a synaptic protein marker. In the chick, NEGRI has
been described as an axonal glycoprotein; there is evidence that the long and short
isoforms are not differentially expressed52. Outside the brain, Negri expression has
been reported only in the skull, intervertebral discs, intestine, ribs and visceral
cranium ofEl 7 rats at the RNA level55.
NEGRI expression is developmentally regulated, in the rat, chick and
mouse14'52'54'56. In the rat, it is very low at E16 and starts rising from E19, peaking
around P30-P70. In the developing chick, NEGRI expression is restricted to subsets
of commissural and longitudinal axon tracts.
NEGRI has been assigned a neurite outgrowth-promoting role in neurones
that express it52. In addition, it has been shown to interact both homophilically and
heterophilically with other IgLONs14. Interestingly, in the mouse, subsequent to a
16
lesion in the entorhinal cortex, Negri expression was induced in reactive astrocytes
in the denervated outer molecular layer of the dentate gyrus, where regenerative axon
sprouting occurs56. This is the first report of an IgLON being expressed by
non-neuronal cells in the brain. Consequently, a hypothesis was proposed that
NEGRI could function as a trans-neural growth-promoting factor for outgrowing
axons following hippocampal denervation.
Additional information on the human NEGRI gene and the protein it encodes
is shown in Figure 1.4; this is not based on published data, but on analysis


































Figure 1.4i NEGRI at a glance
Gene structure (A) and mature mRNA structure (B) of human NEGRI based on
NCBI 1p31.1 sequence and NM_173808 (not to scale). IVS = intron; Ex = exon;
UTR = untranslated region; CD = coding region; AAA = poly(A) track.
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Figure 1.4ii NEGRI at a glance
Human NEGRI proprotein sequence (NCBI NP_776169) annotated with features
(C) and its percentage identity with orthologues and homologous sequences across
species (D). Note that for homologous sequences there is not always a one-to-one
match for a specific IgLON between species.
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1.1.5 Interactions within the IgLON family
It has been mentioned that apart from the ability of each IgLON to participate
in homophilic interactions, heterophilic binding is also possible: OPCML has been
reported to interact with HNT, LSAMP and NEGRI; HNT with OPCML and
LSAMP; LSAMP with OPCML, HNT and NEGRI; and NEGRI with OPCML,
HNT and LSAMP11'14'52. There has been a recent proposition that each IgLON
protein is principally a subunit of a heterodimeric adhesion molecule, termed
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Diglon . The four IgLON proteins can potentially form six Diglons:
LSAMP-OPCML, LSAMP-HNT, HNT-OPCML, NEGRI-OPCML, NEGRI-HNT
and LSAMP-NEGR1. Based on their relative adhesion affinities, the authors
postulated that OPCML and LSAMP interact mostly heterophilically, whilst HNT
can also function homophilically. The role ofNEGRI in these interactions remains to
be confirmed. The ability of IgLONs to associate in dimeric complexes is reflected
on their function: co-transfection of OPCML and HNT in CHO cells resulted in a
significant reduction in their ability to modify neurite outgrowth from cerebellar
granule cells.
1.1.6 The IgLON family in cancer
Sellar and colleagues have proposed that OPCML represents a novel tumour
suppressor gene in sporadic epithelial ovarian cancer2'. Their report was the first one
to link an IgLON with disease, and indeed to focus on an area of IgLON biology that
is not centred on the brain. OPCML was originally identified through a high rate of
complete loss of heterozygosity (LoH) within its second intron on llq25. OPCML
was shown to be expressed in normal ovarian surface epithelium, the site of origin of
EOC, but its RNA expression was abolished in 83% of a panel of ovarian tumours
and 88% of a panel of ovarian cancer cell lines. Mutation screening identified only
one somatic mutation in EOC, a C—>G transversion that results in a missense P95R
substitution in the first Ig domain of the protein. Nonetheless, extensive promoter
hypermethylation was found in ovarian tumour samples and cancer cell lines,
suggesting that the mechanism underpinning OPCML silencing is epigenetic.
Furthermore, it was shown that OPCML has functional features of a tumour
supressor: it suppresses cell growth in vitro, when expressed in the ovarian cancer
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SKOV-3 cell line, and tumourigenicity in vivo, in intraperitoneal and subsutaneous
xenografts. In SKOV-3 cells, it was also found to promote cell-cell aggregation, a
function lost when mutant OPCML, harbouring the P95R mutation, was expressed.
The second IgLON to be linked with cancer is LSAMP. More specifically,
LSAMP was identified by positional cloning to span a breakpoint in familial clear
cell renal cell carcinoma (CCRCC)43. LSAMP RNA was down-regulated in all renal
cell carcinoma cell lines examined relative to its levels in the normal kidney. The
LSAMP promoter was found to be methylated in most of these cell lines, as well as in
26% of a panel of sporadic CCRCC samples and 4 familial CCRCC cases. In
samples where methylation was found, RNA down-regulation was also shown
relative to the normal kidney. Somatic mutations were not identified. When an
LSAMP-EGFP construct was expressed in renal cell carcinoma cell lines, there was
marked growth suppression. Hence, it was postulated that LSAMP might have a
tumour suppressor function in CCRCC. It should be noted, however, that the growth
suppression effect seen should be appreciated with some caution, as the observed




Ovarian cancer is the leading cause of death from gynaecological
malignancy5 . It ranks fourth or fifth as a cause of death from cancer in women
(Figure 1.5), who have a 1 in 48 lifetime risk of developing it59. The incidence of the
disease rises with age, peaking in around the seventh to eighth decade. 90% of
ovarian cancers are epithelial ovarian cancers (EOCs), the rest originating in
granulosa, or rarely stromal and germ cells. Cancer of the ovary is primarily a
sporadic disease, with familial cases accounting for only 5-10% of patients60"61.
In the following sections, an introduction on ovarian cancer biology will be
presented. After discussing some relevant elements of normal ovarian biology,
important aspects of ovarian cancer will be covered, including aetiology, histology
and the genetics of the disease.
UK Incidence 2001: Females
Breast 40 790 !30%)
■ Large trowel 16.040 (12%l
Lung 14740 (11%)
Ovary I 6sao (5%|
Uterus 5650 (4% I
■■■■■I Non-Hodgkrn's I'ympficma 4 370 <3%l
■■■■■ Melanoma 4,130 (3%|
■■■■ Pancreas 3 590 (9%)
Stomacn 3 310 (2%)
■■■ Bladder 3,080 <2%l
Other 32,830 <»%)
Females all malHinant neoplasms excising NMSC 135.410 (iOO%)
Figure 1.5 UK incidence of cancer in females
2001 figures of women's cancer incidence in the UK. Adapted from the Cancer
Research UK Statistics website.
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1.2.1 The ovarian surface epithelium
When examining the features of a human ovary, the ovarian surface
epithelium seems to be obscured by more complex structures (Figure 1.6). It is
relatively recently that this inconspicuous cell layer overlying the ovary, the OSE,
has become the focus of intense study, with respect to both its normal physiology and
pathology62"64.
The OSE, also known as ovarian mesothelium or quite misleadingly as the
"germinal" epithelium, is the single layer of squamous to cuboidal epithelial cells
that is only tenuously attached to the ovary (Figure 1.7). Developmentally, the OSE
is part of the coelomic epithelium, which is the mesoderm-derived epithelial lining of
the intra-embryonic coelom. It remains controversial whether the foetal OSE is also
the developmental source of ovarian granulosa cells. The mature OSE expresses
various keratins (7, 8, 18 and 19), as well as mucin antigen 1, and
17{3-hydroxysteroid dehydrogenase. It features cilia, apical microvilli and a basal
lamina. It is separated from the ovarian stroma by a dense collagenous tissue layer,
the tunica albuginea; this is what gives the ovary its off-white colour. Within the
OSE layer, intercellular contact is maintained by desmosomes and incomplete tight
junctions and facilitated by the presence of several integrins and N-cadherin.
Figure 1.6 The human ovary
Diagram of the basic anatomical features of the human ovary. Reproduced from the
Human Anatomy website of Lake Michigan College.
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Figure 1.7 The ovarian surface epithelium
Human ovary section focusing on the OSE layer. Image courtesy of Dr M. Rae,
Centre for Reproductive Biology, University of Edinburgh.
One of the defining characteristics of the ovarian surface epithelium is its
limited degree of differentiation; it is therefore described as having both epithelial
and mesothelial features. This might explain the current absence of OSE-specific
markers. In response to stimuli that are not fully understood, but are usually part of a
regenerative response, OSE cells undergo epithelial-to-mesenchymal conversion
(EMC) and assume characteristics of stromal cells. These stimuli are exemplified by
ovulatory rupture in vivo and explantation into culture. With age, the ovary tends to
form OSE-lined invaginations, often manifesting as crypts. It is thought that the
propensity of OSE cells to undergo EMC serves as a homeostatic mechanism that
allows cells that have been trapped in cysts to be incorporated in the ovarian stroma
as fibroblasts.
Functionally, the ovarian surface epithelium transports materials to and from
the peritoneal cavity and plays an important role in cycles of ovulation and
post-ovulatory repair. OSE functions are regulated by hormones and inflammatory
mediators. Examples include: gonadotrophin releasing hormone (GnRH), which is an
autocrine growth inhibitor for the normal OSE65; follicle stimulating hormone (FSH)
and various steroid hormones, which interact with their respective receptors
f\f\ f\R
expressed by OSE cells " ; epidermal growth factor (EGF), which stimulates OSE
proliferation and affects its differentiation69; several members of the transforming
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growth factor beta (TGFP) family of growth factors, which inhibit OSE growth70;
and various cytokines, such as IL-1, IL-6, macrophage colony stimulating factor
(M-CSF) and granulocyte macrophage colony stimulating factor71 (GM-CSF). A
number of the aforementioned growth factors and hormones often signal through
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mitogen-activated protein kinases (MAPKs). During ovulation, gonadotrophic
stimulation of plasminogen activator secretion by the OSE part that is contiguous
with the preovulatory follicle elicits a local increase in the concentration of tissue
plasmin. This in turn activates latent collagenases and releases tumour necrosis factor
alpha (TNFa) from the thecal endothelium, which precipitates collagenolysis by the
induction of matrix metaloproteases. Consequently, the apical follicular wall
weakens, leading to stigma formation and finally ovulatory rupture. In post-ovulatory
repair, the OSE is likely to contribute to the restoration of the ovarian cortex through
its capacity to synthesise both epithelial and connective tissue-type components of
the extracellular matrix. The OSE's propensity to undergo epithelial to mesenchymal
conversion is particularly advantageous during post-ovulatory repair, conferring
increased cell motility and contractility and favourable proliferative and
ECM-modifying responses.
1.2.2 Histological types and grades
Histologically, ovarian tumours are considered to be among the most
complex73. Epithelial ovarian tumours are categorised into serous, endometrioid,
mucinous, clear cell, Brenner, undifferentiated, mixed and unclassified types.
Furthermore, they can be classified as benign, borderline (i.e. of low malignant
potential; LMP) and malignant (carcinomas). As previously mentioned, normal OSE
has both epithelial and mesenchymal features and hence can be considered not to be
fully differentiated. Malignant transformation is accompanied by a differentiation
process that drives the cells to acquire a more differentiated epithelial morphotype.
The newly acquired epithelial characteristics are shared by Mullerian duct-derived
epithelia and ovarian carcinomas are categorised according to the structure to which
they resemble (Figure 1.8): serous carcinomas, which constitute the vast majority of
ovarian tumours, resemble the structure of the fallopian tube; endometrioid tumours
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have similar histology to the endometrium; mucinous tumours are reminiscent of the
endocervix; and clear cell tumours resemble mesonephric structures.
In addition, the degree of differentiation of an ovarian tumour is reflected on
its classification by histological grade. There are three grades: grade 1 is
characterised by well-differentiated tumours, grade 2 by moderately-differentiated
ones and grade 3 by poor differentiation status.
Figure 1.8 Epithelial ovarian cancer histological types
Sections of serous (A), endometrioid (B), mucinous (C) and clear cell (D)
carcinomas. Images courtesy of Dr A. Al-Nafussi, Department of Pathology,
University of Edinburgh (B,D) or reproduced from the Internet Pathology Laboratory
for Medical Education, Florida State University website (A) and the "Borderline
ovarian tumours: a web-based atlas" website (C).
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1.2.3 FIGO staging
There are four basic stages of advancement in ovarian cancer according to its
classification by the International Federation of Gynaecology and Obstetrics (FIGO).
In stage I, the hallmark is the formation of inclusion cysts that invade the ovarian
cortex. Malignant growth can be present in one (la) or both ovaries (lb), or following
rupture of a cyst, cancer cells can be extruded in the peritoneal cavity (Ic). Stage II
disease is characterised by peritoneal dissemination to the fallopian tubes and/or the
uterus (Ha) or to other tissues within the pelvis (lib), which can be accompanied by
the presence of ascitic fluid (lie). In stage III, the disease has spread beyond the
pelvis but is still restricted to the peritoneal cavity: there is only microscopic seeding
(Ilia), or presence of nodules smaller than (Illb) or larger than 2 cm (IIIc), or
presence of positive retroperitoneal or inguinal nodes (IIIc). Finally, stage IV disease
is defined by the presence of distant metastases, encompassing pleural effusion and
parenchymal liver. On the whole, ovarian cancer is not an overtly metastatic disease,
as it is mainly associated with locoregional dissemination, rather than spreading to
distant sites. Thus, stage IV disease is quite rare.
1.2.4 Diagnosis, prognosis and treatment
Ovarian cancer is commonly initially indicated by suprapubic or transvaginal
ultrasonography74. Initial findings are evaluated in combination with surgical
exploration and histopathological examination, allowing the precise staging and
grading of the disease. Ovarian cancer has been dubbed the "silent killer", as early
stage disease is relatively asymptomatic and hence is rarely diagnosed by current
means: only 20-25% of patients with invasive EOC are diagnosed with stage I or II
disease. Generally, symptoms include prolonged swelling of the abdomen, which can
be accompanied by pain, digestive problems and weight loss. The only validated
marker in current use for the management of ovarian cancer is the CA125
glycoprotein: approximately 80% of patients with overt symptoms present with
increased levels of immunoreactive CA125. However, the use of this marker in
ovarian cancer diagnosis is problematic, due to the lack of specificity and sensitivity
of tests, the fact that some ovarian cancer types are usually not associated with
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elevated CA125 levels (mucinous tumours) and the detection of false positives in
conditions such as pregnancy, pelvic inflammatory disease, endometriosis etc .
The following factors contribute to the prognosis of ovarian cancer: age,
disease type, stage and grade, volume of residual tumour after initial surgical
"debulking" and patient performance status. Although if diagnosed early ovarian
cancer has a very good prognosis, with a 92% 5-year survival rate, most cases (75%)
are diagnosed at a late stage of disseminated disease when the prognosis is much less
favourable, with only a 25% 5-year survival rate.
Treatment of ovarian cancer varies according to the objectives that are to be
met7 '77. Upon initial diagnosis, previously untreated patients are offered treatment
that aims at curing them and prolonging their survival. Subsequently, maintenance or
consolidation therapy is offered, in order to prevent recurrence of the disease. If
patients relapse after first-line treatment, the primary objective of treatment becomes
mostly palliative, so as to control symptoms, improve quality of life, and increase
disease-free interval, thus prolonging overall survival.
Most patients with early stage disease are cured with standard therapy.
Staging laparotomy will indicate whether a patient has a high (stage I high-grade
tumours, stage Ic tumours, and all stage II tumours) or low (stage la and lb tumours)
risk of recurrence. For the low-risk group, cytoreductive surgery alone is usually
effective in curing more than 90% of patients. In contrast, patients in the high-risk
category of early stage disease have a relapse rate of 40-50%, and many will die
from recurrent disease. For these patients, surgery is commonly accompanied by
adjuvant platinum-based chemotherapy. The value of this approach has been
demonstrated by the ACTION (Adjuvant Chemotherapy in Ovarian Neoplasm)
randomised clinical trial, which reported that immediate platinum-based
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chemotherapy improved overall and recurrence-free survival . However, this
treatment regime is still ineffective in 18% of patients, suggesting better options are
needed.
With respect to the vast majority of patients, who are diagnosed with
advanced-stage disease, treatment commonly consists of cytoreductive surgery and
subsequent combination chemotherapy, employing a platinum-based compound,
such as cisplatin or carboplatin, and either a taxane such as paclitaxel, or an
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alkylating agent such as cyclophosphamide. Recent large prospective studies have
favoured the use of carboplatin and paclitaxel, a combination that tends to become
the standard of care for advanced-stage disease79'80. Nonetheless, approximately
75% of these patients will relapse in less than 5 years post treatment, with a median
survival following recurrence of approximately 2 years.
Finally, in cases wherein platinum-resistance has developed, alternative
treatments can be offered, including the administration of gemcitabine, topotecan,
doxorubicin and taxanes. Unfortunately, the response rate of these chemotherapy
options is particularly low, often below 15%.
1.2.5 Aetiology
It has been long established that parity, lactation and oral contraceptive use
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act as protective factors against ovarian cancer . These factors are in agreement with
the two major hypotheses regarding the aetiology of ovarian cancer that have shaped
thinking on the disease pathogenesis. Moreover, recognised environmental risk
factors in ovarian cancer include diet, talc, industrial pollutants, cigarette smoking,
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asbestos and infectious agents . Family history is a strong determinant in 5 to 10%
of ovarian cancer cases.
The original hypothesis of the aetiology of ovarian neoplasia is the incessant
ovulation hypothesis, as formulated by Fathalla in 1971 . The principal idea of this
hypothesis is that continuous ovulatory cycles are damaging to the ovarian surface
epithelium. Consequently, ovarian cancer arises mainly in species such as human and
chicken, wherein frequent cyclic ovulation occurs, in contrast with rats and mice for
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example . Ovulation is accompanied by cell damage, which in turn translates into an
enhanced potential for aberrant DNA repair, inactivation of tumour suppressor
8S 86 •
pathways and subsequent mutagenesis * . It has been demonstrated that a high
number of ovulatory cycles may be associated with increased levels of
proliferation-linked DNA damage and an increased risk of developing certain types
of EOC87. Although the phenomenon of ovulation is widely accepted as central to the
pathogenesis of ovarian cancer, some of the expectations of the incessant ovulation
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hypothesis have not been confirmed by epidemiologic evidence ' . Notably, the link
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between infertility and ovarian cancer risk is not properly established and factors that
reduce ovulation do not proportionally reduce the risk of ovarian cancer.
The second major hypothesis is the pituitary gonadotrop(h)in hypothesis90.
Key to this hypothesis is the entrapment ofOSE in inclusion cysts within the ovarian
stroma (Figure 1.9). The entrapped epithelium is thought to be subsequently
stimulated by oestrogen or oestrogen precursors, particularly in the presence of high
and persistent levels of luteinising hormone (LH) and follicle stimulating hormone
(FSH), both of gonadotrophic function. As in the incessant ovulation hypothesis, not
all the epidemiologic evidence is in concert with the gonadotrophin hypothesis. For
example, one study that measured the serum levels of gonadotrophic hormones many
years prior to outcome did not find an association between hormone levels and
occurrence of ovarian cancer91. Even if the gonadotrophin hypothesis should not be
accepted in its entirety, it is generally believed that steroid hormones play a role in
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ovarian tumoungenesis . Furthermore, it has been postulated that ovarian cancer
risk is increased by factors associated with excess androgen stimulation of OSE cells
and reduced by factors linked to a greater progesterone stimulation93.
Figure 1.9 Ovarian inclusion cyst
Entrapped epithelium within the ovarian stroma, ic = inclusion cyst.
Reproduced from Auersperg et a/., 2001.
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Increasingly, inflammation has been regarded as an essential element in the
aetiology of ovarian neoplasia94. There is an array of epidemiologic evidence in
support of a role by inflammation, exemplified by risks imposed by talc and asbestos
exposure95'96, endometriosis97 and pelvic inflammatory disease98 and protection by
either hysterectomy without oophorectomy or tubal ligation99. Cytokines normally
secreted by OSE cells, such as IL-1 and IL-6, are also produced by ovarian cancer
cells71'100. The recruitment of these normally secreted cytokines into deregulated
autocrine loops may be essential to the tumourigenic process and could be
contributing to mutagenesis. Furthermore, ovulation is associated with a marked
inflammatory response101. The epithelium in and around the site of ovulation may
replicate more actively, come into contact with a plethora of cytokines and
prostaglandins and be subjected to oxidative stress, thereby increasing the risk of
mutagenesis. Hence, inflammation might be linked to ovarian carcinogenesis through
the same processes that physiologically tie it to ovulation.
1.2.6 Origin, early events and disease progression
The study of early events leading to ovarian carcinogenesis has been greatly
hampered by the lack of animal models until quite recently and methodological
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problems in the culture of ovarian surface epithelial cells . However, with recent
advances, our understanding of how ovarian cancer arises has become better.
It is now generally accepted that epithelial ovarian cancer arises in the OSE.
Histologically, there have been various observations favouring an OSE origin: atypia
is often found in the OSE adjacent to invasive carcinoma; there is an increased
frequency of inclusion cysts in normal ovaries contralateral to malignant ones; the
OSE adjacent to a carcinoma is more metaplastic and dysplastic; and ovaries that
have been prophylactically removed due to a family history of ovarian cancer tend to
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have more inclusion cysts . Nevertheless, it is quite rare to find OSE atypia without
the presence of adjacent invasive carcinoma. This rarity, together with the fact that,
morphologically, ovarian tumours resemble components of Miillerian rather than
OSE origin has created in the past controversy over the true origin of epithelial
ovarian cancer. It was once suggested that components of the secondary Mullerian
system (such as paraovarian and tubal cysts, and rete ovarii) play a role in ovarian
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carcinogenesis104. However, to understand why this argument has been mostly
refuted, one has to appreciate the special nature of the OSE and examine the recent
experimental evidence.
As previously discussed, the OSE is characterised by an incomplete
differentiation, which confers it a propensity to undergo EMC following regenerative
stimuli. EOC is unique among most epithelial cancers in that instead of the cells
acquiring a less differentiated phenotype, ovarian cancer cells are generally more
differentiated than OSE cells. How are these two issues linked and how can they be
explained? It is known that with neoplastic progression, the tendency of OSE to
undergo EMC diminishes and the cells become committed to epithelial
phenotypes102. Cancerous cells acquire specialised epithelial features, exemplified by
the expression of E-cadherin and various mucins, and the development of polarised
epithelia, with papillae, cysts and glandular structures. Only in the late stages of
disease advancement do these specialised features diminish, although they can persist
even when tumours are metastatic or in the form of ascites103. This metaplasia is
particularly evident in surface invaginations and inclusion cysts. Metaplastic cells
express E-cadherin, which may act as a survival factor, while their expression of the
MET oncogene increases, which is known to contribute to the growth and
invasiveness of many types of cancer106. E-cadherin is central to this differentiation
process. It is a transmembrane, calcium-dependent cell adhesion molecule, which
promotes cell-cell adhesion and the formation of adherens junctions, stabilised by its
association with a, [3 and y catenins that are physically linked to F-actin107'108.
Normal OSE cells rarely express E-cadherin, whereas metaplastic OSE cells often
do'05'109. Furthermore, although E-cadherin is scarce or absent in ovarian cancer
metastases, it is almost always present in primary ovarian tumours110"113. When
E-cadherin was expressed in SV40 large T-antigen immortalised OSE cells, the
transfected cells did not undergo EMC; instead, they acquired more epithelial
features, e.g. the expression of cytokeratins and CA125, which are associated with
ovarian metaplasia and neoplasia, suggesting that E-cadherin plays a causal role114.
Major progress has been made recently with respect to animal models in
ovarian cancer by three independent groups. Orsulic and colleagues used
p53-deficient transgenic mice that constitutively express the avian receptor TVA115.
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Ovarian cells were taken from these mice and were infected ex vivo with a
replication-competent avian leucosis virus vector harbouring the coding sequence of
selected oncogenes (Myc and/or Kras and/or Aktl). In vitro, the infected cells
exhibited increased proliferation, especially when both Myc and Aktl were
expressed. When infected cells were reintroduced in the mice, subcutaneously,
intraperiotoneally or homotopically, expression of any two of the three oncogenes
resulted in tumours that were of epithelial origin. The induced ovarian tumours
resembled human ovarian carcinomas in their progression rate and peritoneal
dissemination. Tumours also developed in a p53-proficient background, although
with a much increased latency period. Connolly and co-workers used the Misiir
(Miillerian inhibitory substance type II receptor; official symbol: Amhr2) promoter to
drive the expression of the SV40 large T-antigen in female transgenic mice, taking
advantage of the notion that MISIIR is expressed in ovarian cancer cells but not in
normal OSE cells116. 50% of these mice developed ovarian tumours of epithelial
origin that resembled human ovarian tumours of poor differentiation, with
intraperitoneal dissemination, invasion of the omentum and formation of ascites.
Ascite-derived cell lines exhibited expression of epithelial markers, anchorage
independence, and tumourigenicity when xenografted in SCID mice. Finally,
Flesken-Nikitin and colleagues created a conditional mouse model of ovarian
cancer117. They used immunocompetent mice that are homozygous for floxed alleles
of Tp53 and Rbl, and by administering adenoviral constructs expressing Cre
recombinase in the bursa, they achieved inactivation of the two transgenes in OSE
cells. This resulted in the growth of epithelial ovarian tumours, mostly of serous
histology, which spread intraperitoneally, forming ascites, and metastasised to the
lung and the liver. Interestingly, even early dysplastic lesions had inactivation of
both transgenes. So, what have these studies achieved collectively? Apart from
providing valuable tools to study and understand ovarian cancer in the mouse, they
have strengthened the theory that ovarian cancer arises in the OSE and have cast
some light on the early molecular events that might be required in ovarian
tumourigenesis.
In ovarian cancer, a stepwise sequence of molecular events that accompany
tumourigenesis has not been described103. In contrast, it is a matter of debate whether
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there is a progression from benign tumours to borderline tumours to ovarian
carcinomas. The linear progression hypothesis posits that ovarian cancer arises from
less malignant entities, which progress to full malignancy by the accumulation of
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genetic mutations " . According to this theory, tumours of low malignant
potential, i.e. borderline tumours, represent precursor lesions. As an antithesis, it has
been postulated that LMP tumours and carcinomas are independent, each arising de
novo from the OSE121. The evidence to date, mostly based on comparative genomic
hybridisation studies, does not entirely exclude either hypothesis, although the
growing consensus is arguably leaning on the non-progression theory or a
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combination of both " . A dualistic model proposed by Shih Ie and Kurman
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proposes that ovarian neoplasms arise by two distinct pathways . Type I
carcinomas (low-grade serous, endometrioid, clear cell and mucinous) arise from
precursor lesions of low-malignant potential, whilst type II carcinomas (high-grade
serous and undifferentiated) arise de novo, evolve more rapidly and are more
aggressive. It still remains a matter of debate whether there is progression in ovarian
tumourigenesis, as well as to what extent divergence occurs among different
histological types and between LMP tumours and invasive carcinomas. This problem
might be resolved with the better and more rational classification of ovarian tumours,
which is likely to be available in the future, based on molecular rather than
morphological criteria. A number of microarray studies have already pointed to
127 128molecular separation between distinct histological types of ovarian cancer ' .
1.2.7 Genetics of EOC
Epithelial ovarian cancer manifests with tumours of clonal origin that arise
due to multiple genetic changes129'130. The familial and sporadic types of epithelial
ovarian cancer are thought to differ in their molecular pathogenesis. Hence, the
genetics of each type will be introduced separately in the following sections.
1.2.7.1 Familial EOC
5-10% of ovarian cancer cases are thought to be familial60'131. Three distinct
hereditary ovarian cancer syndromes have been described to date: hereditary
site-specific ovarian cancer, hereditary breast/ovarian cancer and hereditary
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non-polyposis colorectal cancer (HNPCC) . The genetics of hereditary site-specific
ovarian cancer remain obscure, apart from the fact that heredity is autosomal
dominant as in the other two syndromes.
The high-penetrance genes associated with hereditary breast/ovarian cancer
are the extensively studied BRCA1 and BRCA2 genes, both encoding proteins
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thought to regulate the DNA damage response ' . More specifically, the BRCA1
and BRCA2 proteins are involved in the repair of double-stranded DNA breaks by
homologous recombination1 j4. This potentially error-free DNA repair mechanism
requires the localisation of RAD51 to the site of damage, forming foci in the nucleus.
BRCA2 interacts directly with RAD51, whereas BRCA1 is required for the
formation of foci by an as yet unidentified interaction . Cells lacking functional
BRCA1 and BRCA2 are diverted to using more error-prone repair pathways, thus
risking the occurrence of chromosomal abnormalities and genetic instability. Apart
from a role in homologous recombination, which is best documented for BRCA2,
additional functions have been proposed for BRCA1 in nucleotide excision repair,
cell cycle checkpoint control, protein ubiquitination, chromatin remodelling and
• • •• •• • 1 96 19R
transcriptional activation of oxidative stress-responsive genes " .
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BRCA1 was first to be identified and cloned . The human gene spans
approximately 80 kb on 17q 12-21, encoding a protein of 1863 aa. To date, more than
250 BRCA1 mutations have been described, which span the entire coding sequence
of the gene. The majority of these mutations have been identified in families with
multiple cancer cases. 87% of all described germ-line mutations result in either
truncation or absence of the protein, brought about by frameshift, nonsense,
splice-site, and genomic deletion changes. BRCA2 is located on human chromosome
13q 12-13140. It encodes a protein of 3418 aa. As in BRCA1, mutations in BRCA2
have been described throughout its coding region. The majority of mutations are
frameshifts resulting in protein truncation. Population-based studies have suggested
that the lifetime risk of ovarian cancer is about 20-30% in BRCA1 mutation carriers,
albeit this increased risk is not manifest until around the age of 40141. BRCA2
mutations were initially thought to play a much less important role in familial
ovarian cancer, whereas newer evidence suggests that as much as 35% of hereditary
ovarian cancer cases might be attributable to BRCA2 mutations142. A cluster of
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mutations in the BRCA2 gene, known as the ovarian cancer cluster region, is
associated with increased ovarian and decreased breast cancer risk143. The prevalence
of mutations in 316 cases of British origin unselected for family history was found to
be 2.5% for BRCA1 and 2.2% for BRCA2144.
The above-described high-penetrance genes are thought to account only for a
proportion of familial risk. Although there are no reported estimates of the proportion
of excess familial risk conferred by these genes, BRCA1 will account for 16% of this
excess risk, assuming a mutation frequency of 1:1000 and a 20-fold risk, whereas
BRCA2 will account for 8%, assuming a mutation frequency of 1:500 and a 10-fold
increase in risk. Hence, these genes might be contributing only 30% of the known
excess risk131.
HNPCC is characterised by defects in the mismatch repair (MMR) system,
which is responsible for the repair of nucleotide changes during DNA replication,
thus preventing the propagation of mutations. The five main genes associated with
MMR are MLH1, MSH2, MSPI3, PMS1 and PMS2. Mutations in MSH2 and MLH1
account for 70% of HNPCC cases, with PMS1, PMS2 and MSH3 accounting for
some of the rest14'. The cumulative risk of ovarian cancer in MMR gene mutation
carriers from HNPCC families is 12%146.
Low-penetrance susceptibility genes are more difficult to identify mainly due
to issues of experimental design. The experimental approach usually employed
involves association studies, which aim at discovering polymorphisms that confer
risk of developing a disease. With respect to ovarian cancer, there have been
numerous reports of case-control studies of polymorphisms, which have identified
various risk-associated alleles. Examples include polymorphisms in TP53U1,
GSTM1, GSTTlm and HRAS149. TPS3 would appear to be the best candidate thus
far, although the case for this is not proven. The role of TP53 will be elaborated upon
in relation to sporadic EOC, although it is also associated with the familial type of
the disease. It should be noted that problems associated with statistical power and
significance, as well as the importance of modulation by other genes and
environmental factors, have hampered the value of published association studies.
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1.2.7.2 Sporadic EOC
Very few cases of BRCA1 or BRCA2 mutations have been reported in
sporadic EOC150'151. Nonetheless, decreased expression of BRCA1 has been
documented, and accounted for by promoter hypermethylation152. In contrast, the
same study found over-expression of BRCA2 in sporadic EOC, which was also
caused epigenetically, by promoter hypomethylation. The significance of this finding
remains to be elucidated.
A multitude of other genes have been implicated in sporadic EOC60. Most of
the recognized oncogenes are either genes that are implicated in other types of cancer
and were thus chosen for study in ovarian cancer or have been identified by being
over-expressed or amplified and were subsequently pursued in functional studies. It
should be noted that little is known about how and at what level oncogenes
• • 1
participate in the malignant transformation of the ovarian surface epithelium .
Tumour suppressor genes have been identified by positional cloning based on
cytogenetic, linkage and LoH studies; expression and/or promoter methylation
profiling; differential display; and functional analysis134. LoH studies are the most
common approach for identifying TSGs in sporadic cancers. OPCML is one example
of a gene originally identified by LoH and now regarded as a novel TSG in sporadic
21 • •EOC . Interestingly, this gene also exemplifies a growing list of TSGs that are
inactivated primarily or exclusively by epigenetic silencing through promoter
hypermethylation, rather than somatic mutations.
Tables 1.2 and 1.3 illustrate the genes that have been linked to sporadic EOC
to date. These genes were identified by literature searches using the following
criteria: up-regulation and/or activating mutations and/or oncogenic properties for
genes putatively termed oncogenes; down-regulation and/or inactivating mutations
and/or anti-oncogenic properties for genes putatively termed tumour suppressor
genes. These tables exclude genes that have been solely identified by cell line
•
analyses or microarray evidence, or have been reported by studies focusing
exclusively on chemoresponse or clinical outcome. References are given as examples
and are not exhaustive.
More detailed information is provided below on the two most extensively




ERBB2 is an oncogene located on 17q21.1 encoding a member of the epidermal
growth factor (EGF) receptor family of receptor protein kinases155. The ERBB2
protein does not have a ligand-binding domain and therefore binds to other
ligand-bound EGF receptor family members, forming heterodimers that enhance
kinase-mediated activation of downstream signalling pathways'36. Examples
include the MAPK and PI3K pathways.
Amplification and/or over-expression of ERBB2 have been extensively
documented in ovarian cancer (see references in Table 1.2), with conflicting data
regarding associations with clinicopathologic variables. A recent study has
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reported a prevalence of 27% for over-expression of the gene , which is
representative of the central tendency in most studies. Functionally, the
oncogenic properties of ERBB2 have been demonstrated in ovarian cancer, by
1 SR
transfection of the gene in rat OSE cells .
• KRAS
The KRAS gene, which is located on 12p 12.1, encodes an oncoprotein that
belongs to the small GTPase superfamily139"161. It is thought to have a crucial
function in the regulation of growth in eukaryotic cells, by being involved in the
control of cell proliferation, differentiation and apoptosis.
KRAS is frequently mutated in ovarian cancer, in particular mucinous
carcinomas, wherein it has a mutation prevalence of approximately 50% (see
references in Table 1.2). Interestingly, KRAS mutations are also frequent in
borderline tumours, again especially of the mucinous type, suggesting that these
tumours represent a precursor lesion of the invasive carcinoma.
Tumour suppressor genes
• TP53
The TP53 gene on 17pl3.1 encodes a nuclear protein that is pivotal in the
regulation of the cell cycle, particularly in the transition from GO to G1 . Upon
cellular stress, particularly DNA damage, the p53 protein can arrest cell cycle
progression, thus allowing DNA repair, or lead to apoptosis. p53 is a
DNA-binding protein containing DNA binding, oligomerisation and transcription
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activation domains. It is postulated to bind as a tetramer to specific cis elements
and activate expression of downstream genes that inhibit growth and/or invasion,
thereby exhibiting tumour suppressor properties. The protein also has
transcription-independent tumour suppressor functions, in DNA repair and
1/T
#
recombination . TP53 is expressed at very low levels in normal cells; however,
in a variety of transformed cell lines, its expression increases, which is believed
to contribute to transformation and malignancy. Mutations in the TP53 gene
result in the loss of proliferation controls and hence inefficient DNA repair and
genetic instability. The most common alterations in the TP53 gene are missense
mutations in its DNA-binding domain, which result in the loss of its tumour
suppressor activity and over-expression of non-functional p53 in the nucleus.
Alterations of the TP53 gene occur not only as somatic mutations in human
malignancies, but also as germ-line mutations in some cancer-prone families with
Li-Fraumeni syndrome.
TP53 represents the TSG that is most frequently associated with ovarian
1 fx'K • •
cancer . In ovarian cancer, pooled data show TP53 over-expression in 17% of
borderline tumours, 39% of early and 55% of advanced stage cases.
Over-expression of TP53 is more frequent in serous carcinomas (56%) than other
histological types and p53 immunopositivity is highest among grade 3 tumours.
TP53 mutations are met in 45% of all carcinomas, again being more prevalent in
the serous type and advanced-stage disease. In contrast, only 5% of LMP
tumours have TP53 mutations. The majority of studies have not found
associations between aberration of TP53 and ovarian cancer prognosis.
• PTEN
This gene was identified as a TSG on 10q23 that is mutated in a large number of
cancers at high frequency164. It encodes a protein that contains a tension-like
domain, as well as a catalytic domain similar to that of dual specificity protein
tyrosine phosphatases165. Unlike most of the protein tyrosine phosphatases,
however, PTEN preferentially dephosphorylates phosphoinositide substrates. It
negatively regulates intracellular levels of phosphatidylinositol-
3,4,5-trisphosphate, thereby functioning as a tumour suppressor by inhibiting the
AKT/PKB signalling pathway166.
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Mutations in the PTEN gene are well documented in ovarian cancer, although the
• • • 167overall data regarding their frequency and importance are conflicting . A
number of studies have reported mutations and/or loss of PTEN expression (see
references in Table 1.3), whereas others did not find a role for this gene in
EOC168. Aberrations are often associated with endometrioid histology and arise
through diverse mechanisms, such as allelic loss, intragenic deletion and
epigenetic silencing169. Functionally, PTEN expression in ovarian cancer cell
• • • • 170 171lines results in growth suppression and inhibition ofmigration ' .
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Table 1.2 Putative oncogenes involved in sporadic EOC
Potential oncogenes reported in sporadic ovarian cancer. Gene symbols displayed
according to the HUGO Gene Nomenclature Committee.
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Table 1.3 Putative TSGs involved in sporadic EOC
Potential tumour suppressor genes reported in sporadic ovarian cancer. Gene




The hypothesis that OPCML is a tumour suppressor gene in epithelial ovarian
cancer incurred the realisation that the knowledge of the biology of this gene and the
family where it belongs is very limited. The IgLON family has been historically
associated with the central nervous system due to the fact that its members are
prototypically expressed in this locality. Furthermore, the emphasis of IgLON study
has been primarily placed on chick and rat models of neural function. In contrast, our
appreciation of what OPCML and its relatives do outside the brain is rather obscure.
This is mainly due to the fact that until recently there was limited interest on
exploring the biology of the IgLON family at a more generalised level. Nonetheless,
assuming that OPCML plays a role in ovarian carcinogenesis, it has to do so in a way
whereby it has functions in the normal ovary that are impaired in ovarian cancer. It is
imperative that these potential functions be explored; this realisation provided the
momentum for the conception of this project. Not only is there a need to understand
why and how OPCML is linked with ovarian cancer, but also to establish the role of
OPCML in normal ovarian physiology. These issues should be addressed in the
context of the position of OPCML within the IgLON family and its interactions with
the rest of the family.
1.3.2 Objectives
In view of the aforementioned reasoning, the project that is presented in this
thesis has focused on aspects of OPCML and IgLON biology that have not been
previously studied. The primary aim has been the functional characterisation of
OPCML, in particular with regard to roles that are relevant in normal ovarian
physiology and ovarian tumourigenesis. What attributes does OPCML have in order
to function as a tumour suppressor? How does its dysfunction contribute to ovarian
carcinogenesis? In addition to the identification of novel functions, the secondary
objective of this work has been the characterisation of not only OPCML, but also the
IgLON family as a whole, at the level of gene expression. More specically, questions
regarding the expression of the family in development, in normal adult tissues, and
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also in ovarian cancer were raised. Overall, the project was developed to address
issues ofOPCML function and IgLON expression. Attempts to meet these objectives
were shaped by consideration of models and ideas that are significant in ovarian
cancer.
1.3.3 Approach
In order to explore the functions of OPCML in vitro, the gene was expressed
in two different contexts. Firstly, an inducible system of expression was created and
characterised for the purposes of this work. The inducible system used was a Tet-On
system of regulated expression in the cervical cancer HeLa cell line. The HeLa
Tet-On cell line was used to express the wild-type OPCML sequence. Secondly, a
previously generated resource was also used, an over-expression system based on the
ovarian cancer SKOV-3 cell line. Both wild-type and mutant (harbouring the P95R
mutation) OPCML were expressed in SKOV-3 cells. Hence, the functional
characterisation of OPCML was undertaken both at a regulated and an
over-expression level, in two different contexts. To allow the study ofOPCML in an
ovarian cancer cell line in a regulated fashion of expression, a SKOV-3 based Tet-On
system was also developed. However, due to time constraints, this system was not
ready for use in functional work.
Issues of IgLON expression were addressed in both mouse and human using
a variety of experimental approaches at both the RNA and protein levels. IgLON
expression was examined developmentally, in adult life, in cancer cell lines and in
sporadic EOC. Methodologically, it was attempted to use a diverse range of






2.1.1 Transfected cell line resources
The following transfected cell lines were used, which had been previously
generated by members of the research group (Table 2.1):
Designation Cell line Vector Insert
SKOV-3 OPCMLwt SKOV-3 derivative clone pcDNA3.1/Zeo (Invitrogen) wild-type humanOPCML'
SKOV-3 OPCMLMut SKOV-3 derivative clone pcDNA3.1/Zeo (Invitrogen)
mutant human
OPCML"
SKOV-3 HNT SKOV-3 pcDNA3.1 (Invitrogen) human HNT"
SKOV-3 LSAMP SKOV-3 derivative clone pcDNA3.1/Zeo (Invitrogen) human LSAMP"
SKOV-3 NEGRI SKOV-3 derivative clone pcDNA3.1/Zeo (Invitrogen) human NEGRIv
Table 2.1 Available transfected cell lines
Cell lines used in this project that had been previously generated. HeLa is a cervical
cancer cell line; SKOV-3 is an ovarian cancer cell line. Vector maps are shown in
Appendix C.
2.1.2 Maintenance of cell lines
All cell lines were maintained at 37°C in a humidified atmosphere of 5% CO2
in an open-air incubator. Cell culture plasticware was purchased from Nunc™.
Media, PBS (Appendix A) and dissociation solutions were prewarmed to 37°C prior
to use.
The SKOV-3 derivative cell line, as well as SKOV-3 HNT, was maintained
in RPMI 1640 medium (Invitrogen), containing 10% (v/v) heat-inactivated foetal calf
serum (FCS), penicillin (100 units/ml), streptomycin (100 pg/ml), and geneticin (600
(ig/ml). The cell lines transfected with the other IgLON constructs were maintained
in the same medium, with the addition of zeocin (125 pg/pl).
' Nucleotides 24-1110 ofGenBank NM_002542.2
11 As above, but with C>G at position 334 of the sequence
"' Nucleotides 248-1600 ofGenBank AF126426.1
'"Nucleotides 484-1520 of GenBank NM_002338.2
"Nucleotides 84-1233 ofGenBank NM 173808.2
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Double stable HeLa Tet-On cells harbouring an inducible OPCML construct
were cultured in DMEM (Invitrogen) containing 10% (v/v) FCS, as well as the
following antibiotics: penicillin (100 units/ml), streptomycin (100 pg/ml), geneticin
(100 pg/ml) and hygromycin B (100 pg/ml). SKOV-3 Tet-On cell lines were
maintained in RPMI 1640 medium (Invitrogen) supplemented with 10% (v/v) FCS,
as well as the following antibiotics: penicillin (100 units/ml), streptomycin (100
pg/ml), and geneticin (300 pg/ml). SKOV-3 Tet-On OPCMF cells were maintained
in the same medium, with the addition of hygromycin B (50 pg/ml)
The medium was changed twice a week.
2.1.3 Cell passage
Cells were routinely passaged when reaching confluency. The medium was
removed, cells were washed twice with PBS and an appropriate amount of trypsin
was added. Cells were placed in an incubator at 37°C / 5% CO2 until completely
detached. The effect of trypsin was counteracted with the addition of medium
containing 10% (v/v) FCS. An appropriate volume of the cell suspension was
transferred to a fresh cell culture container, the medium was replenished, and the
cells were returned to the incubator.
2.1.4 Stable and transient transfections of cell lines
Two rounds of stable transfections were undertaken in order to create the
SKOV-3 Tet-On cell line expressing wild-type OPCML. In the first round, the
pTet-On vector was introduced in SKOV-3 cells; in the second round, the
pTRE-Tight OPCMF construct was introduced in the selected SKOV-3 Tet-On
clone.
Transfections into cells were carried out using Fipofectin® Reagent
(Invitrogen), according to the manufacturer's guidelines. For stable transfections,
2x1 CP cells were plated out in 6 cm petri dishes, in quadruplicate. The cells were
incubated in the appropriate medium supplemented with 10% (v/v) FCS at 37°C / 5%
CO2 for 18-24 h, until 40-60% confluent. The following day, two sets of 1.5 ml
eppendorf tubes were prepared. The first set contained 100 pi of serum-free medium
without any antibiotics, 2 pg of vector DNA (for the first transfection) or the same
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amount of construct DNA (for the second transfection) and 0.11 gg of Linear
Hygromycin Marker (for the second transfection; from BD Biosciences). The second
set contained 100 gl of serum-free medium without any antibiotics and 12 gl of
Lipofectin. The tubes were allowed to stand at room temperature for 30 min. The
contents of one tube from the first set and one tube from the second set were mixed
in a 15 ml tube and allowed to stand at room temperature for a further 15 min.
During this time, the plates containing the cells were drained and rinsed once with
serum-free medium. 1.8 ml of serum-free medium without any antibiotics were
added to each 15 ml tube, which was then tapped gently to mix. The contents of each
tube were poured onto the appropriate plate. The plates were placed in an incubator
at 37°C / 5% CO2. After six hours, the medium was replaced with serum-containing
medium without any antibiotics and the plates were returned to the incubator. After
48 h, the cells were trypsinised and transferred into a 175 cm2 flask. 50 ml of
selection medium was added [RPMI 1640 (Invitrogen) containing 10% (v/v) FCS,
penicillin (100 units/ml), streptomycin (100 gg/ml) and geneticin (600 gg/ml) for
transfection with pTet-On; as above, but with the addition of hygromycin B (50
gg/ml) for transfection with pTRE-Tight OPCML]. The flasks were refilled with 30
ml selection medium every 3-4 days until all the cells in the control flask had
completely died and colonies were clearly visible in the other flasks. At that point,
the medium was removed from the flasks, which were washed twice with PBS. A
drop of trypsin was added to each colony with a fine pastette. Using the pastette, the
colony was gently scraped while being aspirated and transferred to a 24-well plate.
When all colonies had been transferred, the 24-well plates were placed in an
incubator at 37°C / 5% CO2.
For transient transfections, the same protocol was followed, however, instead
of selection medium, the cells were grown for 48 h in medium containing 10% (v/v)
FCS, but no selection antibiotics. After this period, the cells were assayed for gene
activity.
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2.1.5 Cryopreservation of cells: freezing and recovery
Prior to being frozen, cells were grown until 70-80% confluent. They were
washed twice with PBS, trypsinised and pelleted. The cell pellets were resuspended
in an appropriate volume of ice-cold freezing medium [1% (v/v) DMSO in FCS] and
transferred into cryovials in 1.5 ml aliquots. The cryovials were placed in a -70°C
freezer for one to two days and then transferred to a liquid nitrogen tank for
permanent storage.
In order to recover cells from liquid nitrogen storage, they were thawed at
37°C in a water bath. When almost thawed, cells were slowly added to tubes
containing 10 ml of medium with 10% (v/v) FCS. The cell suspensions were pelleted
by centrifugation at 500 g for 5 min, washed with 10 ml of medium containing 10%
(v/v) FCS and respun. Upon resuspension in the appropriate medium, the cell
suspension was transferred to cell culture flasks and placed in an incubator at 37°C /
5% CO2. The following day, if confluent, the cells were passaged; otherwise, the
medium was replaced.
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2.2 Cloning and general nucleic acid manipulation
2.2.1 Cloning overview
In order to generate riboprobes for the detection of mouse IgLON messages
by whole-mount in situ hybridisations, the respective cDNAs were amplified from
mouse brain and cloned into the pGEM®-T Easy Vector (Promega; Appendix C).
This vector contains SP6 and T7 promoter sites, enabling in vitro transcription.
For the generation of inducible human IgLON constructs, the respective
cDNAs were excised from pGEM®-T Easy, wherein they had been previously
cloned, and cloned into pTRE-Tight (BD Biosciences; Appendix C).
2.2.2 Digestion of DNA with restriction endonucleases
Digestion with restriction enzymes (REs) was used widely in this project for
three main purposes: linearization of plasmids, obtaining nucleic acid fragments for
cloning and screening for integration of inserts. Restriction enzymes and
accompanying digestion buffers were purchased from Roche. DNA was mixed with
an appropriate amount of RE and incubated from 1.5 to 3 h at 37°C. Complete
digestion was confirmed by agarose gel electrophoresis of the digestion reaction.
2.2.3 Extraction of DNA fragments from agarose gels
In order to extract DNA from an agarose gel, the QIAquick® Gel Extraction
Kit was used (Qiagen). DNA fragments were subjected to electrophoresis on a
low-melting SeaPlaque® (BMA) agarose-TAE gel stained with ethidium bromide.
The bands were visualised by UV light and excised from the gels using a clean
scalpel. The gel slices were transferred to 1.5 ml microcentrifuge tubes and weighed.
A volume of Buffer PB equivalent to three times the weight of each slice was added.
The tubes were heated at 50°C and vortexed periodically until the gel slices
dissolved. One gel volume of isopropanol was added to each tube and the samples
were mixed. The samples were applied to columns placed on collection tubes, which
were centrifuged for 1 min at 13,000 rpm in a microcentrifuge. The flow-through
was discarded. To remove all traces of agarose, 0.5 ml of Buffer QG was added to
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the columns, which were centrifuged for 1 min at 13,000 rpm in a microcentrifuge.
The columns were washed by adding 0.50 ml of Buffer PE and letting stand for 3
min. They were then centrifuged for 1 min at 13,000 rpm in a microcentrifuge. The
flow-through was discarded and the columns were centrifuged for an additional 1
min at 13,000 rpm in a microcentrifuge, to remove residual Buffer PE. The columns
were transferred to clean 1.5 ml microcentrifuge columns. To elute DNA, 30 pi of
Buffer EB were added to the centre of each column; the columns were let to stand for
1 min and were spun for 1 min at 13,000 rpm in a microcentrifuge. Eluted DNA was
quantified (section 2.2.10) and then stored at -20°C.
2.2.4 Phenol extraction and ethanol precipitation of DNA
In order to purify DNA from a solution, an equal volume of 24:24:1 (v/v/v)
phenol/chloroform/isoamyl alcohol (Sigma) was added to it in a 1.5 ml
microcentrifuge tube. The tube was vortexed rigorously for 10 s and
microcentrifuged for 30 s at 13,000 rpm and room temperature. The aqueous phase
was carefully removed and transferred to a fresh 1.5 ml microcentrifuge tube. An
equal volume of 24:1 (v/v) chloroform/isoamyl alcohol (Sigma) was added, the tube
was vortexed rigorously for 10 s and microcentrifuged for 30 s at 13,000 rpm and
room temperature. The aqueous phase was carefully removed and transferred to a
fresh 1.5 ml microcentrifuge tube. 1/10 volume of 3 M sodium acetate pEl 5.2 was
added and the solution was mixed by flicking several times. 2 to 2.5 volumes of
ice-cold absolute ethanol were added; the solution was vortexed and placed at -70°C
for an hour. Following microcentrifugation for 15 min at 13,000 rpm and 4°C, the
supernatant was discarded and the pellet was washed with 1 ml of 70% (v/v) ethanol
for 10 min at 13,000 rpm at room temperature. The supernatant was removed by
pipetting and the pellet was dried in a SpeedVac® Plus (Savant) evaporator. The
pellet was finally dissolved in an appropriate volume of ultra-pure water and stored
at -20°C.
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2.2.5 Dephosphorylation of vector DNA
Before setting ligation reactions between a vector and an insert, the former
needs to be dephosphorylated in order to minimise its propensity for self-ligation. 50
pi of purified linearised vector (equivalent to 20 pg before purification) were mixed
with 2 U of Shrimp Alkaline Phosphatase (Roche), 6 pi of lOx Dephosphorylation
Buffer (Roche) and 2 pi of ultra-pure water. The mixture was incubated for 30 min at
37°C. After dephosporylation and before the vector was considered ready to use in
ligations, it was subjected to a further round of purification.
2.2.6 Ligation reactions
fa
Ligation reactions were performed using the components of the pGEM -T
Easy Vector System (Promega). Reactions were set up by combining the following
(Table 2.2):
Component Amount
2x Rapid Ligation Buffer 5 pi
Vector 50 ng
Purified PCR product 3 pi
T4 DNA Ligase (3 Weiss units/pl) 1 pi
Table 2.2 Ligation reaction
Reactions were mixed by pipetting and incubated over-night at 4°C.
2.2.7 Transformation of bacteria
JM109 High Efficiency Competent Cells (Promega) were used as a bacterial
system that is compatible with blue/white colour screening and standard ampicillin
selection. Aliquots of the above cells were removed from storage at -70°C and
thawed on ice, until just thawed. The cells were mixed by gently flicking the tubes.
Meanwhile, 2 pi of a ligation reaction or 1 ng of plasmid DNA were added to sterile
17x100 mm polypropylene tubes on ice. 50 pi of thawed cells were added to each
tube; the tubes were gently mixed by flicking and placed on ice for 20 min. The cells
were then heat-shocked for 45-50 s in a water bath at exactly 42°C. After the heat
shock, the tubes were returned on ice for 2 min. 950 pi of room temperature SOC
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medium (Appendix A) were added to each tube. The cells were incubated with
shaking for 1.5 h at 37°C and 180 rpm. 100 or 900 pi of each transformation culture
were plated onto LB plates, containing the appropriate selection additives: ampicillin
at 100 mg/ml, X-gal at 80 mg/ml and 0.5 mM IPTG. The plates were incubated
over-night at 37°C.
2.2.8 Preparation of bacterial glycerol stocks
10 ml of over-night cultures were centrifuged at 3,220 g for 10 min. Each cell
pellet was resuspended in 3 ml of 20-30% (v/v) glycerol in LB medium, divided into
two 1.5 ml aliquots and stored at -20°C.
2.2.9 Purification of plasmid DNA
(r)
Small-scale purifications of plasmid DNA were prepared using the QIAprep
Spin Miniprep kit (Qiagen), according to the manufacturer's instructions. 5 ml of
over-night bacterial cultures were centrifuged at 3,220 g for 10 min. The pellets were
resuspended in 250 pi Buffer and transferred to 1.5 ml microcentrifuge tubes. 250 pi
of Buffer P2 were added and the tubes were inverted 6 times. 350 pi of Buffer N3
were added and the tubes were inverted 6 times. The tubes were then centrifuged for
10 min at 13,000 rpm in a microcentrifuge. The supernatants were transferred into
spin columns placed on a vacuum manifold and vacuum was applied. The columns
were washed by adding 0.5 ml of Buffer PB and applying vacuum. The columns
were then washed with 0.75 ml of Buffer PE and by applying vacuum. The columns
were transferred to their receptacles and centrifuged for 1 min at 13,000 rpm in a
microcentrifuge. The columns were placed in 1.5 ml microcentrifuge tubes. Finally,
50 pi of Elution Buffer were added to the centre of each column; the columns were
incubated for 1 min and centrifuged at 13,000 rpm in a microcentrifuge to elute the
DNA. The DNA samples were quantified (section 2.2.10) and then stored at -20°C.
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2.2.10 Quantification of DNA
In order to determine the concentration and purity of DNA samples,
appropriate dilutions were made (usually 1 in 200) in ultra-pure water. The optical
densities of the diluted samples were then measured at 260 and 280 nm in a Unicam
UV2 Spectrometer. The concentration was calculated according to the rule that DNA
with an optical density (OD) at 260 nm of 1 has a concentration of 50 mg/ml. Purity
was determined by the OD260/OD280 ratio, with acceptable ratios being between 1.6
2.2.11 Treatment of PCR products prior to sequencing
Prior to being sequenced, PCR products were subjected to enzymatic removal
of excess primers and unincorporated nucleotides. 3 pi of a PCR product were
combined with 5 U of Exonuclease I (Amersham Biosciences), 1 U of Shrimp
Alkaline Phosphatase (Amersham Biosciences) and 3.5 pi of ultra-pure water. The
reactions were incubated at 37°C for 15 min and then at 80°C for 15 min. The
purified products were then either prepared for sequencing or stored at -20°C until
used.
2.2.12 Preparation of reactions for fluorescent cycle sequencing
In order to prepare sequencing reactions, the BigDye® v3.1 Dye Terminator
Cycle Sequencing Kit (Applied Biosystems) was used, according to the
manufacturer's instructions. For a 10 pi reaction, the following were combined in a
0.5 ml eppendorf tube: 100 ng ofDNA or 3 pi ofPCR product, 1.6 pmol of primer, 2
pi of BigDye and ultra-pure water to the final volume. The reaction was mixed by













The reactions were removed from the thermal cycler and briefly spun. 2.5 pi
of 125 mM EDTA and 30 pi of absolute ethanol were added to each tube. After
vortexing, the tubes were incubated for 15 min at room temperature and spun in a
microcentrifuge at 13,000 rpm for 20 min. The ethanol was removed by pipetting and
30 pi of 70% (v/v) ethanol was added. The tubes were spun in a microcentrifuge at
4°C and 13,000 rpm for 5 min. The ethanol was removed and the tubes were allowed
to air-dry.
The pellets were given to the Wellcome Trust Clinical Research Facility,
Western General Hospital, for automated processing in a 3730 Genetic Analyser
(Applied Biosystems).
2.2.13 RNA extraction and DNase I treatment from cultured cells
RNA was extracted from cells in culture using the Absolutely RNA™
RT-PCR Miniprep Kit (Stratagene), according to the manufacturer's instructions.
The medium was removed from exponentially-growing cells, usually growing in a 75
cm" flask or a 10 cm dish. A mixture of 600 pi of Lysis Buffer and 4.3 pi of
beta-mercaptoethanol was added per flask and spread evenly over the surface. The
lysates were mixed and collected by repeated pipetting and transferred to 1.5 ml
microcentrifuge tubes. The tubes were vortexed and stored at -70°C for future
processing.
To isolate RNA, the homogenates were thawed and transferred to Prefilter
Spin Cups seated in 2 ml receptacle tubes and spun in a microcentrifuge at 13,000
rpm for 5 min. An equal volume of 70% (v/v) ethanol was added to each filtrate and
the tubes were vortexed for 5 s. Half of each mixture was transferred to a
Fibre-Matrix Spin Cup seated in a fresh 2 ml receptacle and spun in a
microcentrifuge at 13,000 rpm for 1 min. The filtrates were discarded and the
centrifugation was repeated for the remainder of the mixtures.
600 pi of Low-Salt Wash Buffer were added to each sample. The samples
were spun in a microcentrifuge at 13,000 rpm for 1 min. The filtrates were discarded
and the samples were spun for 2 min. 55 pi of DNase solution (5 pi of RNase-Free
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DNase I and 50 pi of DNase Digestion Buffer) were added directly onto each fibre
matrix. The samples were incubated at 37°C for 30 min in an air incubator.
600 pi of High-Salt Wash Buffer were added to each spin cup and the
samples were spun in a microcentrifuge at 13,000 rpm for 1 min. The filtrates were
discarded, 600 pi of Low-Salt Wash Buffer were added, and the samples were spun
again as previously. The filtrates were discarded, 300 pi of Low-Salt Wash Buffer
were added and the samples were spun in a microcentrifuge at 13,000 rpm for 2 min
to dry the fibre matrix.
The spin cups were transferred to 1.5 ml microcentrifuge tubes. Elution
Buffer was warmed at 60°C and 50 pi were added directly onto the centre of the fibre
matrix. The samples were incubated at room temperature for 2 min and then spun in
a microcentrifuge at 13,000 rpm for 1 min. The elution step was repeated with a
further 50 pi ofElution Buffer.
The purified RNA was quantified (section 2.2.15) and stored at -70°C.
2.2.14 RNA extraction from mouse brain
(r) • • • •
Total RNA was prepared from tissue using the RNeasy Midi Kit (Qiagen),
according to the manufacturer's instructions. A whole mouse brain was firstly
weighed and then divided in two using a sterile disposable scalpel. Each piece of
tissue was transferred to a 15 ml tube, into which 1 ml of Buffer RLT was added.
The tissue was dismembranated at 180 rpm for 1 min. 3 ml of Buffer RLT were
added and the lysates were centrifuged at 21,885 g and 23°C for 10 min. The
supernatants were transferred to 15 ml centrifuge tubes. 4 ml of 70% (v/v) ethanol
were added and the tubes were mixed immediately by rigorous shaking. Each
sample was then split into two and applied to RNeasy columns placed on 15 ml
centrifuge tubes. The tubes were centrifuged at 21,885 g and 23°C for 5 min. After
discarding the flow-through, each column was washed with 4 ml ofBuffer RW1. The
tubes were again centrifuged as above. The flow-through was discarded and each
column was washed with 2.5 ml of Buffer RPE. The tubes were centrifuged at
21,885 g and 23°C for 2 min. The wash was repeated, followed by an extended
centrifugation for 5 min. The columns were then transferred onto fresh 15 ml
centrifuge tubes. RNA was eluted in two elution steps. Each step involved the
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addition of 150 pi of ultra-pure water, incubation at room temperature for 1 min and
centrifugation at 21,885 g and 23°C for 3 min. At the end of the elution, the contents
of each tube were mixed together.
The purified RNA was quantified (section 2.2.15) and stored at -70°C.
2.2.15 Quantification of RNA
In order to determine the concentration and purity of purified RNA samples,
appropriate dilutions were made (usually 1 in 100) in ultra-pure water. The optical
densities of the diluted samples were measured at 260 and 280 nm in a Unicam UV2
Spectrometer. The concentration was calculated according to the rule that RNA with
an optical density (OD) at 260 nm of 1 has a concentration of 40 mg/ml. The purity
was determined by the OD260/OD280 ratio, with acceptable ratios being between 1.6
and 2.1.
2.2.16 DNase I treatment of RNA
When samples had not been DNase I-treated during the RNA extraction
process, they were treated using the DNA-free™ DNase Treatment and Removal
Reagents (Ambion), as per the manufacturer's instructions. 0.1 volume of lOx DNase
I Buffer and 1 pi of DNase I (i.e. 2 units) were added to 10 pg of RNA. The sample
was mixed gently and incubated at 37°C for 30 min. 0.1 volume or 5 pi (whichever
was greater) of DNase Inactivation Reagent were added to the sample. After mixing
well, the sample was incubated at room temperature for 2 min and centrifuged at
10,000 g for 1 min to pellet the DNase Inactivation Reagent. The DNase-treated
sample (supernatant) was then transferred to a fresh tube and stored at -70°C.
2.2.17 First strand cDNA synthesis from total RNA
cDNA was synthesised from total RNA using the 1st Strand cDNA Synthesis
Kit for RT-PCR (AMV) by Roche, following the manufacturer's guidelines. 1 pg of
DNase I-treated total RNA was mixed with ultra-pure water to a final volume of 8.2
pi.
The following components were mixed in a sterile 0.5 ml microcentrifuge
tube (Table 2.3):
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Reagent Volume for 1 sample (pi)
10x Reaction Buffer 2
25 mM MgCI2 4
Deoxynucleotide Mix 2
Random Primer p(dN)6 2
RNase Inhibitor 1
AMV Reverse Transcriptase 0.8
RNA 8.2
Table 2.3 First strand cDNA synthesis reaction
The above volumes are for synthesis of 20 yil of cDNA. For lower or higher scales of
synthesis, these volumes were adapted as appropriate.
The mixture was briefly vortexed and centrifuged to collect it at the bottom of
the tube. The reaction was incubated at 25°C for 10 min and then at 42°C for 60 min
on a PCR block. Finally, the reverse transcriptase was denatured by incubation at
99°C for 5 min, followed by cooling on ice for 5 min.
Samples were stored at -70°C.
2.2.18 Agarose gel electrophoresis
DNA or RNA fragments were visualised using agarose-TAE gel
electrophoresis. Gels were prepared by dissolving 1% or 2% (w/v) agarose in lx
TAE buffer (Appendix A). Ethidium bromide was added to a final concentration of
approximately 0.5 pg/ml. Samples were mixed with gel loading dye (Appendix A),
loaded and run in lx TAE buffer. Bands were visualised by UV illumination and
their sizes were determined by comparison to markers (Ready-Load™ 1 kb and 100
bp DNA Ladders from Invitrogen).
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2.3 Biological material
2.3.1 Multiple-tissue cDNA panels
The following multiple tissue cDNA panels were used (all purchased from
BD Biosciences): Human MTC™ Panels I and II; Human Foetal MTC™; and Mouse
MTC™ Panels 1 and III.
2.3.2 Mouse embryos
Embryos were collected from CD1 mice observing good animal handling
practices. Time of conception was estimated by cervical smearing of mated female
mice.
2.3.3 Mouse sections
Mouse embryo sections were purchased from Zyagen. Mouse tissue arrays
were purchased from Chemicon International.
2.3.4 Human ovarian samples
Primary ovarian tumour material and non-malignant tissues were obtained
from patients having undergone gynaecological surgery in the Lothian University
Hospitals NHS Trust under ethical approval granted by the Lothian NHS Board
Local Research Ethics Committee. Tissue samples were excised and stored in liquid
nitrogen. Non-malignant tissue samples were derived from patients that underwent
bilateral oophorectomies for suspected malignancy, but were found to have benign
histologies; samples were collected from apparently normal contralateral ovaries.
2.3.5 Human embryo sections
Human embryo sections were provided by the Human Developmental
Biology Resource. Ethical approval for the use of these sections was granted
specifically for this work by the Lothian NHS Board Local Research Ethics
Committee.
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2.4 Reverse transcription polymerase chain reaction
2.4.1 General
RT-PCR was carried out extensively in this project, either to amplify cDNA
fragments for cloning purposes, or to detect RNA messages of interest in expression
studies. The same principles of optimisation were applied for both kinds of
experiments: specificity of target amplification and sensitivity of the reaction to the
desired extent. Reactions were prepared as follows: 0.5 pM of each primer, 0.2 mM
of dNTPs, lx reaction buffer, 1.5 mM of MgCfi [all three aforementioned reagents
were included in the 1st Strand cDNA synthesis kit for RT-PCR (AMV) from
Roche], 1 U of Pic Taq polymerase (Cancer Research UK) and 1/12.5 volume of
cDNA. Cycling consisted of an initial denaturation for 5 min at 94°C, followed by a
4-cycle touchdown (30 s at 94°C, 30 s at 67°C decreasing by 3°C per additional
cycle, and 45 s at 72°C) and then 30 cycles of 30 s at 94°C, 30 s at 55°C and 45 s at
72°C, and a final extension for 5 min at 72°C. MJ Research DNA Engine Tetrad
thermal cyclers were used for all RT-PCR. All primers that were used are listed in
Appendix B. These were designed using Primer3 v0.2 (Whitehead Institute of
Biomedical Research).
2.4.2 Real-time quantitative RT-PCR
2.4.2.1 General considerations
In designing real-time PCR experiments, several factors were taken under
consideration. A basic requirement was that the target sequence be short, around 100
bp. The conditions of cycling were optimised such that the reactions could be
satisfactory with respect to both sensitivity and specificity. The RNA sources (cell
line or tissue) for the standard curves were carefully chosen based on high levels of
expression for the respective genes of interest. An additional requirement was that
the melt curves of the products were specific to each gene having one clearly
distinguishable peak corresponding to a specific melting temperature.
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2.4.2.2 Performing qRT-PCR
Quantitative RT-PCR was performed using Rotorgene 2000 and 3000
real-time cyclers (Corbett Research). 15 pi reactions were set up using 40 ng of
RNA, 0.3 pM of each primer and the QuantiTect SYBR Green one-step RT-PCR kit
(Qiagen), according to the manufacturer's guideline. Reactions were set up in
quadruplicate for reverse-transcribed samples and non-template PCR contamination
controls, in triplicate for the standard curve points and in duplicate for the
non-reverse-transcribed DNA contamination controls (beta actin runs). Fluorescence
was detected using the FAM channel (source 470 mm; detector 510 nm). Analysis
and quantification was performed using Rotorgene v4.6, v5.0 and v6.0 software. The
criteria for acceptability of a run were: R-value of at least 0.99; R2-value of at least
0.89; efficiency value from 0.99 to 1.10; melting curves with the same and specific
peak; absence of PCR contamination; and in actin runs, absence of DNA
contamination. Inter-run variation was corrected for by the use of a "normaliser"
sample that was included in all runs.
Cycling conditions were set as follows: Reverse transcription at 50°C for 30
min, followed by a 15 min polymerase activation at 95°C, and 40 cycles of
denaturation at 94°C for 15 s, annealing at 57°C for 30 s and extension at 72°C for 30
s. After a final extension at 72°C for 1 min, product melting was set across a 72 to
99°C temperature ramp, with 5 s steps of 1°C.
All primers that were used are listed in Appendix B. These were designed
using Primer3 v0.2 (Whitehead Institute of Biomedical Research).
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2.5 General manipulation of protein
2.5.1 Protein extraction from cultured cells
Cells to be harvested for protein extraction were firstly rinsed in ice-cold
PBS. The PBS was drained and residual amounts were removed by a pastette. An
appropriate amount of protein extraction buffer (Appendix A) was added in order to
completely cover the surface of the flask or plate. The flasks or plates were placed on
ice for 10 min. The cells were detached with a scraper and then collected into 1.5 ml
microcentrifuge tubes. These were spun at 13,000 rpm in a microcentrifuge for 10
min. The supernatants, i.e. the cell lysates, were transferred into fresh tubes and
stored at -20°C.
2.5.2 Protein quantification
Total protein concentration in cell lysates was measured using the Bio-Rad
Protein Assay. The assay dye was prepared by diluting the stock solution 1:5 in
deionised water and filtration through a Whatman No 1 filter paper. Protein standards
were prepared by making serial dilutions of BSA in deionised water, starting from a
known concentration. The samples to be assayed were also diluted to a range of 1:3
to 1:5 in deionised water. 20 pi of standards or samples were transferred to test tubes,
into which 1 ml of the dye was added. The tubes were vortexed and 200 pi of
samples or standards were transferred to a 96-well plate in triplicate. The plate was
read in a BP 800 Biohit plate reader at 595 nm. A standard curve was calculated from
the absorbance readings of the standards and the protein content of each of the
lysates was determined by comparison thereto.
2.5.3 Deglycosylation of protein lysates
Deglycosylation of protein lysates was undertaken using a peptide
N-Glycosidase (PNGase F) kit (New England Biolabs). 20 pg of total protein were
denatured in lx Glycoprotein Denaturing Buffer at 100°C for 10 min. 1/10 of volume
of each lOx G7 Buffer and 10% NP-40 were added, together with 1000 U of PNGase
F. The reaction was incubated at 37°C over-night.
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2.5.4 Western blotting
2.5.4.1 SDS-polyacrylamide gel electrophoresis of protein samples
Discontinuous acrylamide gels were prepared as follows: For the resolving
gel, the following were combined in deionised water: an appropriate volume of
37.5:1 acrylamide/bis acrylamide depending on the final concentration desired,
usually 10% (v/v); 0.4 mM Tris pH 8.85; 0.1% (w/v) SDS; 0.25% (v/v) TEMED;
and 0.03% (w/v) AMPS. For the stacking gel, the following were combined in
deionised water: 3.5% or 5% (v/v) acrylamide/bis acrylamide; 131 mM Tris pH 6.8;
0.1% (w/v) SDS; 0.1% (v/v) TEMED; and 0.1% (w/v) AMPS. The gel system used
was the Mini-PROTEAN 3 (Bio-Rad). Firstly, the resolving gel was poured into the
casting apparatus and allowed to polymerise under a layer of isopropanol. Once set,
the isopropanol was drained, the stacking gel was poured, the appropriate comb was
inserted into it and the gel was allowed to polymerise.
To prepare the protein samples, an appropriate amount of each lysate (usually
10 or 20 pg) was denatured by heating at 95°C for 10 min with lx denaturing sample
buffer (Appendix A). After denaturation, the samples were placed on ice to cool,
then spun briefly and placed again on ice. Deglygosylated samples had already been
denatured; hence, they were not mixed with denaturing sample buffer, but only with
1/10 vol glycerol.
The samples were loaded into the gel and run in gel running buffer (Appendix
A) for approximately 1 h at 200 W, alongside a molecular weight marker (New
England Biolabs).
2.5.4.2 Transfer ofproteins onto membrane
Proteins were transferred from the gel to an Immobilon-P membrane
(Millipore) using the Mini-PROTEAN 3 Trans-Blot Cell (Bio-Rad). The transfer was
performed either over-night at 30 V and 4°C in transfer buffer (Appendix A) or at
100 V for 1.5 h in transfer buffer containing 20% (v/v) methanol.
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2.5.4.3 Blocking, antibody incubations and washes
The membranes were rinsed twice in TBS (Appendix A) containing 0.1%
(v/v) Tween-20 (TBS/Tween) and then washed three times by rocking in the same
solution, 5 min each wash, at room temperature. The membranes were then blocked
by rocking in 1% (v/v) Blocking Agent [contained in the BM Chemilluminescence
Blotting Substrate kit (Roche)] in TBS/Tween for 1 h at room temperature. The
blocking agent was drained and the membranes were probed with an appropriate
dilution of the primary antibody in TBS/Tween, by rocking over-night at 4°C.
The following day, the membranes were rinsed twice in TBS/Tween and then
washed three times in TBS/Tween and twice in 0.5% (v/v) blocking agent in
TBS/Tween: these washes were done by rocking for 5 min each time, at room
temperature. The membranes were then probed with an appropriate dilution of the
secondary antibody in TBS/Tween, by rocking for 1 h at room temperature.
Following this incubation, the membranes were rinsed twice in TBS/Tween; washed
three times by rocking in TBS/Tween, 5 min each wash, at room temperature; rinsed
twice in TBS; and washed three times in TBS as previously.
The following primary/secondary antibody combinations were used in
western blotting (Table 2.4):
Primary antibody Dilution Secondary antibody Dilution
anti-OPCMLvi 1/2000 goat anti-chick (Abeam) 1/2000
anti-ACTIN (Calbiochem) 1/500000 goat anti-mouse (Calbiochem) 1/4000
Table 2.4 Antibodies used in immunoblotting




The signal was detected using the BM Chemilluminescence Blotting
Substrate (Roche), according to the manufacturer's instructions. The luminol was
prepared by combining 10 ml of Luminescence Substrate A and 100 pi of Starting
Solution B and was let to stand at room temperature for half an hour before use. The
membranes were treated with luminol for 1 min and then transferred to an X-ray film
cassette. In a dark room, the membranes were overlaid with Hyperfilm™ (Amersham
Biosciences) for a period ranging from 1 s to 5 min, depending on signal intensity.
Films were developed in a Curix 60 developer (Agfa).
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2.6 Whole-mount in situ hybridisation
2.6.1 Synthesis of digoxygenin-labelled riboprobes
2.6.1.1 In vitro transcription
Firstly, the plasmid DNA was linearised using a restriction endonuclease that
digests downstream of the appropriate promoter. Linearised plasmid DNA was
subjected to phenol extraction and ethanol precipitation (section 2.2.4).
In order to produce digoxygenin-labelled RNA probes, the DIG RNA Labelling
Kit (SP6/T7) (Roche) was used, according to the manufacturer's instructions. The
following components were combined with ultra-pure water to a final volume of 20
pi on ice:
• 1 pg of linearised plasmid DNA
• 2 pi of 1 Ox NTP Labelling Mixture
• 2 pi of 10 x Transcription Buffer
• 1 pi ofProtector RNase Inhibitor
• 2 pi of appropriate RNA polymerase
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The restriction enzyme and RNA polymerase (Pol) used for each construct can be
seen in Table 2.5.













Shh Antisense Hindlll T3
Fg/8 Antisense Hindlll T3
Table 2.5 In vitro transcription for the creation of labelled probes
The reaction components were mixed gently, spun briefly and incubated for 2 h at
37°C.
After the incubation, 1 pi of each reaction was run on a 2% (w/v) agarose gel
stained with EtBr to visually inspect the synthesised probes.
2 pi of DNase I were added to each sample and reactions were incubated for
15 min at 37°C. The reactions were then stopped by the addition of 2 pi of 0.2 M
EDTA pH 8.0.
2.6.1.2 Quantification of synthesised probes
Standards were prepared using the DIG-labelled riboprobe control of known
concentration from the kit used for the synthesis of the probes. The RNA was diluted
in RNA dilution buffer [5:3:2 (v:v:w) EhO:20xSSCvll:formaldehyde] to give
concentrations ranging from 10 ng/pl to 0.01 pg/pl. The synthesised probes were
diluted to an approximate concentration of 10 ng/pl based on the appearance of probe
bands when run on an agarose gel (see previous section). 1 pi from the standards and
the probe dilutions was applied to spots on a positively-charged nylon membrane.
™ DEPC-treated and autoclaved (Sigma)
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The RNA on the membrane was fixed by UV cross-linking in a Bio-Rad GS Gene
Linker UV Chamber, using the appropriate programme. The membrane was washed
twice in PBT (Appendix A), for 1 min each time, and then blocked with lx Blocking
Reagent (Roche) in maleic acid buffer (Appendix A) for 2 min. The membrane was
probed with a 1:5000 dilution of anti-digoxigenin-AP, Fab fragments (Roche) in lx
Blocking Reagent for 3 min and then washed twice in PBT, for 1 min each time. The
membrane was treated with BM Purple (Roche) at room temperature for
approximately 30 min, until the staining developed. Finally, the membrane was
rinsed with deionised water and dried between paper towels. Riboprobe
concentrations were estimated according to which standards matched the spots of
unknown concentrations in colour intensity.
2.6.1.3 Precipitation ofprobe RNA
10 pi of TE buffer pH 8.0 (Appendix A), 10 pi of 4 M LiClviii and 300 pi of
ethanol were added to each sample, which was then mixed and incubated at -20°C
for 30 min. The samples were then spun in a microcentifuge at 13,000 rpm and 4°C
for 10 min. The pellets were washed with 70% (v/v) ethanol and air-dried. Finally
they were redissolved in TE Buffer pH 8.0 to an approximate final concentration of
0.1 mg/ml, aliquoted and stored at -20°C.
2.6.2 Collection & fixation of mouse embryos
Embryos were collected at the following ages: E8.5, E9.5, E10.5, El 1.15,
E12.5 and E13.51X. The extra-embryonic membranes and the amnion were removed
from the embryos in ice-cold PBS. The brain and heart of embryos older than E8.5
were pierced by a needle. Samples were fixed in ice-cold 4% (w/v)
paraformaldehyde for at least 4 h; the fixative was changed once. Samples were
washed twice in PBT at 4°C for 5 min each wash. Samples were then dehydrated by
successive washes by rocking in 25%, 50% and 75% (v/v) methanol in PBT at room
temperature, for 5 min each wash. Finally, samples were washed twice with 100%
methanol, for 5 min each wash, and stored after the second wash in the same solution
at -20°C until used. All the above steps were undertaken in RNase-free conditions.
Vl" DEPC-treated and autoclaved
lx E corresponds to embryonic age (days post coitum)
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2.6.3 Whole-mount in situ hybridisations of mouse embryos
All the steps until and including hybridisation were carried out in RNase-free
conditions. All washes were done at room temperature and by rocking, unless
otherwise stated.
The fixed embryos were rehydrated by successive washes in descending
grades ofmethanol to PBT: 100%, 75%, 50% and 25% (v/v). The embryos were then
washed three times in PBT, for 5 min each time and digested with 10 pg/pl








Table 2.6 Duration of proteinase K digestion
After the digestion, the samples were post-fixed with freshly prepared 4%
(w/v) paraformadehyde with 0.2% (v/v) glutaraldehyde in PBT for 45 min on ice.
Warm prehybridisation solution (Appendix A) was added and the embryos were
allowed to sink in their containers. This was repeated and then the solution was
removed and an appropriate volume of warm prehybridisation solution was added.
The embryos were incubated for 1 h at 65°C by rocking. The solution was changed
and incubation continued for a further 3 h. The solution was then replaced with
hybridisation solution containing 250 ng/ml DIG-labelled riboprobe, enough to cover
the samples. Hybridisation was carried out at 65°C over-night by rocking.
The following day, the hybridisation solution was removed and kept at 4°C to
be reused for a maximum of three further times. Post-hybridisation solution
(Appendix A) was added and the samples were washed at 65°C for 10 min. The
69
embryos were then washed with 25% (v/v) 2x SSC, pH 4.5X in post-hybridisation
solution at 65°C for 10 min. The washes were repeated with 50% and then 70% (v/v)
2x SSC, pH 4.5 similarly. The samples were washed twice, for 30 min each time, in
0.1% (v/v) CHAPSX1 / 2x SSC at 65°C, followed by another two 30 min washes at the
same temperature in 0.1% (v/v) CHAPS / 0.2x SSC, pH 4.5. The samples were then
washed with TNT buffer (Appendix A) at room temperature for 10 min.
In order to block the samples, they were incubated for at least 4 h in blocking
solution at 4°C. They were then incubated with a 1:2000 dilution of
anti-digoxigenin-AP, Fab fragments (Roche), in blocking solution at 4°C over-night
with gentle agitation.
The following day, samples were washed with 0.1% (w/v) BSA in TNT
buffer five times, 1 h each time and left to wash in fresh solution at 4°C over-night.
In the final day of the protocol, the embryos were washed twice, for 30 min
each time, in NTMT buffer (Appendix A) and then twice in NTM buffer (Appendix
A), for 10 min each time. To visualise the hybrids, the samples were incubated in
BM Purple (Roche) in the dark. The samples were rocked for the first 20 min of
development and then monitored by eye until staining developed. Finally, the stain
was fixed in 4% (w/v) paraformaldehyde at 4°C over-night.
Stained embryos were photographed using an AxioCam camera (Carl Zeiss) and
AxioVision v3.1 software (Carl Zeiss).
x Made from a 20x DEPC-treated and autoclaved stock solution (Sigma)
X1 Made from a 2x stock solution (Sigma)
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2.7 Immunohistochemistry of paraffin-embedded sections
For immunohistochemical experiments, sections were first dewaxed in
xylene, by two 5 min washes. Then they were rehydrated in descending grades of
ethanol to water, as can be seen in Table 2.7:
Step Duration
1. 100% (v/v) ethanol 2 min
2. 100% (v/v) ethanol 5 min
3. 100% (v/v) ethanol 2 min
4. 95% (v/v) ethanol 2 min
5. 70% (v/v) ethanol 3 min
6. Water 3 min
Table 2.7 Rehydration of sections
The rehydrated sections were then treated with fresh 3% (v/v) hydrogen
peroxide [made from diluting a 30% stock solution in water] for 30 min. Following a
5 min wash in water, antigen retrieval was performed by heating the sections in
citrate buffer pH 6.0 (10 mM citric acid monohydrate) in a microwave oven at 700
W. This was done in three 5 min steps, after each of which cold citrate buffer was
used to top up the boiling solution. At the end of antigen retrieval, the sections were
left immersed in citrate buffer to cool down for 20 min.
The sections were washed in 0.05 M TBS by rocking for 5 min and then
blocked with 20% (v/v) foetal calf serum in TBS (TBS/FCS) for 10 min at room
temperature. Excess blocking solution was drained and the sections were incubated
with a 1/60 dilution of the anti-OPCML antibody in TBS/FCS for 2 h at room
temperature.
After two 5 min washes in TBS by rocking, the sections were incubated with
a 1/250 dilution of a pre-absorbed goat anti-chick IgY (Abeam) in 20% (v/v)
FCS/TBS for 30 min at room temperature.
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The sections were washed twice in TBS by rocking, for 5 min each time,
incubated with a 1/20 dilution of the tertiary antibody [Link antibody from the
Multilink® Super Sensitive™ Link-Label IHC Detection System (Biogenex)] in TBS
for 30 min at room temperature, and washed again twice in TBS as previously.
To develop the stain, the sections were treated with Liquid DAB (Biogenex) for 5
min in the dark. Subsequently, the sections were subjected to the following washes
and treatments:
• Wash in water for a few minutes
• Counterstaining with haematoxylin for 2 min
• Wash in water for 2 min
• Treatment with acid alcohol [0.1% (v/v) concHCl in 70% (v/v) EtOH] for 30 s
• Wash in water for 2 min
• Wash in Scott's tap water (Appendix A) for 1 min
Finally, the stained sections were dehydrated in ascending grades of ethanol to
water, in reverse of the rehydration steps; cleared in xylene, for 5 min each time; and
mounted in DPX medium (Fisher Scientific).
Stained sections were photographed using a SPOT1M Insight 14.2 Color Mosaic
camera (Diagnostic Instruments Inc.) and SPOT™ v4.1.2 software (Diagnostic
Instruments Inc.).
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2.8 Cell biology assays
2.8.1 Migration assay
Migration assays were performed using the QCM™-Collagen I, -Fibronectin
and -Vitronectin Quantitative Cell Migration Assays (Chemicon International),
according to the manufacturer's instructions. These assays utilise Boyden chambers
with an 8 pm pore size to measure haptotaxis towards an immobilised ECM protein
gradient. The assay chambers are precoated with either an ECM molecule or BSA,
the latter serving as a negative control. For each assay, two microplates are used:
one test plate, containing ECM-coated chambers, and one control plate, with
ECM-coated wells (serving as an adhesion control) and BSA-coated chambers.
The cells to be assayed were serum-starved, i.e. grown in media lacking FCS,
for 48 h prior to the experiments. The assay plates were equilibrated to room
temperature. The cells were washed twice with PBS, and trypsinised. Trypsin was
counteracted by the addition of quenching medium [DMEM with 5% BSA (w/v)].
The cells were counted and resuspended in quenching medium. Single-cell
suspensions were created by passing the cells three times through a 21G needle. 300
pi of quenching medium were added to the first row of wells of the test plate,
beneath the Boyden chambers. Similarly, quenching medium was added to the
second row of wells in the control plate. After pipetting the cells gently to resuspend,
2.5 x 105 cells of the first sample were placed into an ECM-coated Boyden chamber
on the test plate. The same number of cells were added to ECM-coated wells in the
first row of the control plate and the BSA-coated Boyden chambers on the control
plate. The above steps were repeated for the rest of the samples. All the samples were
done in duplicate. The plates were then incubated for approximately 22 h at 37°C /
5% C02.
The following day, 6 drops of Cell Stain Solution were added to each well of
the second row of wells in the test plate and the third row of wells in the control
plate. Using a clean pipette for each well, the medium was removed from the
ECM-coated control wells in the first row of the control plate, and 6 drops of Cell
Stain Solution were added to each of these wells. The medium was carefully
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removed from the ECM-coated Boyden chambers in the first row of the test plate.
Using forceps, the first ECM-coated Boyden chamber was removed from the test
plate, without touching the underside of the chamber. The medium from the inside of
the chamber was gently swabbed using a flattened cotton bud, taking care not to
puncture the chamber membrane. The cleaned chamber was then placed into a well
containing cell stain and the process was repeated for the next chamber. After
cleaning all the test chambers, the same was done for the BSA-coated control
chambers, placing each chamber in its respective stain well once completed (second
row of wells in the test plate and third row of wells in the control plate). The plates
were then incubated for 30 min at room temperature. The cell stain was removed
from the ECM-coated control row with a pipette and wells in this row were washed
three times with 1 ml PBS per well. 300 pi of PBS were added to each ECM-coated
control well. 300 pi of Extraction Buffer were added to all the wells in the empty
third row of the test plate and the empty fourth row of the control plate. Using
forceps, one ECM-coated chamber was removed each time from the stain, and
washed thoroughly in deionised water by submersion. The inside of each chamber
was then cleaned with a flattened cotton bud as before and the cleaned chambers
were placed in Extraction Buffer. The test and control plates were placed on a shaker
and the stain was eluted for 10 min. 100 pi of stain solution from elution wells were
removed per sample and transferred into a microplate. Optical density was read at
570 nm in a BP 800 Biohit plate reader.
The results were analysed by subtracting the BSA-coated readings from the
ECM-coated ones.
2.8.2 Invasion assay
Invasion assays were carried out using Biocoat™ Matrigel™ Invasion
Chambers and Control Inserts (BD Biosciences). Invasion chambers contain 8 pm
pore size PET membranes with a thin layer of Matrigel basement membrane matrix:
these allow cell invasion. In contrast, control inserts only have the membrane, and
thus allow cell migration.
After matrigel and control inserts were allowed to come to room temperature,
0.5 ml ofDMEM was added to the bottom of the wells and to the interior ofmatrigel
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inserts. The matrigel chambers were rehydrated for 2 h in an incubator at 37°C / 5%
CO2. Meanwhile, exponentially-growing cells were washed twice with PBS,
trypsinised and counted. Single-cell suspensions were prepared at 5 x 104 cells/ml in
DMEM, by passing the cells three times through a 21G needle. The medium was
removed from the bottom of the wells and the matrigel inserts and 0.75 ml DMEM
with 5% (v/v) FCS was added to the wells of the companion plate, in order to act as a
chemoattractant. Using sterile forceps, the inserts were transferred to the wells,
avoiding the creation of bubbles. Immediately, 0.5 ml of single-cell suspension was
added to each chamber and the plates were placed for 24 h in an incubator at 37°C /
5% C02.
The following day, non-invading cells were scrubbed from the upper surface
of the membranes using cotton buds: firstly, using dry cotton buds and then using
cotton buds moistened with DMEM. The inserts were transferred onto wells
containing 0.5 ml MTT at 0.2 mg/ml (Sigma) in PBS, the plate was covered with
aluminium foil and placed in an incubator for 3 h at 37°C / 5% CO2. The crystals
were removed from the lower surface of membranes using cotton buds. The tips of
the cotton buds were cut and placed in tubes containing 1 ml spectrometric grade
DMSO (Sigma). The tubes were vortexed in order to solubilise the crystals. Three
200 pi aliquots per sample were transferred to a microplate and optical density was
measured at 570 nm in a BP 800 Biohit plate reader.
The results were calculated as follows:
OD (invading cells)
% invasion = x 100%
OD (migrating control cells)
2.8.3 Cell-ECM adhesion assay
In order to measure the adhesion of cells on proteins of the extracellular
matrix, the CytoMatrix™ Screen Kit (Chemicon International) was used, according
to the manufacturer's instructions. This kit uses 8-well removable strips in a 96-well
plate frame. The wells in the first seven rows of each strip are coated with an ECM
component, namely Fibronectin, Vitronectin, Laminin, Collagen I or Collagen IV.
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The last well of each strip is coated with BSA, which serves as a negative assay
control.
The strips were rehydrated with 200 pi of PBS per well for at least 15 min at
room temperature. Before the assay, the PBS was removed from the rehydrated
strips. Exponentially-growing cells were washed twice with PBS, trypsinised and
counted. Single-cell suspensions at 2.5 x 105 cells/ml were created by passing the
cells three times through a 21G needle. 100 pi of each cell suspension was added to
the ECM-coated wells in duplicate or the BSA-coated well. The plate was incubated
at 37°C / 5% CO2 for 45 min. The plate was gently washed three times with PBS
containing Ca2+/Mg2+ (200 pi per well). 100 pi of 0.2% (w/v) crystal violet in 10%
(v/v) ethanol were added to each well. The plate was incubated for 5 min at room
temperature. The stain was removed from the plate, which was then gently washed
five times with PBS containing Ca2+/Mg2+ (200 pi per well). 100 pi of solubilisation
buffer [a 1:1 mixture of 0.1 M NaEEPO/t, pH 4.5 and 50% (v/v) ethanol] were added
to each well. The strips were allowed to incubate by gently shaking at room
temperature for 5 min, until the cell-bound stain was solubilised. The absorbance at
570 nm was read in a BP 800 Biohit microplate reader.
2.8.4 Cell-cell adhesion assay
The cell-cell adhesion assay measures the adhesion of fluorescently-labelled
cells on non-labelled cell monolayers. For each assay, two plates were used, a test
and a control. Washing steps were omitted for the control plate in order to determine
total cell fluorescence. Each plate also contained non-labelled cells incubated on cell
monolayers, so that background fluorescence could be measured.
In order to prepare the monolayers, cells were washed twice with PBS,
trypsinised and counted. 2.5 x 104 cells were added to each well. The plates were
incubated over-night at 37°C / 5% CO2.
Cells to be labelled were washed twice with PBS, trypsinised and counted.
They were resuspended in serum-free medium at 5 x 10" cells/ml and passed three
times through a 21G needle. Calcein AM (Molecular Probes) was added to the
single-cell suspensions to a final concentration of 5 pM. The suspensions were mixed
well and incubated at 37°C / 5% CO2 for 30 min. Unlabelled cell suspensions were
76
also prepared and incubated alongside the labelled ones. After the incubation, both
labelled and unlabelled cells were washed twice with serum-free medium and
resuspended to 5 x 105 cells/ml.
The medium was removed from the monolayers by aspiration. 100 pi of
either labelled or unlabelled cell suspension (i.e. 5 x 104 cells) were added to each
well. The cells were incubated at 37°C / 5% CO2 for 90 min. The non-adherent cells
were removed from the test plate only by carefully washing five times: 200 pi of
serum-free medium were added to each well and the plate was gently swirled. The
plate was inverted and excess liquid was blotted onto paper towels. 200 pi of PBS
were added to each well of the test plate, whereas 100 pi of PBS were added to each
well of the control plate. Fluorescence was measured using a filter with an excitation
wavelength of 485 nm and an emission wavelength of 520 nm in a Fluoroskan
Ascent FL (Labsystems) plate reader. The percentage of cell-cell adhesion was
determined by dividing the background-corrected fluorescence of adherent cells by
the total background-corrected fluorescence of cells and multiplying by 100%.
2.8.5 Growth assay
Exponentially-growing cells were washed twice with PBS, trypsinised and
counted. Single-cell suspensions were created by passing the cells three times
through a 21G needle. 100 cells were plated in 1 ml medium supplemented with 10%
(v/v) FCS and the appropriate antibiotics in triplicate in 24-well plates. At each
time-point, one plate of cells was washed twice with PBS, trypsinised and
resuspended in medium. The cells were syringed as above to create a single-cell
suspension and counted using a Coulter counter.
2.8.6 Cell proliferation assay by dual colour flow cytometry
Cell proliferation was measured using the Absolute-S™ Kit (Chemicon
International), according to the manufacturer's guidelines. The protocol used was as
... 2follows. Exponentially-growing cells were seeded at a specific density in 175 cm
flasks one or two days prior to performing the experiment, depending on the cell line.
SKOV-3 cells were seeded one day before the experiment at 106 cells per flask,
77
whereas HeLa cells were seeded two days before the experiment at 2 x 106 cells per
flask.
In the first day of the assay, cells were washed twice with PBS, trypsinised
and counted. 10 ml single-cell suspensions were made by passing the cells three
times through a 21G needle and 20 pi of the BrdUrd Photolyte™ stock solution were
added per suspension. The cells were incubated at 37°C / 5% CO2 for 30 min.
Following this incubation, DMSO was added to the cell suspensions, to a final
concentration of 2% (v/v). Immediately, 20 pi of Photolyte Enhancer™ were added
per suspension and the cells were incubated for an additional 20 min at 37°C / 5%
C02.
The cells were then centrifuged for 5 min at 300 g and the supernatant was
removed by aspiration. The cells were resuspended in 1 ml of Wash Buffer and the
centrifugation step was repeated. After removing the supernatant by aspiration, the
cells were resuspended in the residual Wash Buffer by gently vortexing the tubes. 3
ml of 70% (v/v) ice-cold ethanol were added and the cells were stored at -20°C
over-night.
The following day, 1 ml of the BrdUrd-incorporated cells was transferred to
12x75 mm polystyrene test tubes. The tubes were centrifuged at 300 g for 5 min, and
the supernatant was removed by aspiration being careful not to disturb the cell
pellets. 2 ml ofWash Buffer were added in each tube and the tubes were centrifuged
at 300 g for 5 min. The supernatants were removed by aspiration and the cell pellets
were resuspended in 0.5 ml of Wash Buffer. The cells were irradiated on a UV light
box for 5 min.
[NB All the above steps were performed with minimal exposure to light]
After illumination, 1 ml ofWash Buffer was added to each tube and the tubes
were centrifuged at 300 g for 5 min. The supernatants were removed by aspiration.
Each cell pellet were resuspended in 50 pi of the DNA labelling solution
prepared as described below (Table 2.8):
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Component Volume per sample (pi)




Table 2.8 DNA labelling solution
The cells were incubated in the DNA labelling solution for 60 min at 37°C in a water
bath. Every 15 min the tubes were shaken in order to resuspend the cells.
At the end of the incubation, 2 ml of Rinse Buffer were added to each tube
and the tubes were centrifuged at 300 g for 5 min. The supernatants were removed by
aspiration.
The cells were then resuspended in 100 pi of FITC-BrdU antibody solution,
prepared by combining 5 pi of FITC-BrdU with 100 pi of Rinse Buffer per sample.
The cells were incubated in the FITC-BrdU antibody solution in the dark for 30 min
at room temperature. 0.5 ml of the Propidium Iodide / RNase A Solution was then
added per tube and the cells were incubated in the dark for a further 30 min at room
temperature.
Finally, the cells were analysed in a FACSCaliburIM flow cytometer (BD
Biosciences), using Cellquest™ v3.2.1 software (BD Biosciences). Samples were run
in triplicate; for each replicate, 10,000 events were acquired. A dot plot of linear red
fluorescence against log green fluorescence was gated on FF2A versus FF2W to
exclude DNA doublets and on FSC versus SSC to exclude cellular debris. Cells in S
phase were identified by high green fluorescence, whereas G0/G1 or G2/M
populations were defined by a combination of low green fluorescence and low or
high red fluorescence respectively. Results were expressed as percentages of the total
gated events in the dot plot.
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2.8.7 Annexin V assay by flow cytometry
FACS-based apoptosis studies were undertaken using the TACS™ Annexin
V-FITC Apoptosis Detection Kit (R&D Systems). Cells to be assayed were seeded
on 175 cm" flasks and the following day the medium was changed. If required,
camptothecin (used from a 2 mM stock solution in DMSO) was added in the medium
to the final concentration of 1 pM. After approximately 48 h, the media, containing
floating cells, were emptied from the flasks and set aside. The cells were washed
twice with PBS and trypsinised. To counteract the effect of trypsin, the media that
were saved were re-introduced in their respective flasks. The combined suspensions
of trypsinised and floating cells were pelleted, resuspended and counted in a Coulter
counter. 5 x 105 cells were transferred to a 12x75 mm polystyrene test tube. The
tubes were spun down at 400 g for 5 min. The cells were resuspended in ice-cold
PBS and then spun down as previously. The cells were gently respunded in 100 pi of
lx Binding Buffer (made by diluting the lOx stock solution in deionised water). 10 pi
of Propidium Iodide and 2 pi of Annexin V-FITC were added to each tube.
Alongside the experimental samples, three controls were prepared: with only
Propidium Iodide or Annexin V-FITC, or without either. The cells were incubated in
the dark for 15 min at room temperature.
Finally, the cells were analysed in a FACSCalibur™ flow cytometer (BD
Biosciences), using Cellquest™ v3.2.1 software (BD Biosciences). Samples were run
in triplicate; for each replicate, 10,000 events were acquired. A dot plot of log red
fluorescence against log green fluorescence was gated on FSC versus SSC to exclude
cellular debris. Quadrant markers were used to distinguish the different populations.
Early-stage apoptotic cells were defined as the population with high green
fluorescence and low red fluorescence, whereas late-stage apoptotic or necrotic cells
as having high green and high red fluorescence. Results were expressed as
percentages of the total gated events in the dot plot.
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2.9 Statistical analysis
Except in the expression study in ovarian cancer, all other statistical
comparisons were undertaken in Microsoft Excel by Student's t test.
In the aforementioned expression study, all statistical analyses were
conducted in SPSS vl2 (SPSS Inc.). Non-parametric comparisons between
unmatched samples were made using the Mann-Whitney (U) test for two samples or
the Kruskal-Wallis {X) test for more than two samples. Non-parametric correlations
were tested using the Spearman rank (rs) test. Regression models were made using
linear regression analysis. Survival curves were produced using the Kaplan-Meier
method and tested with the log-rank test. Survival models were estimated using Cox
proportional hazards regression analysis.
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Chapter 3
Creation and characterisation of
inducible cell lines expressing OPCML
3.1 Introduction
Historically, mammalian systems of inducible gene expression have relied on
a family of prokaryotic DNA binding proteins, exemplified by the E. coli Tet
repressor protein (TetR)258. TetR negatively regulates the genes of the
tetracycline-resistance operon on the Tn10 transposon. It inhibits transcription of
these genes by binding to the tet operator sequences tetO in the absence of
tetracycline. Tetracycline-inducible systems are based on this transcriptional
regulation. They are categorised into Tet-Off and Tet-On systems. In a Tet-Off
system, the regulatory protein is a 37 kDa fusion of amino acids 1-207 of TetR and
the C-terminal 127 amino acids of the HSV VP 16 activation domain259. VP 16
converts the TetR repressor into an activator. The fusion protein is called the
tetracycline-controlled transactivator (tTA). In Tet-On systems, four amino acid
changes in TetR convert it into a "reverse" TetR (rTetR), with the fusion protein
termed rtTA. Thus, in Tet-Off systems tTA activates genes in the absence of
tetracycline, whilst in Tet-On systems rtTA activates genes in the presence of
tetracycline.
Inducible systems have two components: a regulatory component, based on a
plasmid encoding the TetR-derived regulatory protein; and a response component,
based on a plasmid that allows the tetracycline-responsive expression of a gene of
interest. Hence, the regulatory plasmid either encodes tTA or rtTA (for Tet-Off and
Tet-On systems respectively) and the response plasmid harbours the gene of interest
driven by a minimal promoter placed under the influence of a tetracycline response
element (TRE). The TRE derives from the tetO sequences, thus allowing binding of
the regulatory protein in the absence (Tet-Off) or presence (Tet-On) of tetracycline.
Since the groups of Bujard and Hillen first demonstrated the efficacy of this
regulated system in mammalian cells, the unparalleled advantages of inducible
systems have established their usage as a tool of remarkable potential260'261. Firstly,
as the critical regulatory elements are prokaryotic, tetracycline-inducible systems
have no effects on host genes. The interpretation of any observed phenotypes is thus
simplified by the absence of pleiotropic effects. Moreover, the inducer is
incorporated in the transcription factor complex and hence its concentration directly
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correlates with the concentration of the latter allowing the expression of genes of
interest at narrowly defined levels. This greatly simplifies the study of genes
encoding products that are growth-inhibitory or toxic, or whose functions are tightly
linked to their level of expression. It also becomes possible to study the effect of
genes at expression levels approximating physiological ones, avoiding
over-expression artefacts. Another advantage of inducible systems is that
comparisons can be made within the same clone, between the induced and uninduced
state, thus obliterating the issue of clonal variation. Finally, as tetracyclines are
antibiotics whose use is extensively documented in humans, they can be excellent
candidates for gene regulation in gene therapy.
Tet-inducible systems have been extensively used, both in vitro and in vivo,
to study a variety of genes and their functions. In vitro, important cancer-related
genes, such as TP53, have been placed under the regulation of tet-responsive
969 • • 96^
systems . Studies have focused on such diverse areas as cell signalling , the
immune response264 and microarray comparisons between induced and uninduced
96S
states . Recent advances have made the study of two genes possible by an inducible
266
system" . In vivo, retroviral derivatives of tet systems have been extensively used in
the generation of inducible models of gene expression in animal studies . Recently,
Belteki and colleagues have combined a conditional transgene expression system,
based on Cre-loxP, with an inducible system, based on Tet-Off, to study Vegfa
96R
during embryonic development and postnatally in mice .
This chapter presents the work carried out in order to create two inducible
systems of OPCML expression: a Tet-On system based on the HeLa cervical cancer
cell line and a Tet-On system based on the SKOV-3 ovarian cancer cell line. The
former was created using a commercially-available HeLa Tet-On cell line and was
characterised in order to be used in further analysis and functional studies as will be
discussed in later chapters. The latter was developed ab initio and will be used in
future studies. Overall, the main objective of this part of the project was to create an
inducible resource of OPCML expression to complement the existing
over-expression system in studies of OPCML and IgLON expression as well as
OPCML function.
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3.2 The HeLa Tet-On system
3.2.1 Background to the creation of a double stable HeLa Tet-On
OPCML cell line
In order to identify the functions of OPCML, the inducible system that was
employed is the commercial HeLa Tet-On system available by BD Biosciences. The
reason behind the choice of a non-ovarian cell line to study the functions of a
potential tumour suppressor gene in ovarian cancer is that when this work
commenced there was no commercially available ovarian inducible cell line. The
HeLa system was therefore chosen as an alternative that could provide an in-vitro
model of gynaecological cancer. The HeLa Tet-On system should allow exploiting
the advantages offered by any inducible system, i.e. the achievement of
near-physiological levels of expression and the avoidance of clonal variation. Having
a SKOV-3 over-expression system in addition would help address the issue of
context specificity in any phenotype that would be identified.
Figure 3.1 shows the basic features of the HeLa Tet-On system. As supplied,
the HeLa Tet-On stable cells harbour the pTet-On plasmid (Appendix C), which
encodes the rtTA regulator protein and also has a neomycin-resistance gene. These
cells can be transfected with a response plasmid, which in the case of this work was
pTRE2hyg, a vector that contains a hygromycin-resistance gene (Appendix C).
When the gene of interest is cloned in pTRE2hyg, it is placed under the control of the
tetracycline-response element, TRE. This consists of seven direct repeats of a 42 bp
sequence containing the tetO, located just upstream of the minimal CMV promoter.
In the Tet-On system, rtTA binds the TRE and activates transcription in the presence
of doxycycline (dox; an antibiotic of the tetracycline family).
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rtTA
Figure 3.1 The BD Tet-On system
The system comprises two plasmids: a regulatory plasmid and a response plasmid.
The former produces the regulatory protein, which upon addition of dox, binds the
TRE in the latter, which then drives the transcription of the gene of interest,
(reproduced from the BD Tet-Off and Tet-On Gene Expression Systems User
Manual).
The creation of double stable clones had been previously undertaken. In brief,
either a wild-type human OPCML coding sequence or a sequence harbouring the
21P95R mutation (the only identified somatic mutation in sporadic EOC to date ) had
been cloned in the pTRE2hyg vector. The vector had been transfected in HeLa
Tet-On cells and the present project commenced with the screening of double stable
clones.
3.2.2 Selection of inducible HeLa Tet-On OPCML clones
In order to select inducible double stable clones the following strategy was
employed (Figure 3.2). Each clone was treated with 1 pg/ml dox for 48 h or left
untreated. Lysates were collected, RNA was extracted and DNase I-treated, and
cDNA was synthesised. The assay used to demonstrate induction was an RT-PCR
using a forward primer that anneals on the OPCML sequence and a reverse primer
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that anneals on pTRE2hyg, thereby amplifying specifically the dox-induced OPCML
transcript. The criteria for acceptable clones were high fold-induction, i.e. a sufficient
difference between uninduced and induced expression levels of OPCML, and absent
or minimal "leaky" (uninduced) expression.
The perfect clone
+ - dox





Figure 3.2 Screening strategy for HeLa Tet-On OPCML clones
Diagrammatic representation of the strategy used to select inducible HeLa Tet-On
OPCML clones. Clones were grown for 48 h in the presence or absence of dox, and
assayed by RT-PCR for OPCML expression.
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More than fifty clones for each genotype were screened by RT-PCR; Figure
3.3 shows one experiment as an example. Clone 1 demonstrated moderate OPCML
expression in the induced state and a high uninduced level; clone 2 had no expression
at all; clone 3 had almost equal levels of non-induced and induced expression; clone
4 had slightly stronger induced expression, but high uninduced expression as well;
and clone 5 had only very low induced expression. This experiment is very
representative of the inducibility patterns of most of the clones that were screened.
The vast majority of the clones that were screened failed to satisfy the criteria of
acceptability. In fact, there was not any clone that satisfied both criteria absolutely.
OPCML
L 1 2 3 4 5




Figure 3.3 Screening for inducible HeLa Tet-On OPCML clones
Clones were grown for 48 h with or without dox and then assayed for OPCML
induction by RT-PCR. Products were run on a 2% (w/v) agarose gel stained with
EtBr. DNA and PCR contamination controls were negative (data not shown).
Numbers represent different clones. L = 100 bp DNA ladder; ACTG1 = gamma
actin.
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After extensive screening, the two most promising clones that were identified
are shown in Figure 3.4. One wild-type and one mutant OPCML clone are shown,
both exhibiting an acceptable fold-induction, although both also having some
uninduced expression. The absence of clones that strictly satisfied the criteria of
selection led to the selection of these two clones for further characterisation.
L WT Mut
+ - + dox
OPCML 381
ACTG1 181
Figure 3.4 The two selected HeLa Tet-On OPCML clones
The two selected clones were grown for 48 h with or without dox and then assayed
for OPCML induction by RT-PCR. Products were run on a 2% (w/v) agarose gel
stained with EtBr. DNA and PCR contamination controls were negative (data not
shown).
WT = wild type; Mut = mutant; L = 100 bp DNA ladder; ACTG1 = gamma actin.
3.2.3 Characterisation of the selected HeLa Tet-On OPCML clones
The two selected clones were subjected to further characterisation so as to
investigate quantitatively the induction of OPCML at both the RNA and the protein
levels. Firstly, the wild-type and the mutant clones were treated with increasing
amounts of dox (ranging from 100 to 1000 ng/ml) and 48 h post-induction, protein
and RNA lysates were collected. Expression at the protein level was measured by
western blotting using the anti-OPCML antibody. Expression at the RNA level was
quantified by qRT-PCR, using an assay similar to the one used in screening. As can
be seen in Figure 3.5, both clones expressed OPCML upon induction with dox and
expression increased in line with the concentration used. OPCML was clearly
detectable after induction with as little as 100 ng/ml in the wild-type and 500 ng/ml
in the mutant. In both the wild-type and the mutant clones, there was a very good
positive correlation between dox concentration and amount of protein detected by
densitometry (r = 0.98 for the wild-type and 0.99 for the mutant). In order to validate
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the specificity of the anti-OPCML antibody, two controls were used: the SKOV-3
OfCMf-transfected cell line as a positive control and the untransfected parental cell
line as negative control. Presence of immunoreactivity in the positive control and
absence thereof in the negative control confirmed the specificity of the antibody
employed. Notably, OPCML was detected as a doublet in all lysates. The
approximate size of the doublet is 55 kDa. At the RNA level, OPCML expression
rose as the concentration of dox increases (r = 0.98 for both the wild-type and the
mutant). Low levels of uninduced expression were also observed, in accordance with
the non-quantitative RT-PCR data. It is also important to note that a comparison
between the protein and RNA data confirmed that they were well correlated (r = 0.97
for both the wild-type and the mutant). Moreover, it is interesting that although the
mutant clone exhibited overall lower expression levels at the protein level in







Figure 3.5 Characterisation of the selected HeLa Tet-On OPCML
clones at the protein and RNA level
The two selected clones were induced for 48 h with a gradient of dox concentrations
and assayed for OPCML expression by western blotting (A, B) and qRT-PCR (C).
Panel B shows the densitometric quantification of panel A. RNA expression was
calculated relative to beta actin. DNA and PCR contamination controls were
negative (data not shown).
WT = wild type; Mut = mutant; +ve = positive control (SKOV-3 OPCML);
-ve = negative control (SKOV-3 parental); [dox] = dox concentration ranging from
100 to 1000 ng/ml; IOD = integrated optical density.
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Having established the concentration of dox needed for OPCML protein
induction in the selected clones based on the above experiment, the minimum dox
concentration required for each clone was subsequently examined. This would
facilitate the expression of OPCML at a level approximating the physiological one,
which previous work had suggested to be low in the human ovary. The previous
experiment was therefore repeated, but the concentrations of dox used for each clone
were centred around the lowest ones identified in the previous experiment that were
sufficient to induce detectable OPCML protein. Hence, for the wild-type clone a dox
range of 50 to 500 ng/ml was used, whereas for the mutant clone the range was 100
to 750 ng/ml. The two clones were treated with dox for 48 h, and protein lysates
were collected. Figure 3.6 shows this experiment's western blot with the
anti-OPCML antibody and its quantification. As can be seen, the OPCML doublet
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Figure 3.6 Finding the minimal dox concentration required to induce
OPCML expression in the selected HeLa Tet-On OPCML clones
The two selected clones were induced for 48 h with a gradient of dox concentrations
and assayed for OPCML expression by western blotting (A, B). Panel B shows the
densitometric quantification of panel B.
WT = wild type; Mut = mutant; +ve = positive control (SKOV-3 OPCML);
-ve = negative control (SKOV-3 parental); [dox] = dox concentration in multiples of x,
where x = 50 ng/ml; IOD = integrated optical density.
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It is known that OPCML is a glycosylated protein; the detection of a doublet
by western blotting is likely to indicate isoforms bearing different degrees of
glycosylation, as has been previously reported. To demonstrate this, protein lysates
prepared for the two HeLa Tet-On clones, as well as the SKOV-3 OPCML cell line
and the SKOV-3 untransfected parent, were treated with a deglycosylation enzyme,
PNGase F. The treated samples were immunoblotted alongside untreated samples.
Deglycosylation resulted in the two bands of each doublet merging into a single band
of a reduced size, approximately 38 kDa (Figure 3.7). Notably, it was evident in this
blot, as in previous ones (e.g. Figure 3.6), that only one band of the SKOV-3 doublet
is met in the doublet of the HeLa Tet-On cells. Hence, it appeared that the OPCML
glycoprotein species differ in the two cell lines.
WT Mut +ve -ve
+ - + + PNGase F
55 kDa
38 kDa
Figure 3.7 Deglycosylation experiment
Lysates from the two selected HeLa Tet-On OPCML clones were collected after
induction with dox for 48 h. The lysates were treated with PNGase F or left
untreated and were immunoblotted with the anti-OPCML antibody.
WT = wild type; Mut = mutant; +ve = positive control (SKOV-3 OPCML);
-ve = negative control (SKOV-3 parental).
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3.3 The SKOV-3 Tet-On system
As previously mentioned, the reasons for choosing an inducible system so as
to study the functions ofOPCML included the ability to work at a level of expression
that is comparable to the physiological level and hence avoids over-expression
artefacts, as well as being able to make comparisons in the same clone without the
issue of clonal variation. Furthermore, the choice of a non-ovarian cell line was
based on availability constraints. The hope was that HeLa cells transfected with
OPCML would behave similarly as SKOV-3 cells as a model of gynaecological
cancer in vitro, and if not, comparisons would be valuable in respect with context
specificity. However, some serious problems were encountered that led to a change
of direction for the future. Firstly, both selected HeLa Tet-On OPCML clones
exhibited "leaky", uninduced, expression (Figure 3.5), which as will be seen in
chapter 4 is actually comparable to the expression of OPCML in the human ovary
(Figure 4.12) and thus likely to be functional. Secondly, as will be discussed in
chapter 5, transfection of OPCML into the non-ovarian HeLa cells does not incur the
same phenotypic attributes as those in the ovarian SKOV-3 cells. As a result, the
HeLa system is not an optimal tool to study a tumour suppressor gene in ovarian
cancer. It was therefore important to change strategy for the future and try to
establish an inducible system in an ovarian cell line. This would have to be
undertaken in two steps: initially, creating a SKOV-3 Tet-On cell line by transfection
of a regulatory plasmid; and then creating a double stable cell line by a further
transfection of an OPCML-encoding response plasmid. The regulatory plasmid used
was the same pTet-On plasmid that the commercial HeLa Tet-On cells contain
(Appendix C); however, the response plasmid was a second generation version,
which is reported to offer a tighter regulation of gene expression, avoiding
"leakiness" typical of its older version. The plasmid used was pTRE-Tight from BD
Biosciences (Appendix C).
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3.3.1 Creation of a stable SKOV-3 Tet-On cell line
The first step in the creation of a successful SKOV-3 based inducible system
was to stably transfect SKOV-3 cell with the pTet-On plasmid. The cells were
subjected to three independent transfections and selection based on neomycin
resistance. Approximately 30 clones were picked from each transfection, expanded
and subjected to screening.
3.3.2 Selection of an inducible SKOV-3 Tet-On clone
The selection of an inducible stable SKOV-3 Tet-On clone was based on
screening by three independent methods: reporter assays, growth curves and transient
transfections with OPCML.
The principle behind screening by reporter assays is that the temporary
introduction of a luciferase-encoding response plasmid into the SKOV-3 Tet-On
clones should allow to test which clones exhibit favourable inducibility profiles by
examining luciferase extivity. The screening was performed after transiently
transfecting the clones under test with pTRE2hyg-Luc, which is a response plasmid
harbouring the luciferase gene as a reporter. Following the transient transfections, the
clones were treated with dox for 48 h or left untreated and then assayed for luciferase
activity. The criteria for selection were as previously: high fold-induction (more than
20-fold) and low uninduced activity. Figure 3.8 shows the four clones that were
selected after screening based on the aforementioned criteria. All four SKOV-3
Tet-On clones exhibited more than 20-fold induction, as well as a low uninduced
luciferase activity. It was therefore inferred that these clones have the potential to
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Figure 3.8 The four selected SKOV-3 Tet-On clones based on reporter
assays
SKOV-3 Tet-On clones were transiently transfected with pTRE2hyg-Luc, grown in
the presence or absence of dox for 48 h and assayed for luciferase activity by a
reporter assay.
Fold-induction = ratio of induced over uninduced luciferase levels;
RLU = relative luminescence units.
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The next round of screening aimed at examining the growth characteristics of
the selected clones in order to ensure that they grow similarly to the parental cell
line. The four clones were thus used in a growth curve experiment, whereby Tet-On
cells were seeded and counted over a 9-day period so that their growth characteristics
could be compared to the parental cells. As can be seen in Figure 3.9, all clones grew
relatively similarly to the SKOV-3 parent, apart from clone 3.8 that grew



























Figure 3.9 Growth curves of selected SKOV-3 Tet-On clones
The four selected SKOV-3 Tet-On clones were tested in growth characteristics
against their parental cell line. Cells were seeded and counted over a period of nine
days. Error bars represent the SD of three replicates.
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The ultimate selection assay examined the potential of the four Tet-On clones
to allow induction of our specific gene of interest, i.e. OPCML. To this end, the four
clones were subjected to transient transfections with the pTRE-Tight vector
containing the human OPCML sequence (see following section). The
transiently-transfected clones were treated with dox for 48 h or left untreated and
RNA was collected. Inducibility was examined by RT-PCR using a forward
OPCML-specific primer and a reverse vector-specific primer. As is evident in Figure
3.10, the Tet-On clone that satisfied best the selection criteria was clone 2.33: it
exhibited minimal uninduced expression and sufficiently strong induction of
OPCML, in this transient transfection assay. SKOV-3 Tet-On clone 2.33 was
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Figure 3.10 Transient transfections of selected SKOV-3 Tet-On clones
with pTRE-Tight OPCML
The four selected SKOV-3 Tet-On clones were transiently transfected with a
response plasmid encoding OPCML, grown for 48 h with or without dox and
assayed for expression of OPCML by RT-PCR. Products were run on a 2% (w/v)
agarose gel stained with EtBr. DNA and PCR contamination controls were negative
(data not shown). L = 100 bp DNA ladder; ACTG1 = gamma actin.
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3.3.3 Creation of a double stable SKOV-3 Tet-On OPCML cell line
As the response vector to be used in the second round of transfections was
not the same as the one used in the HeLa Tet-On OPCML cells, the OPCML
sequence had to be cloned in the new vector, pTRE-Tight (Appendix C). The
respective cDNA fragment was excised from the pcDNA3.1/Zeo construct (used in
the SKOV-3 OPCML cell line; see chapter 2) and cloned into pTRE-Tight. Figure
3.11 shows plasmid DNA from six potentially insert-containing colonies digested
with a restriction endonuclease that allows separation of the vector and the insert. As
can be seen, five out of six colonies did actually contain the insert. In order to
confirm the sequence integrity of the inserts and also determine the orientation of
insert integration in the vector, these five positive clones were sequenced (data not
shown). Finally, one clone was selected that was sequence-perfect and where the
insert had ligated in the sense orientation.
L 1 2 3 4 5 6
<- Vector (2.6 kb)
<- Insert (-1.1 kb)
Figure 3.11 Cloning of OPCML into pTRE-Tight
The wild-type OPCML sequence was cloned into pTRE-Tight. After transformation
of competent bacteria, potentially positive colonies were picked, plasmid DNA was
prepared and digested with Notl to release the insert.
Products were run on a 1% (w/v) agarose gel stained with EtBr.
L = 1 kb DNA ladder; numbers 1 to 6 represent six individual colonies.
The pTRE-Tight OPCML construct was co-transfected into the SKOV-3
Tet-On 2.33 clone in combination with a linear cDNA encoding a
hygromycin-resistance marker. Three independent stable transfections were carried
out, and the cells were placed under hygromycin selection. Hygromycin-resistant
colonies were picked and expanded for further analysis. SKOV-3 Tet-On OPCML
double stable clones are currently under test for inducibility profiles by qRT-PCR,
using an OPCML-specific primer set. Figure 3.12 shows an experiment
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Figure 3.12 Screening of SKOV-3 Tet-On OPCML clones
Clones were grown for 48 h with or without dox and then assayed for OPCML
induction by qRT-PCR. Expression is shown relative to beta actin. DNA and PCR
contamination controls were negative (data not shown). Numbers represent different
clones. Fold-induction = ratio of induced over uninduced relative expression.
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3.4 Discussion
In the quest to understand better what OPCML does and identify functions
that have not been studied before in the locality with which it has been typically
associated, i.e. the brain, an inducible system of expression was developed to
complement an already-existing over-expression system21. The parallel use of the
two systems would allow the investigation of OPCML biology from different
perspectives. An inducible system offers advantages that a traditional system lacks: it
allows the study of a gene of interest in a regulated fashion, such that level of
expression can be linked to function; working at expression levels that are not
exaggerated renders functional characterisation potentially more reliable avoiding
over-expression artefacts and better approximating physiological roles; and finally,
comparisons between induced and uninduced states within the same clone surpass
concerns of clonal variation.
Even though the over-expression system is based on a SKOV-3 ovarian
cancer cell line, arguably offering a better-suited platform to investigate a novel
tumour suppressor gene in ovarian cancer, the inducible resource used is a HeLa
cervical cancer Tet-On system. HeLa cells are considered to be particularly stable tet
responders260. Another advantage in using the HeLa system is that even if
transfection of OPCML results in a different phenotype than in SKOV-3 cells, any
differences identified would underpin the significance of context specificity.
When an inducible system of expression is created, the ultimate expectation
is the identification of clones that do not exhibit "leaky", uninduced expression, but
offer robustly regulated induced expression. Extensive screening of HeLa Tet-On
OPCML clones did not yield any clones of such characteristics. The clones that were
selected, one wild-type and one mutant OPCMZ-expressing clones, both exhibit
some level of uninduced expression. The selection of these two clones relied on the
assumption that the levels of uninduced expression were sufficiently low to be
functionally insignificant. Reported work is often based on such less-than-optimal
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In both the wild-type and mutant Tet-On clones, doxycycline induction
results in a well-regulated expression of OPCML both at the RNA and protein levels.
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RNA was induced in concert with the amount of the inducer used, supporting the
hypothesis that in defined circumstances transcription can occur in a graded rather
270than threshold manner . Protein levels are also in concert with the amount of
doxycycline used to induce OPCML expression. Importantly, for each clone, there is
a clear correlation between RNA and protein levels, suggesting that the regulated
transcription of OPCML can be used to achieve a regulated functional expression.
Interestingly, even though the same amount of doxycycline induces a higher OPCML
RNA expression in the mutant than the wild-type clone, the converse is true for
protein expression. This probably suggests that, as a clone, HeLa OPCMLMut Tet-On
has lower translation efficiency than its wild-type counterpart; alternatively, the
mutant OPCML protein might be less stable. In contrast, HeLa OPCMLWT Tet-On is
generally more responsive to doxycycline induction at the protein level, with much
lower amounts of the inducer needed.
OPCML is reported to have six putative N-linked glycosylation sites9,
although our in silico analysis has identified five. In fact all IgLONs undergo
post-translational glycosylation and this has been confirmed by deglycosylation
• • R S4
experiments for multiple members of the family ' . In both the HeLa cells and the
SKOV-3 cells the OPCML protein is detected as a doublet of an approximate
molecular weight of 55 kDa. Removal of glycosylation results in the detection of
OPCML as a single band at approximately 38 kDa. This is in fact the predicted
molecular weight of the native protein, confirming that the apparent size of the 55
kDa protein is due to glycosylation. The two bands of the doublet are likely to
exemplify processed proteins of different degrees of glycosylation. Of potential
interest is the fact that there is a difference in the appearance of the HeLa doublet in
comparison to the SKOV-3 one. This disparity in the OPCML protein is the first
example of divergence between the two systems and might be a contributing factor in
any functional differences identified and discussed in chapter 5. Differences in
glycosylation, which are conferred post-translationally, often have functional
consequences271.
Despite the usefulness of the effort devoted in the development of the HeLa
Tet-On OPCML system, issues that are related to the link of OPCML with ovarian
cancer are better addressed by the use of an ovarian system, such as the SKOV-3
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OPCML resource. In addition, potential obstacles arising from the "leakiness" that
has been identified in the HeLa Tet-On system prompt the use of a more refined
inducible system. These two factors have made the consideration of a SKOV-3
inducible system imperative, albeit with a priority that became evident towards the
end of this work. Hence, the generation of a SKOV-3 Tet-on cell line was
undertaken.
In order to maximise the chances of a successful system, the selection of a
favourable SKOV-3 Tet-On clone was thee-fold. Clones were initially selected on
the basis of inducibility after transient transfections with a response plasmid that
encodes luciferase, the activity of which can be easily measured by reporter assays.
Four clones were selected, all with high fold-induction and low background levels.
These clones were further tested to ensure that they grow similarly to their parental
cell line. Finally, transient transfections with a response plasmid encoding OPCML
demonstrated how these four clones would potentially act as hosts that allow the
regulated expression of an exogenous gene. Taken together, the data from the three
independent selection methods pointed to the most favourable SKOV-3 Tet-On
clone.
The creation of a SKOV-3 inducible system of OPCML expression would
have to ensure that precautions were taken to minimise the risk of "leaky", i.e.
uninduced, expression. To this end, OPCML was cloned in a second-generation
response plasmid, pTRE-Tight, which should offer a tighter regulation of the
exogenous gene by the inducer than its predecessor. After stably transfecting
pTRE-Tight OPCML into the selected SKOV-3 Tet-On clone, extensive qRT-PCR
screening is currently being performed. Thus far, several clones with favourable
inducibility profiles have been identified. In spite of the fact that these clones became
available at the end of this work and thus were not further characterised, it is hoped
that they will be a valuable resource for the study of OPCML function in the future.
If more time were available, the screening would continue until selecting a few
clones that satisfied best the inducibility criteria. Subsequently, these clones would
be further characterised at both the RNA and protein levels, similarly to the HeLa
Tet-On clones. Finally, the selected and characterised SKOV-3 Tet-On OPCML
clones could be used in functional studies.
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Overall, the work desrcribed in this chapter has established two important
tools that would allow the study of OPCML function. Firstly, an inducible system of
gene expression in HeLa cells was created and characterised fully. This system was
subsequently used in the functional characterisation of OPCML, alongside the
SKOV-3 over-expression system, as will be presented in chapter 5. Secondly, a
SKOV-3 inducible system was also created in order to provide a better platform to
study the functions of OPCML in an ovarian context. This resource has not been
fully developed yet, but once the screening and characterisation is complete, it will
provide a valuable tool for the future.
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Chapter 4
Studies on IgLON expression
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4.1 Introduction
The exploration of the expression profiles of the IgLON family has been a central
theme in this work. In its pursuit, the ultimate aim was to build a detailed picture of
the expression patterns of the four IgLONs in order to complement and extend
existing data. A holistic characterisation of the IgLON family at the level of
expression will enhance our understanding of the biology of this group of adhesion
molecules and add essential information to the knowledge that has been thus far
acquired mainly by studies in the chick and rat nervous systems.
So, what is currently known about the expression of IgLON family members?
Briefly reiterating what has been extensively presented in chapter 1, it is known that
IgLON expression patterns in the brain are distinct but also overlapping: OPCML is
1 R
mainly expressed in the grey matter , HNT in the sensorimotor cortex and the
cerebellum27, LSAMP in the cortical and subcortical neurones of the limbic system^3
and NEGRI in the cerebrum and brain stem54.
This chapter presents results that extend the study of IgLON expression to
additional levels. Expression studies were undertaken in two species, namely mouse
and human, as well as various human cancer cell lines. In the mouse and human,
studies were undertaken both in adult tissues, and also in development. Moreover,
the expression of the family was established in epithelial ovarian cancer, in addition
to the normal ovary. All these diverse expression analyses were approached by a
multitude ofmethods, ranging from the molecular to the histological level.
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4.2 IgLON expression in cell lines
As a starting point of IgLON expression profiling, the first line of experiments
focused on establishing the expression levels of the family in various human cancer
cell lines of both ovarian and non-ovarian origin. The only similar data to date exist
• 91
with respect to OPCML, as reported by Sellar et al. . Hence, establishing the
profiles of the other family members in a wider panel of cell lines can be regarded as
a pilot experiment before addressing expression in cancer.
4.2.1 IgLON RNA expression in a panel of cancer cell lines
In order to determine the RNA levels of the four IgLONs in cancer cell lines,
a panel comprising 17 ovarian and 14 non-ovarian cell line samples was used.
Expression of each IgLON was measured in the panel by qRT-PCR. Figure 4.1
illustrates the results. OPCML expression was not detected in any cell line.
Significant HNT RNA expression was only detected in two cell lines, namely
CaOV-3 and 59M, both of ovarian origin. LSAMP was expressed in 11 out of the 14
ovarian cell lines, showing a range of expression levels, from extremely high to low.
In addition, it was expressed highly in only one non-ovarian cell line, PANC-1,
which is of pancreatic origin; it also exhibited low expression in other two
non-ovarian cell lines. Finally, there appeared to be three groupings in NEGRI
expression in ovarian cell lines: six cell lines exhibited high expression, five cell
lines exhibited low expression and the remaining seven minimal to none. With
respect to non-ovarian cell lines, there were three high-expressers, one low-expresser






Figure 4.1 IgLON RNA expression in a panel of cell lines
RNA levels of OPCML (A), HNT (B), LSAMP (C) and NEGRI (D) in a panel of
cancer cell lines, as measured by qRT-PCR. IgLON expression in ovarian (salmon)
and non-ovarian (turquoise) cell lines is shown relative to beta actin expression, in
decreasing order. DNA and PCR contamination controls were negative (data not
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4.2.2 IgLON RNA expression in OPCML-transfected cell lines
The functional characterisation of OPCML, as will be presented in chapter 5,
is based on the use of two cell line resources: an over-expression system in SKOV-3
ovarian cancer cells and an inducible expression system in HeLa cervical cancer
Tet-On cells. There is considerable homology within the IgLON, both at the level of
the structure of the genes and the protein sequence they encode, as well as the
postulated functions of the latter. A lot of these functions are thought to be mediated
by IgLONs interacting with each otheft7. Thus, the examination of the relative levels
of all the IgLONs in the OPCML-transfected cell lines was a necessary step in order
to be able to point to differences between the two systems that might be reflected on
phenotypic divergence. It also directly addresses any potential expression
relationships that IgLONs might have, in addition to how these are affected by
OPCML.
The examination of IgLON expression was restricted to the RNA level, as
fully optimised antibodies were not available for all the IgLONs. As shown in Figure
4.2, parental SKOV-3 cells did not express OPCML; after transfection with either
wild-type or mutant OPCML, there was high expression of both cDNAs, with mutant
OPCML expression being lower than that of the wild-type. How did this reflect on
the expression of the rest of the IgLONs? HNT RNA was not detectable in the
SKOV-3 cell lines. LSAMP expression showed a 43-fold drop in the wild-type
OPCML expresser (p = 0.002) and a 25-fold decrease in the mutant (p = 0.002)
relative to the parental cell line. NEGRI expression was halved after expression of
OPCML, both in the wild-type (p = 0.001) and mutant (p < 0.001) expressers. In
HeLa Tet-On cells, significant expression of OPCML was demonstrated at the high
level of induction. Like SKOV-3 cell lines, HeLa Tet-On cells did not express HNT
at the RNA level. LSAMP RNA expression was very low, whilst NEGRI expression
was much higher than in SKOV-3 cells; it did not differ after induction of OPCML
though.
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It is interesting to note that in the SKOV-3 cell lines, OPCML expression was
negatively correlated with both LSAMP and NEGRI (r = -0.97 for both). LSAMP
expression was directly proportional to that of NEGRI (r = 1.00). In HeLa Tet-On
cells, OPCML expression did not correlate with either LSAMP or NEGRI. The

















Figure 4.2 IgLON expression in the OPCML-transfected cell lines
Expression of OPCML (A), HNT (B), LSAMP (C) and NEGRI (D) in the SKOV-3
OPCML and HeLa Tet-On OPCML cell lines. RNA expression is shown relative to
beta actin. DNA and PCR contamination controls were negative (data not shown).
Error bars represent the SEM of three independent experiments.
**
p < 0.01 as compared to parental/uninduced cell lines by Student's t test.
WT = wild type; Mut = mutant; Par = parent;
+ dox, ++ dox, - dox = 48 h treatment with 100 ng/ml dox, 1000 ng/ml dox and no
dox respectively.
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4.2.3 Confirmation of the transcriptional effect of OPCML
The effect of OPCML expression on the expressions of LSAMP and NEGRI
was quite pronounced, even if only demonstrated at the RNA level. It was decided to
investigate this transcriptional effect further, by attempting to reproduce it in an
independent context. A first test was to examine the expression of IgLONs in an
alternative SKOV-3 OPCML clone, deriving from an independent transfection of the
same wild-type OPCML construct used in the SKOV-3 OPCMLWT clone. To be able
to distinguish them, let this alternative clone be called SKOV-3 OPCMLWT2.
As can be seen in Figure 4.3, OPCML expression influenced the expression
of both LSAMP and NEGRI in the SKOV-3 OPCMLWT2 clone. Relative to the
parental cell line, there was a three-fold decrease in the expression of LSAMP and a
four-fold decrease in the expression of NEGRI. Notably, the expression of OPCML
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Figure 4.3 The effect of OPCML expression on the transcription of
LSAMP and NEGRI: confirmation on an independent SKOV-3 OPCML
clone
Expression of the four IgLONs at the RNA level in the SKOV-3 OPCMLWT2 clone
and its parent as determined by qRT-PCR. RNA expression is shown relative to
beta actin. DNA and PCR contamination controls were negative (data not shown).
WT.2 = wild-type clone 2; Par = parent.
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Having confirmed the effect of OPCML expression on LSAMP and NEGRI
expression in SKOV-3 cells, two questions emerged: firstly, whether this effect is a
feauture of this particular cell line; secondly, whether the effect on LSAMP is
independent of the effect on NEGRI or the effect on one secondarily results in an
effect on the other as the two are correlated. In order to address these two issues, two
other ovarian cancer cell lines were used. PEA2, a cell line expressing very little
LSAMP RNA, and PE023, a cell line expressing minimal NEGRI RNA. To express
OPCML in these cell lines, transient transfections were undertaken, with the same
wild-type OPCML construct used in SKOV-3 OPCML cells.
Figure 4.4 shows the RNA levels of the IgLONs in the two ovarian cell lines
following transient transfections with the OPCML-containing plasmid. In both PEA2
and PE023 cell lines, the transient transfections caused successful expression of
OPCML. In PEA2 cells, expression of OPCML resulted in a 1.8-fold decrease in the
RNA level of LSAMP and a 1.5-fold decrease in the level ofNEGRI. In PE023 cells,
expression of OPCML was accompanied by a 2-fold drop in LSAMP RNA
expression, whereas the minimal NEGRI expression was abolished. It should be
noted that the transfection efficiencies were not estimated for these experiments.
Thus, the observed fold-differences are likely to be an under-estimation of a more





















































Figure 4.4 The effect of OPCML expression on the transcription of
LSAMP and NEGRI: confirmation on two additional ovarian cell lines
Expression of the four IgLONs at the RNA level after transiently expressing OPCML
in PEA2 (A) and PE023 (B) cells as determined by qRT-PCR. RNA expression is
shown relative to beta actin. DNA and PCR contamination controls were negative
(data not shown). Note differences in y-axis scale.
Con = untransfected control.
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4.3 IgLON expression in the mouse
The first species wherein extensive expression studies were undertaken was
the mouse. The mouse was initially chosen as a well-suited organism to address the
issue of developmental expression. Studies were subsequently extended in the adult
mouse.
4.3.1 Developmental study of IgLON expression by whole-mount in
situ hydridisations
One of the most suitable ways to study expression patterns of genes of
interest is by in situ hybridisation. This technique is widely used to profile the
expression of genes at the RNA level and is particularly suited for developmental
studies. Developmental profiling is useful in two ways. Firstly, it provides evidence
for whether a gene is developmentally regulated and hence is likely to play a role in
normal development. Secondly, associations between expression of genes and
specific developmental windows can suggest potential functions.
Whole-mount in situ hybridisation (WISH) can be used as a means to acquire
developmental profiles when previous knowledge is limited and there is no particular
tissue of interest. One can thus establish where and when genes are expressed by
using one sample for each developmental time-point.
The technique of whole-mount in situ hybridisation was used in order to
profile the expression of the four IgLON genes in mouse development. In brief, the
work consisted of three stages: the generation of mouse IgLON-specific riboprobes,
the collection of sufficient numbers of mouse embryos at different stages of
development and the implementation of the in situ protocol.
115
In order to generate the mouse IgLON RNA probes, the individual mouse
sequences were firstly identified by comparison to the respective human sequences.
At the time, there were complete mouse coding sequences for Hnt, Lsamp and
Negri, but not for Opcml. For the latter, the sequence used was derived from two
separate sequences (GenBank NM_177906.2 and XM_134679.2), which were
merged to give the complete Opcml coding sequence. The criteria for selection of
target regions consisted of a size restriction, aiming at targets of up to 1 kb, but most
importantly target specificity. IgLON sequences are highly similar and also there are
various potential alternative isoforms based on in silico evidence. These criteria had
to be applied when designing the primers to amplify the targets regions, which would
then be cloned in the appropriate expression vector. Hence, primer-annealing sites
had to be unique for one particular IgLON, i.e. in areas of acceptable sequence
divergence within the family, and representative of all potential isoforms, i.e. in areas
where all these isoforms are identical. These criteria restricted the number of
potential probes to only one probe per gene. The alignment of mouse IgLON coding
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AAATGACAAGTGGTGCCTAGATCClTCGTgfGGTCCTCCTGAGTjAACACCCAGACCCAGTA 2 93







agtatcatgatccagaatgtggatgtatacgatgaaggtccatacacctgctctgtgca 3 5 3
agcattgagatccagaatgtggatgtgtacgatgagggcccttatacctgctcggtaca 3 53
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Figure 4.5 Target regions for mouse WISH probes
ClustalW multiple sequence alignment of partial mouse IgLON coding sequences.
Highlighted sequences show selected target regions. Boxed sequences indicate
primer-annealing sites. Asterisks denote identical nucleotides in all four sequences.
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Once the target regions had been chosen, they were amplified from mouse brain
cDNA using the specific primers. Brain was chosen, as this locality is where the




Figure 4.6 Mouse IgLON products for cloning in expression vector
Mouse cDNAs for cloning in expression vector for generation of IgLON riboprobes.
The targets regions were amplified from mouse brain cDNA and the PCR products
run on a 2% (w/v) agarose gel stained with EtBr.
L = 100 bp DNA ladder; O = Opcml; H = Hnt; L = Lsamp\ N = Negri.
The above sequences were cloned into pGEM-T easy, which is both a basic
cloning as well as an expression vector, containing the appropriate promoters
(Appendix C). DIG-labelled riboprobes were generated in antisense and sense
orientations, the latter to serve as negative controls.
Various WISH protocols were attempted. However, none of the generated
riboprobes was successful (data not shown). There was no signal with any of the
probes tested in any developmental stage. In contrast, two probes used as positive
controls worked as expected (Figure 4.7). These probes recognised their respective
transcripts, namely Shh and Fgf8, revealing the involvement of these two genes in
limb bud development.
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Figure 4.7 Staining of mouse embryos with the control probes
E10.5 mouse embryos stained with positive control riboprobes by WISH. Images
taken after 1 h of signal development. Staining with the Shh antisense probe (A,B)
and the Fgf8 antisense probe (C,D); details showing limb bud signal (B,D).
4.3.2 IgLON expression in multiple-tissue cDNA panels
In order to examine the expression of the IgLON family in the mouse at the
RNA level, panels of cDNAs from multiple adult tissues, as well as embryonic
stages, were used. As can be seen in Figure 4.8, Opcml was strongly expressed in the
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brain and testis; its expression level varied in the rest of the tissues, being
undetectable only in the lymph node, the liver and the kidney. Hnt was strongly
expressed in the eye, the uterus and the brain and to a varying degree in all other
tissues apart from smooth muscle. Lsamp was detected strongly in the eye, the
prostate, the uterus and the brain, with again varying expression across the rest of the
panel and negative expression in the bone marrow and the spleen. Negri exhibited
strong expression in the brain, and varying levels of expression elsewhere except in
the placenta and the spleen where no expression was detected. Notably, all the
IgLONs seemed to be developmentally regulated, with expression levels that
increased with embryonic age. This trend was particularly pronounced for Opcml and
Negri. Moreover, although at E7 there was hardly any Opcml or Negri expression,
Hnt and Lsamp were visibly expressed.
L PI Ey LNsM Pr Th St Ut^ve+ve-ve He Br Sp Lu Li SM KiTe E7 El 1 E1S E17
L PI Ey LNsM Pr Th St Ut+« +ve _ve He Br Sp Lu Li SM KiTe E7E11E15E17
Hnt
Lsamp
L PI Ey LNsM Pr Th St Ut+Ve +ve -ve He Br Sp Lu Li SM KiTe E7E11EI5E17
Negri
Actb
L PI Ey LN sM Pr Th St Ut+Ve +ve -ve He Br Sp Lu Li SM KiTe E7 El 1 E15 E17
L PI Ey LNsM Pr Th St Ut+ve +ve ,ve He Br Sp Lu Li SM KiTe E7E11E15E17
Figure 4.8 Mouse IgLON expression in multiple-tissue panels
Expression of the four IgLONs in multiple-tissue mouse cDNA panels by RT-PCR.
L = 100 bp DNA ladder; Actb = beta actin; PI = placenta; Ey = eye; LN = lymph
node; sM = smooth muscle; Pr = prostate; Th = thymus; St = stomach; Ut = uterus;
He = heart; Br = brain; Sp = spleen; Lu = lung; Li = liver; SM = skeletal muscle;
Ki = kidney; Te = testis; E7-11 = embryonic days 7 to 11; +ve = panels' positive
controls; -ve = PCR contamination control.
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4.3.3 Expression of Opcml in embryo sections
As the attempt to establish the expression patterns of the IgLON family in
mouse development by WISH was not fruitful, the issue of developmental expression
was addressed by an immunohistochemical approach. More specifically, this was
restricted to the study of Opcml only, due to antibody availability limitations.
The expression of Opcml was examined in the developing mouse embryo, from
the age of El 1 to E17. Staining in these embryo sections can be seen in Figure 4.9.
As can be seen, Opcml expression was very low at El 1 and increased gradually until
El7. Various tissues were positive for Opcml staining, including: parts of the brain,
muscle, heart, liver, skin, and epithelia of the intestine and kidney.
Figure 4.9i Opcml expression in mouse development
Staining of mouse embryo sections for Opcml expression by immunohistochemistry.
Antibody controls were negative (data not shown). Images are at 1.6x magnification
and have the same aspect ratio.
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Figure 4.9ii Opcml expression in mouse development (continued)
Staining of mouse embryo sections for Opcml expression by immunohistochemistry.
Antibody controls were negative (data not shown). Images are at 1.6x magnification
and have the same aspect ratio.
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Figure 4.9iii Opcml expression in mouse development (continued)
Staining of mouse embryo sections for Opcml expression by immunohistochemistry.
Antibody controls were negative (data not shown). Images are at 1.6x magnification
and have the same aspect ratio.
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Figure 4.9iv Opcml expression in mouse development (continued)
Staining of mouse embryo sections for Opcml expression by immunohistochemistry.
Antibody controls were negative (data not shown). Images are at 1.6x magnification






Figure 4.9v Opcml expression in mouse development (continued)
Staining of mouse embryo sections for Opcml expression by immunohistochemistry.
Antibody control was negative (see Figure 4.9vi). Images are at 1.6x magnification
and have the same aspect ratio. CP = cerebellar primordium; Mb = midbrain; Fb =
forebrain; TgG = trigeminal ganglion; MO = medulla oblongata.
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Figure 4.9vi Opcml expression in mouse development (continued)
Staining of mouse embryo sections for Opcml expression by immunohistochemistry:
an example of negative antibody control staining. Images are at 1.6x magnification
and have the same aspect ratio.
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4.3.4 Expression of Opcml in tissue arrays
In order to complete the profiling of Opcml in the mouse, its expression was
examined histologically in tissue arrays representing 26 different organs. The results
are summarised in Table 4.1 and shown in Figure 4.10.
Organ Opcml expression
Bladder Strong epithelial and moderate smooth muscle staining.
Bone marrow Undefined staining.
Breast Epithelial/myoepithelial staining in lobular structures.
Cerebral cortex Diffuse staining.
Diffuse staining throughout; strong in specific cell types, e.g.
Purkinje cells.
Strong retinal staining in ganglion cell layer, of neuronal
processes in outer and inner plexitorm layers, of inner segments
in photoreceptor layer and of pigment cells.
Strong epithelial and some weak stromal staining.
Staining of all main cardiac tissue types; might be unspecific
(weaker antibody control staining).
Staining in tube and duct structures; might be unspecific
(weaker antibody control staining).
Strong epithelial staining in villi and crypts. Moderate staining in
muscularis mucosa.
Strong staining of outermost epithelium.
Staining of undefined cell populations.
Moderate staining around bronchial/alveolar structures.
Staining throughout.
Staining in follicular and derivative structures. Undetermined
OSE staining due to "edge effects".
Staining throughout.
Staining in grey matter, probably of central horns.
Staining of epidermis only.
Staining in red pulp mostly.
Staining in glands, i.e. of mucous and peptic cells.
Staining of undefined cell populations.
Negative.
Table 4.1 Opcml expression in a mouse tissue array: data synopsis
Notes on the staining of a mouse normal tissue array for Opcml expression by




















Figure 4.1 Oi Opcml expression in a mouse tissue array
Examples of positive specific staining of a mouse normal tissue array for Opcml
expression by immunohistochemistry. Antibody controls were negative (see
examples in Figure 4.10iii). All images are at 10x magnification. Bladder (A);
cerebellum (B); eye (C); fallopian tube (D); large intestine (E); muscle (F).
E = epithelium; SM = smooth muscle; WM = white matter; GL = granular layer; ML =
molecular layer; P = Purkinje cells; OPL = outer plexiform layer; IPL = inner




Figure 4.1 Oii Opcml expression in a mouse tissue array (continued)
Examples of positive staining of a mouse normal tissue array for Opcml expression
by immunohistochemistry. Antibody controls were negative (see example in Figure
4.10iii). All images are at 10x magnification. Ovary (G); spleen (H); stomach (I);
thyroid (J).
F = follicle; CL = corpus luteum; RP = red pulp; MC = mucous cells; PC = peptic
cells.
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Figure 4.1Oiii Opcml expression in a mouse tissue array (continued)
Examples of negative antibody controls in the mouse normal tissue array. All images
are at 10x magnification. Bladder (K); cerebellum (L); large intestine (M); muscle
(N); spleen (O); thyroid (P).
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4.4 IgLON expression in the human
The second species wherein the issue of IgLON expression was addressed is
the human. With OPCML being a putative TSG in epithelial ovarian cancer,
particular attention was paid to the expression of OPCML and its relatives in EOC as
well as the normal ovary.
4.4.1 IgLON RNA expression in epithelial ovarian cancer
21
Expression of OPCML is reported to be reduced in sporadic EOC . Another
IgLON, LSAMP, has been reported to exhibit reduced expression in another type of
43
cancer, namely clear cell renal cell carcinoma . Moreover, the IgLONs are thought
to participate in heterophilic interactions57. All these clues prompted for an
examination of the IgLON family as a whole in sporadic epithelial ovarian cancer so
as to judge whether family members other than OPCML are relevant. Thus, a study
was undertaken to examine the expression of the four IgLONs in a well-characterised
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panel of 11 normal human ovaries and 57 EOC samples (Appendix D) . The details





















Median survival (years) 2.25
Table 4.2 The panel of normal ovaries and EOC samples
Details of the panel used in the expression study of the IgLON family in EOC.
FIGO = Federation Internationale de Gynecologie et d'Obstetrique.
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In order to evaluate the RNA expression levels of the four IgLON family
members in the panel, a real-time qRT-PCR approach was followed. OPCML,
LSAMP and NEGRI exhibited reduced expression in the majority of tumour samples
as compared with the normal ovaries (Figure 4.11). In contrast, tumour samples had
elevated HNT expression in relation to the normal ones. The distribution of data for
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Figure 4.11 IgLON RNA expression in EOC and normal ovary samples
RNA expression levels of OPCML (A), HNT (B), LSAMP (C) and NEGRI (D) in the
panel of EOC samples and normal ovaries as determined by qRT-PCR. IgLON
expression in normal ovaries (blue) and ovarian tumour samples (orange) is shown
relative to beta actin expression, in decreasing order. DNA and PCR contamination
controls were negative (data not shown).
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Upon observing graphs illustrating the median values of the four genes in the
EOC samples collectively and the normal ovaries, the aforementioned trends become
clearer (Figure 4.12). There was a 2.5-fold decrease in OPCML RNA levels in the
EOC samples as compared to the normal ovaries (not significant). LSAMP
expression was reduced by 3-fold (p = 0.038) and NEGRI expression by 11-fold (p =





Figure 4.12 IgLON RNA levels in EOC and the normal ovary
Median expression levels of the IgLONs in the EOC samples collectively versus
normal ovaries. The y-axis denotes expression relative to beta actin.
*
p < 0.05 as compared by Mann-Whitney test.
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Observing the expression data more closely, there were statistically
significant differences between normal ovaries and tumour histological subgroups for
all four IgLONs (Figure 4.13). More specifically, OPCML expression was
significantly reduced in clear cell carcinomas (p = 0.039); LSAMP expression was
reduced in endometrioid tumours (p = 0.012); and NEGRI expression was decreased
in serous (p = 0.014), clear cell (p = 0.009) and endometrioid (p - 0.001) tumours.
On the contrary, HNT expression was increased in serous carcinomas with respect to
















Figure 4.13 IgLON RNA levels in EOC according to histology
Median expression levels of the IgLONs in EOC histological subtypes versus normal
ovaries. The y-axis denotes expression relative to beta actin.
*
p < 0.05, ** p < 0.01 compared to normal ovaries by Mann-Whitney test.
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Does expression of one IgLON influence that of the others in the panel? To
address this question, potential correlations were tested non-parametrically. The
strongest correlation found was a positive correlation between the expressions of
LSAMP and NEGRI (rs = 0.55, p < 0.001).
In addition, IgLON expression was tested for associations with
clinicopathologic variables. Firstly, to establish whether IgLON expression was a
function of age in the panel, the expression of each gene was tested for correlation
with age as a continuous variable. However, significant correlations were not found.
With respect to the categorical variables, stage was not found to differentiate IgLON
expression. Nonetheless, there was a statistically significant difference in LSAMP
expression among tumours of different grades (p = 0.035). In fact, as can be seen in
Figure 4.14, this difference was even more significant when comparing grade 3
tumours (i.e. poorly-differentiated tumours) to the rest of the panel:
poorly-differentiated carcinomas had lower levels of LSAMP than moderately- or
well-differentiated ones (p = 0.017).
Figure 4.14 LSAMP expression according to differentiation status
Median expression levels of LSAMP in histological grade subgroups. The tumour
group was divided into grade 3 samples (i.e. poorly differentiated tumours) and
grades 1+2 samples (i.e. well- and moderately-differentiated tumours). The y-axis
denotes expression relative to beta actin.
136
The effect of IgLON expression on the survival of patients was tested at two
levels. Firstly, correlation between expression of each gene and overall survival was
examined. This highlighted LSAMP as having a negative correlation (rs = -0.30, p =
0.025). Secondly, patients were divided into high and low expressers for each gene,
using the median values of the normal samples as cut-off points. Survival curves
were plotted and the two groups compared (data not shown). However, statistically
significant differences were not found for any of the four genes on this split.
In order to investigate whether the expression level of an IgLON gene can
predict survival, the expression variables, as well as the clinicopathologic ones, were
tested for prognostic value by Cox regression analysis. As can be seen in Table 4.3,
in univariate analyses, LSAMP expression and stage were both found to be negative
predictors of overall survival. Both variables were still found to be significant
predictors of overall survival when tested together by multivariate analysis.
95% Confidence
Interval
Variable Odds ratio Lower Upper Significance
OPCML1 0.84 0.50 1.41 0.506
HNT' 1.15 0.84 1.57 0.376
u
LSAMP1 1.63 1.10 2.41 0.015
NEGRI1 1.30 0.86 1.% 0.221
Stage2 8.86 2.10 37.82 0.003
Grade3 22.06 0.04 13126 0.343
A/1
LSAMPf 1.85 1.14 3.02 0.013
iVl
Stage2 10.21 2.40 43.77 0.002
Table 4.3 Survival models
IgLON expression and clinicopathologic variables tested for prediction of overall
survival in the panel by Cox regression analysis.
U = univariate; M = multivariate.
1 Log-transformed.
2
Early (i.e. stages I and II) versus late (i.e. stages III and IV).
3
High (i.e. grade 3) versus rest (i.e. grades 1 and 2).
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4.4.2 IgLON RNA expression in an OSE-enriched sample
As discussed in chapter 1, epithelial ovarian cancer arises in the single-cell
layer overlying the ovary, the ovarian surface epithelium. The study undertaken to
examine IgLON expression in the normal ovary and EOC was based on whole ovary
samples, hence an issue that logically arose was at what levels IgLON expression is
detected in OSE cells. One of the ways this issue can be addressed is by using an
ovarian sample that is known to be representative of that cell population. Thus,
IgLON RNA expression was examined in an OSE-enriched sample. The results are
shown in Figure 4.15. In the OSE sample, OPCML and LSAMP exhibited
approximately double the expression as compared to the median expression in the
normal ovaries. NEGRI showed an even higher increase in the OSE sample, of
approximately 9 times. In contrast, HNT expression is approximately 6 times lower








Figure 4.15 IgLON RNA expression in an OSE sample
Expression levels of the four IgLONs in an OSE-enriched sample as determined by
qRT-PCR. Expression is shown relative to beta actin. DNA and PCR contamination
controls were negative (data not shown). For comparison, the median relative
expression in whole normal ovaries is also shown.
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4.4.3 IgLON expression in multiple-tissue cDNA panels
As in the mouse, the expression of IgLON genes was investigated in panels
representing various organs by RT-PCR. In the human, foetal panels were used in
addition to adult ones.
Figure 4.16 shows the results for the foetal panel. As can be seen, expression
of OPCML was detected mainly in the brain, but also the kidney and spleen. HNT
was expressed mostly in the brain, the lung, the kidney and the heart, with minimal
expression detected in the rest of the organs. LSAMP expression was very similar to
that of HNT, whereas NEGRI was robustly expressed in all tissues apart from the
liver and spleen where expression was minimal.
In the adult (Figure 4.17), OPCML expression was detected in the heart, the
brain, the pancreas, the small intestine and the colon. HNT exhibited a very similar
pattern. LSAMP was expressed in the heart, the brain, the pancreas, the prostate, the
testis and the colon, with low expression in the ovary and the small intestine. Finally,
NEGRI expression was only detected in the testis and colon. Although the two bands
were apparently slightly different in size, this was probably a gel artefact, as














Figure 4.16 Human IgLON expression in a foetal multiple-tissue panel
Expression of the four IgLONs in a cDNA panel of foetal human tissues by RT-PCR.
PCR controls were negative (data not shown).
L = 100 bp DNA ladder; ACTG1 = gamma actin; Br = brain; Lu = lung; Li = liver; Ki =
kidney; He = heart; Sp = spleen; Th = thymus; SM = skeletal muscle.
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Figure 4.17 Human IgLON expression in an adult multiple-tissue panel
Expression of the four IgLONs in a cDNA panel of adult human tissues by RT-PCR.
L = 100 bp DNA ladder; ACTG1 = gamma actin; He = heart; Br = brain; PI =
placenta; Lu = lung; Li = liver; SM = skeletal muscle; Ki = kidney; Pa = pancreas; + =
panel's positive control; - = PCR contamination control; Sp = spleen; Th = thymus;
Pr = prostate; Te = testis; Ov = ovary; SI = small intestine; Co = colon; PBL =
peripheral blood lymphocyte.
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4.4.4 Expression of OPCML in embryo sections
In the mouse, an extensive study of OPCML expression in development was
undertaken. In the human, the same immunohistochemical approach was followed to
a more limited extent. The staining patterns of three different human embryonic
stages can bee seen in Figure 4.18. The staining by CS21 was not as strong as in the
latest mouse stage. Some parts of the brain were positive, as well as the heart, the
epithelial lining of the intestine and the liver.
CS13 CS16 CS16 -ve
Figure 4.18i OPCML expression in human development
Staining of human embryo sections for OPCML expression by
immunohistochemistry. Antibody controls were negative; one example shown.
Images are at 1.6x magnification and have the same aspect ratio.
CS = Carnegie stage; -ve = antibody control.
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CS21
Figure 4.18ii OPCML expression in human development (continued)
Staining of human embryo sections for OPCML expression by
immunohistochemistry. Antibody controls were negative (data not shown). Images
are at 1.6x magnification and have the same aspect ratio.
CS = Carnegie stage; Fb = forebrain; Md = midbrain; Hb = hindbrain.
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4.4.6 Expression of OPCML in normal ovary sections
Due to its potential role as a TSG in ovarian cancer, the expression of
OPCML was also examined specifically in sections of human normal ovaries. As can
be seen in Figure 4.19, OPCML was expressed in the ovarian surface epithelium, as
well as the stroma. In the former, it was strongly expressed, whereas in the latter it
was weakly expressed, apart from some undefined patches of strong staining.
Figure 4.19 OPCML expression in the human ovary
Staining of human normal ovary sections for OPCML expression by
immunohistochemistry. Whole ovary section, 1.6x (A) and its negative antibody
control (B); detail showing epithelial staining, 40x (C).
144
4.5 Discussion
All the studies described in this chapter had a common aim: the acquisition of
information regarding the patterns of expression of the IgLON family. By taking an
approach that is multilateral and accommodates a variety of methods and levels of
examination, a lot of useful knowledge has been gathered.
IgLON expression was firstly examined in human cancer cell lines.
Information on cell line expression can often provide valuable hints on whether a
gene might be subjected to expression alterations in cancer. A surprising finding was
the fact that OPCML expression was not detectable in any of the examined cell lines
by qRT-PCR. This partially disagrees with a previous report by Sellar and colleagues
wherein, although most cell lines did not express OPCML, six did exhibit expression
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at varying levels , and these cell lines were represented in the panel used in this
work. The experimental approach used in the original study was the same as in the
present one, i.e. a qRT-PCR based method employing the same primer set. However,
two factors differed: the real-time thermal cycler and the standard curve. As the
expression of experimental samples is calculated against a standard curve, which
derives from an over-expressing cell line or tissue, the choice of standard curve
source sets a sensitivity threshold. This could be accentuated by the use of a different
PCR machine. The qRT-PCR protocol has integral quality-assurance measures, for
example the standard curve also serves a positive control; hence, the absence of
OPCML expression in cell lines in the present study cannot be accounted for by PCR
failure. Hence, the most likely explanation for the discrepancy between the two
studies is related to sensitivity. There is also a possibility that the data from the
present study are genuinely representative of cell line expression, despite being
surprising. Preliminary protein data support the absence of OPCML in cell lines (E.
Miller, personal communication). If the absence of OPCML expression were a true
feature, it might be explained by the promoter methylation status of the cell lines, as
it has been reported to be the case when OPCML is silenced, or it might actually be
an effect incurred by cell culture per se. Another IgLON, namely HNT, was found to
have a very restricted expression in the panel of cell lines. Only two cell lines, both
of ovarian origin, were found to express HNT. On the other hand, the expression
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levels of LSAMP and NEGRI were more variable across the panel. LSAMP was
found to be strongly expressed in a minority of cell lines, whereas most of them had
very low LSAMP expression. The establishment of the promoter methylation status
in these cell lines will indicate if epigenetic silencing accounts for this low
expression or absence thereof, as in renal carcinoma cell lines reported by Chen and
colleagues43. Finally, the expression of NEGRI in the panel of cell lines could be
grouped into high, low and absent, with particular samples exemplifying each of
these groups.
When examining the expression of IgLONs in the two transfected cell line
systems that were used in studies of OPCML function, it became evident that the
SKOV-3 cell lines differ to the HeLa inducible one in the complement of IgLONs at
the RNA level. SKOV-3 cells express LSAMP robustly and little NEGRI, in contrast
to HeLa cells that have minimal LSAMP and high NEGRI expression. This might
partially account for the phenotypic differences that will be presented in chapter 5.
More interestingly, in the SKOV-3 cells, OPCML transfection was shown to have a
striking effect on the expression of both LSAMP and NEGRI at the RNA level. When
OPCML is expressed in SKOV-3 cells, it significantly reduces the expression of
LSAMP and NEGRI. This effect would have to be corroborated at the protein level
once IgLON antibodies are available and fully optimised. Nonetheless, the fact that
the effect of OPCML on the expression of LSAMP and NEGRI was confirmed both
in an independent SKOV-3 clone, but also in two alternative ovarian cancer cell
lines, makes it likely to be significant. Not only does OPCML have an effect on
LSAMP and NEGRI, which most likely is independent for each, but also there is a
striking positive correlation between LSAMP and NEGRI RNA expression. The
extent to which these relationships between IgLON expression levels are
context-dependent remains to be clarified. This could be addressed using the same
experimental approach but in cell lines of different origin. Overall, these findings are
noteworthy in being the first reported trends of transcriptional coordination within
the IgLON family.
One of the objectives of this work was to establish the expression of the
IgLON family in development. This was initially attempted in the mouse by
whole-mount in situ hybridisations. Unfortunately, this approach was not successful.
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It is likely that the probes that were used were not optimal, since the protocol per se
worked when used with two positive control probes. The limb bud-specific signal
that was acquired using these two control probes is in agreement with published
data27j'274. The IgLON probes used were unique, as they had to account for issues of
IgLON homology and potential isoforms; the design of alternative probes would be
very difficult. Hence, the issue of developmental expression was tackled by IHC.
Due to the fact that within the available time-frame only the anti-OPCML antibody
had been fully optimised for use in histology, the expression of only this IgLON was
examined. Opcml expression was found to be minimal in the first embryonic age
examined, Ell, and was found to rise with age. Indeed, by El7, Opcml was
expressed in most of the tissues that is shown to be expressed in adult life. This
developmental activation of Opcml was also evident at the RNA level, as was the
case for Negri as well, in agreement with reported evidence of IgLON expression
increasing with age in development22^4. By El7, OPCML was found to localise in a
variety of tissues, and it was only completely absent in bone and cartilage.
In the adult mouse, OPCML was histologically detected in three broad
groups: nervous tissue, epithelial cell populations and muscle. At the RNA level, the
IgLON genes were detected in a variety of different organs, with high expressions in
the brain and eye.
In the human, the overall picture is quite similar. It was evident that by
Carnegie stage 21 (embryonic day 54), OPCML has not reached its peak of
expression. This in not surprising given that this stage of human development
corresponds to mouse embryonic day 15, which is earlier relative to the latest mouse
stage examined, i.e. embryonic day 17. Hence, it is likely that the expression of
OPCML will be rising after CS21 to reach its peak at a subsequent stage of
embryonic/foetal developmental or even early adult life. At the RNA level, the rest
of the IgLONs are expressed again in variety of foetal and adult tissues.
Paradoxically, NEGRI was only detected in the colon and testis in the adult human.
This is likely to be due to a PCR or cDNA problem rather than being a genuine
result, as it would be very unconventional for NEGRI, being an IgLON, not to be
expressed in the adult brain.
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Overall, both in the mouse and human the IgLON genes demonstrate quite
similar patterns of expression, suggesting that more often than not, the individual
genes are co-expressed at the organ level. There are however examples of
divergence, such as in the mouse liver and placenta, and in the human prostate and
testis, indicating that even though overall similar, IgLON expression patterns can
also be distinct. This notion does not take into account the sub-organ localisation. At
the level of particular cell types the IgLONs might exhibit more distinct expression
patterns. Confirmation of this would require the histological examination of the other
members of the family. In addition, expression in mouse and human was found to be
generally conserved. Again, some exceptions were recorded, such as in the kidney,
muscle, prostate and testis. These exceptions are in agreement with the postulation
30that one of the IgLONs, HNT, has expression disparities between rat and human .
Developmentally, the presented data are in agreement with reports of the IgLON
family being developmentally regulated22'30'54. In the human, there were some
instances where the expression was more restricted in the adult as opposed to the
foetus. This observation renders the scenario of specific developmental windows
when IgLONs can be switched on or off attractive. It has been reported that OPCML
expression is higher in the visual cortex of kittens than of older cats and this was
linked to a developmental window of plasticity24'23. The extent that similar
developmental switching occurs in the rest of the IgLON family merits further
investigation.
One of the most striking conclusions based on the expression data is that
IgLON expression is not as restricted as has been widely reported. There are tissues
such as the heart and the lung where IgLON expression seems to be as omnipresent
as in the brain. Even though there were instances where the present study was in
agreement with published data, e.g. in the localisation of OPCML in the eye, there
were also instances of complete disagreement, e.g. in the expression of Opcml by
cerebellar Purkinje cells. As the present study used a variety of different methods,
tissues and ages, and was undertaken in two species, it has become evident that
results can change based on the method of expression detection and its sensitivity
and specificity. For example although in the multiple tissue cDNA panel OPCML
was not detected in the ovary by standard RT-PCR, it was clearly detected by
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qRT-PCR in other ovarian samples. Apart from the method, the other factor that
might influence results is the tissue or organ under examination itself. Potential
problems can arise due to issues such as the cell representation in a particular
preparation, but also age, as we have seen that IgLON expression might fluctuate
with age. Finally, the importance of isoforms should not be underestimated,
especially as some approaches focus on particular isoforms, whilst others examine
expression collectively, like the present study. Not only is it an issue of alternative
transcripts, but also it can be an issue of alternative post-translational modifications.
In the rat brain, it has been shown that the two commonly detected OPCML protein
species show differential patterns of developmental expression14.
One of the IgLON genes, OPCML, has been proposed as a tumour suppressor
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in sporadic epithelial ovarian cancer" . Its expression, as well as the expression of the
rest of the family members, was examined in sporadic EOC and the normal human
ovary, in order to investigate the relevance of the family as a whole in this type of
979 • •
human cancer . The unselected patient cohort whereon the study was based, albeit
relatively small, is very representative of the Scottish population, as described in
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larger studies . What became evident is that with respect to EOC, it is not just
OPCML, but the other IgLONs as well that might be playing a role. It was shown
that the expression of all the IgLONs differs between normal ovaries and EOC at the
RNA level. The expression levels of OPCML, LSAMP and NEGRI are all
significantly decreased in EOC, in contrast to that of HNT, which is significantly
increased. Confirmation of these differences at the protein level will merit
investigating whether, apart from OPCML, LSAMP and NEGRI could also act as
TSGs in sporadic EOC. Interestingly, a recent microarray study has also identified
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HNT as being up-regulated in clear cell endometrial carcinoma .
It is known that the cause of reduction in the expression of OPCML in EOC is
mainly epigenetic21, as is of LSAMP in clear cell renal cell carcinoma43. Elence, it is
likely that the reduction in LSAMP and NEGRI expression in EOC is accounted for
by epigenetic mechanisms. Although epigenetic changes are often age-dependent,
age was not found to affect IgLON expression in the EOC panel.
Moreover, a significant positive correlation between the expressions of
LSAMP and NEGRI was identified. The same correlation was evident in the
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OPCMZ-transfected SKOV-3 cell lines. Consequently, it can be postulated that both
genes need not be genetically or epigenetically silenced in EOC; the reduction in the
expression of the one could result in a reduction in the expression of the other,
potentially through a mechanism of coordinated transcriptional regulation.
Interestingly, although when OPCML is introduced in SKOV-3 cells, its expression
is accompanied by a decrease in the RNA expression of both LSAMP and NEGRI, in
the EOC study this negative correlation was not seen. This is probably a reflection of
the more complicated nature of a tumour as opposed to a clonal cell line that is
genetically homogeneous.
There is currently debate regarding the most suitable normal control in EOC
expression studies277. One might argue that as the present EOC study was based on
whole-ovary preparations, the differences in expression seen might be due to the
presence of stroma in the normal ovary. Examination of IgLON expression levels in
an OSE-enriched sample provided evidence against this possibility. The three genes
that were found to have a reduced expression in EOC, namely OPCML, LSAMP and
NEGRI, all exhibited high expression in the OSE sample; NEGRI, the gene that
exhibited the highest reduction in EOC, was the one that had the highest expression
in the OSE sample relative to the median expression in the panel's normal ovaries. In
contrast, HNT, which exhibited highly elevated expression in EOC, was very lowly
expressed in the OSE sample. It is also worth stressing that the observed variability
of the data for the normal ovary samples could be partially accounted for by the
fragile nature of the OSE, which renders it susceptible to accidental removal during
surgery. Moreover, OPCML was shown to be strongly expressed in the epithelial
layer of normal human ovary sections. Hence, it is likely that all differences observed
in the EOC are genuine and not due to the fact that microdissected tissue was not
used.
It was demonstrated that in EOC the importance of each IgLON might be
specific to histological type. OPCML expression is reduced in clear cell carcinomas,
LSAMP in endometrioid, and NEGRI in all but the mucinous tumours. In contrast,
HNT expression is elevated in serous carcinomas. It should be noted, however, that
with respect to mucinous carcinomas, the lack of statistical significance could be due
to the under-representation of this type of tumour in the panel. In EOC, malignant
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transformation is characterised by a differentiation process, whereby the tissue of
origin, the ovarian surface epithelium, acquires specialised differentiated features of
specific histological morphology, depending on the type of tumour62. As IgLONs
have partially distinct patterns of histological subtype expression, they could be part
of different malfunctioning pathways that underpin this differentiation process.
Notably, LSAMP expression was found to be higher in differentiated tumours. This
suggests that the level of LSAMP expression is likely to be a biological function of
differentiation. It can be argued that the significance of the reduction in LSAMP
expression in the process of OSE transformation could lie in the cells' acquiring a
less differentiated morphotype, which is considered to be of higher malignant
potential.
Furthermore, LSAMP was found to be a negative prognostic factor in addition
to being negatively correlated with overall survival. At both levels of statistical
testing, the impact of LSAMP on survival is not high. This connexion might seem
paradoxical, given that its overall tumour levels are significantly lower in the EOC
than in normal ovaries. Nevertheless, the role of residual LSAMP in a tumour might
be antithetical to its original function in the normal ovary. In terms of the
multifactorial outcome described as survival, ovarian tumours might be
disadvantaged by not expressing LSAMP and losing its novel functions. The true
explanation of this paradoxical finding remains as yet undetermined.
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Chapter 5
Studies on OPCML function
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5.1 Introduction
Having developed the necessary tools to allow the study of OPCML biology,
the next major strand of this work was devoted to using these tools in order to
identify key functions of the gene, and understand the mechanisms behind its link
with ovarian cancer.
To sum up the current knowledge on the functions of OPCML, as was
extensively presented in chapter 1, here is what is known to date: There is indirect
evidence that OPCML might have a role in cell recognition and cell adhesion12, in
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dendritic plasticity ' ' , and the inflammatory response" . Functional studies in the
brain of the rat and chick have indicated potential roles in cell-cell adhesion and cell
recognition, effected by homophilic and/or heterophilic interactions with other
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IgLONs ' ' ' ' . Finally, OPCML has been proposed as a tumour suppressor gene
in sporadic epithelial ovarian cancer, in view of growth suppression properties in
vitro and tumourigenicity suppression properties in vivo21. Although the mechanism
of OPCML silencing in EOC is mainly epigenetic, one somatic mutation has been
reported, resulting in a proline to arginine substitution at position 95 of the amino
acid sequence (P95R).
Ultimately aiming at furthering our understanding of OPCML, its functions
were examined in two expression systems: the ovarian cancer SKOV-3
over-expression system and the cervical cancer HeLa inducible system. In the
former, the phenotypic effects of both wild-type and mutant (P95R) OPCML were
examined, whilst in the latter the effects ofwild-type OPCML were examined at low
and high levels of induction. Apart from identifying the phenotypic consequences of
expressing OPCML in these cell lines, comparisons made between the two systems
can be useful in addressing the issue of context specificity. Furthermore, an
important aspect of the functional characterisation ofOPCML was to investigate how
potential functions might comply with the role of a tumour suppressor.
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This chapter presents the functional characterisation of OPCML in the
SKOV-3 and HeLa Tet-On cell lines. A multitude of phenotypic assays were
undertaken, and the results are presented and discussed. Finally, the significance of
these findings is elaborated in the context of the role of OPCML as a TSG in
epithelial ovarian cancer.
154
5.2 Haptotactic cell migration
Migration is a fundamental phenomenon of normal cellular activity, manifesting
in a variety of processes, such as embryonic development, angiogenesis, and the
immune response278. Cells mainly migrate within the extracellular matrix (ECM),
due to interactions between cell surface adhesion receptors and ECM ligands. Cells
can migrate both on the extracellular matrix (haptotaxis) and towards chemical
signals, such as growth factors and chemokines (chemotaxis). Cell surface receptors,
exemplified by the integrin family, govern a range of different cell functions, such as
adhesion and migration, as well as cell attachment and polarity, growth and
differentiation. In addition, cell migration is an important aspect of cancer
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pathogenesis, as it intrinsically linked to invasion . Cancer cell motility involves
integrin signalling, focal contact formation and actomyosin-dependent contractility.
Cancer cells are motile due to the activation or deregulation of a variety of proteins,
such as MET, EGF receptors, RAS proteins and PTEN. In addition to these intrinsic
factors, determinants of cell motility are provided in the context of the tumour
microenvironment.
Cell migration towards components of the ECM is the cellular property that
was investigated by Boyden chamber-based migration assays. The principle of these
assays is that cells migrate through the porous membrane of the Boyden chamber by
haptotaxis towards an immobilised ECM protein gradient. More specifically, the
effect on haptotactic migration that expression of OPCML confers on cells was
examined. Hence, comparisons where made between OPCML-expressing SKOV-3
cells and their parental non-expressing controls, and between doxycycline-induced
HeLa Tet-On cells and their uninduced counterparts.
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In SKOV-3 cells, OPCML did not have any significant effect on haptotactic
cell migration (Figure 5.1). SKOV-3 cells exhibited minimal migration to Collagen I.
There was a very weak trend of increased migration to vitronectin, by both the
wild-type and mutant OPCML expressing cells relative to the parental cell line,
which was, however, not significant. There was also a weak trend of decreased
migration to fibronectin by SKOV-3 OPCMLMlIt cells, which was again not
significant.
In HeLa Tet-On cells, induction of OPCML, at both low and high levels of
expression, resulted in an increase in migration towards Collagen I. There was no
clear-cut effect on migration to either vitronectin or fibronectin. Overall, HeLa cells
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Figure 5.1 The effect of OPCML on haptotactic migration
Haptotactic cell migration in the SKOV-3 OPCML (A) and HeLa Tet-On OPCML (B)
cell lines as quantified by migration assays. Assays were performed using Boyden
chambers, where cells were allowed to migrate on ECM gradients for a period of
approximately 22 h. Results are expressed as ratios of migration on ECM over
migration on BSA, the latter serving as a background control. Error bars represent
the SD of three replicates.
WT = wild type; Mut = mutant; Par = parent;
+ dox, ++ dox, - dox = 48 h treatment with 100 ng/ml dox, 1000 ng/ml dox and no
dox respectively.
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5.3 Invasion through matrigel
The property of invasiveness is one of the sine qua non features of all
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malignancy . Cancer is malignant because cancerous cells can invade beyond the
constraints of the normal tissue of origin into neighbouring tissues. Although the
phenomenon of cell invasion occurs also in normal embryonic development, as well
as in healthy adult organisms, it has been extensively studied with respect to cancer
pathogenesis, in particular in the aspect of metastasis. In cancer, cells spread either as
single cells, or as cell clusters, and can explore both lymphatic and haematogenous
routes of dissemination.
As in cellular migration, interactions with the extracellular matrix are
instrumental for the invasive cell, although in invasion, the ECM can be regarded as
a barrier. Cells have specific strategies in order to overcome ECM resistance that
involve changes in cell shape, contraction-dependent matrix remodelling and
proteolysis. Hence, cell invasion can be considered to combine the aspects of
adhesion, migration and proteolysis. More than being a barrier, however, the ECM
also provides factors that will determine the survival of cells in their new
environment.
Invasion assays are one of the tools to investigate the invasive potential of
cells in vitro. A commonly used variation is based on the use of matrigel, which
serves as a reconstituted basement membrane. Matrigel was developed from the
supernatant of a Schwannoma cell line and predominantly contains laminin, collagen
•281IV and nidogen . The matrigel matrix is usually applied on a porous membrane, as
part of a Boyden chamber. The occlusion of its pores blocks non-invasive cells from
migrating through the membrane. In contrast, invasive cells can invade through the
matrigel matrix and the membrane pores. In order to attract cells from one side of the
membrane to the other, a chemoattractant is often employed. Essentially, this form of
invasion assay is a chemotactic migration assay that has been modified by the
addition ofmatrigel, which provides a physical barrier that the cells have to traverse.
Comparisons can be made either between cells that are non-invasive and invasive
cells, or between cells of different degrees of invasiveness.
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In order to study the connexion of OPCML to cell invasion, the invasive
potential of cells expressing OPCML was compared against that of non-expressing
cells, in both the SKQV-3 and the inducible HeLa systems. When invasion assays
were undertaken in the former, the effect of either wild-type or mutant OPCML on
the invasive properties of cells was determined by comparison of the transfected to
the parental cells. For the HeLa Tet-On system, comparisons were made between
two different levels of wild-type OPCML induction and the uninduced state. In the
particular type of invasion assays used, invasion through matrigel is measured
relative to chemotactic migration.
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As can be seen in Figure 5.2, in SKOV-3 cells, both wild-type and mutant
OPCML significantly increased cell invasion. More specifically, SKOV-3
OPCMLwt cells exhibited a 15% increase in invasion relative to the parental cell line
(p = 0.040), while SKOV-3 OPCMLMut cells had an 11% increase (p = 0.020). In
HeLa cells, both low- and high-level induction of OPCML resulted in a decrease in
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Figure 5.2 The effect of OPCML on cell invasion
Percentage invasion in the SKOV-3 OPCML (A) and HeLa Tet-On OPCML (B) cell
lines as quantified by invasion assays. Assays were performed using Boyden
chambers, where cells were allowed to either invade through a Matrigel matrix or
migrate through a membrane without the matrix towards medium containing 5%
FCS used as a chemoattractant for a period of 24 h. Invasion was calculated relative
to migration. Error bars represent the SEM of three independent experiments.
*
p< 0.05 compared to parental cell line by Student's t test.
WT = wild type; Mut = mutant; Par = parent;









Taking a closer look at the significant difference in invasion between
SKOV-3 OPCML and SKOV-3 parental cells, it can be seen that this difference
actually lay in the chemotactic migration of the cells, rather than the absolute
invasion through matrigel (Figure 5.3). Percentage invasion was calculated as the
ratio of the latter to the former and as chemotactic migration was smaller, the ratio
was increased. In fact, SKOV-3 OPCMLWT cells exhibited a significantly reduced
chemotactic migration relative to the parental cell line (p = 0.010) and so did the



















Figure 5.3 A closer look on the effect of OPCML on cell invasion in
SKOV-3 cells
Absolute invasion through matrigel (A) and chemotactic migration (B) in the SKOV-3
OPCML cells as quantified by invasion assays. Error bars represent the SEM of
three independent experiments.
*
p < 0.05, ** p < 0.01 compared to parental cell line by Student's t test.
OD = optical density; WT = wild type; Mut = mutant; Par = parent.
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5.4 Adhesion to the extracellular matrix
Apart from the role of cell-ECM interactions in the context of cellular
migration and invasion, these interactions are also critical in "arresting" the cells
inside the matrix. Whether it is normal tissue architecture, or the establishment of a
tumour mass, the adhesion of cells to the extracellular matrix by means of cell
surface receptors is a prerequisite.
Assays that measure the attachment of cells on ECM proteins are a useful aid
in studying cell-ECM interactions directly. Attachment assays examine how the
cells adhere onto surfaces coated with specific ECM molecules in a quantitative
and/or qualitative manner.
In order to examine the effect of OPCML on cellular adhesion to the ECM,
comparisons were made between OECMZ-expressing SKOV-3 cells and their
parental non-expressing controls, or between induced HeLa Tet-On cells and their
uninduced counterparts.
As can be seen in Figure 5.4, in SKOV-3 cells, expression of wild-type
OPCML significantly increased adhesion on fibronectin in relation to the parental
cell line by approximately 30% (p = 0.015). In contrast, expression of mutant
OPCML did not have an effect: SKOV-3 OPCMLMut cells exhibited comparable
adhesion on fibronectin as the parental cells. Hence, there was a significant
difference between the wild-type and the mutant OPCML-expressing cells (p =
0.021). With respect to adhesion on vitronectin, expression of wild-type OPCML
significantly increased adhesion by approximately 36% (p = 0.010), whilst ofmutant
OPCML by approximately 16% (not significant), as compared to the parental cell
line. Again, there was a significant difference between the wild-type and the mutant
OPCML-expressing cells (p = 0.045). OPCML expression was not found to
significantly influence adhesion on laminin, collagen I or collagen IV, irrespective of
being wild-type or mutant. There was however a trend for mutant
OPCMZ-expressing cells to show less adhesion than wild-type ones. In HeLa Tet-On
cells, expression of OPCML did not have any effect on adhesion to any ECM
component at any level of induction.
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Figure 5.4 Effect of OPCML on adhesion to the ECM
Cell adhesion in the SKOV-3 OPCML (A) and HeLa Tet-On OPCML (B) cell lines as
quantified by attachment assays. Cells were seeded and allowed to attach to either
ECM-coated or BSA-coated strips for a period of 45 min. Results are expressed as
ratios of attachment to ECM over attachment to BSA, the latter serving as a
background control. Error bars represent the SEM of three independent
experiments.
*
p < 0.05 compared to parental cell line by Student's t test.
WT = wild type; Mut = mutant; Par = parent;
FN = fibronectin; VN = vitronectin; LN = laminin;
COLI = collagen I; COLIV = collagen IV;




Thus far, the phenotypic properties ofOPCML that were examined concerned
cell-ECM interactions. Cells, though, and in particular epithelial cells, do not only
form contacts with the ECM, but also with other cells. Cell-cell contacts, whether
stabilized by tight, adherens or gap junctions, provide mechanical strength and
polarization within any organised tissue, and can even promote the locomotion of
cells. Apart from playing an important role in normal physiology, cell-cell adhesion
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is often the focus of study in tumour biology . Elomotypic epithelial cell-cell
adhesion prevents the escape of cells into neighbouring tissues and can even
withhold cell invasion by well-differentiated epithelial strands.
The measurement of cell-cell adhesion is commonly undertaken using
commercially available fluorochrome probes283. Calcein AM is a soluble fluorescein
derivative, which is taken up by cells as an ester and hydrolysed by internal
esterases, reflecting cytoplasmic activity and hence indicating cell viability. A simple
and sensitive cell-cell adhesion assay that involves the use of calcein AM is carried
out in three steps: labelling of cells to be tested, adhesion of labelled cells to
confluent unlabelled monolayers, and measurement of the fluorescent signal using
microfluorimetry.
This section presents work that assessed the ability ofOPCML as an adhesion
molecule to influence cell-cell adhesion. Apart from investigating adhesion in cells
that express OPCML, the role of the other IgLONs was also investigated in order to
test whether interactions operate at the level of cell-cell adhesion.
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5.5.1 In SKOV-3 OPCML cells
How does expression of OPCML influence the ability of cells to adhere to
each other? To tackle this question, cell-cell adhesion assays were undertaken that
examined the adhesion of cells expressing or not expressing OPCML. Due to the
nature of these assays, which rely on two cell populations, the inducible system was
not used, as it would have been difficult to fine-tune the induction timings to ensure
that both populations had undergone the same degree of induction. Hence, these
assays were only carried out in the SKOV-3 cells.
As is evident in Figure 5.5, expression of OPCML significantly increased
cell-cell adhesion. More specifically, labelled SKOV-3 OPCMLwr cells adhered
twice as much to a monolayer of the same cell type (p = 0.027) or of SKOV-3
OPCMLMut cells (p = 0.019) than to a monolayer of the parental cell line. There was
a trend for labelled SKOV-3 OPCMLMut cells to adhere more to a monolayer of the
same type or of their wild-type counterpart than to the parental cells; however,
differences were not statistically significant. Finally, labelled SKOV-3 parental cells
adhered almost twice as much to a monolayer of cells expressing either wild-type























Figure 5.5 The effect of OPCML on cell-cell adhesion
Percentage cell-cell adhesion in the SKOV-3 OPCML cell lines as quantified by
adhesion assays. Cells under test were fluorescently-labelled and allowed to attach
on unlabelled cell monolayers for 90 min. Values are corrected for background
fluorescence. Error bars represent the SEM of three independent experiments.
*
p < 0.05, ** p < 0.01 compared to parental cell line by Student's f test.
WT = wild type; Mut = mutant; Par = parent.
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5.5.2 In SKOV-3 IgLON cells
It has been hypothesised that IgLONs carry out their normal functions mainly
by forming homodimers and also herodimers, termed Diglons. The availability of
SKOV-3 cell lines transfected with members of the IgLON family other than
OPCML offers an opportunity to test this hypothesis in an ovarian background.
Having optimised the cell-cell adhesion assay, potential interactions could be
examined by focusing on this particular functional aspect.
In order to test potential IgLON interactions, cell-cell adhesion assays were
carried out using four IgLON-expressing SKOV-3 cell lines. Apart from the
SKOV-3 cell line transfected with wild-type OPCML, SKOV-3 cell lines expressing
HNT, LSAMP and NEGRI were used. However, as can be seen in Figure 5.6,
statistically significant interactions were not identified. More specifically, labelled
SKOV-3 OPCMLwr cells attached better to monolayers composed of either cells of
the same type or of NEGRI-expressing cells; HNT- and ZSHMP-expressing
monolayers were somewhat less favourable adhesion substrates. HNT-expressing
labelled cells attached more to OPCML- and ZSTMP-expressing monolayers;
ZSHMP-expressing labelled cells attached more to an OPCML-express'mg
monolayer; and NEGR-expressing labelled cells attached mostly to
OPCML-expressing monolayers as well as homotypic monolayers. All these
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Figure 5.6 The effect of IgLONs on cell-cell adhesion
Percentage cell-cell adhesion in the SKOV-3 IgLON cell lines as quantified by
adhesion assays. Cells under test were fluorescently-labelled and allowed to attach
on unlabelled cell monolayers for 90 min. Values are corrected for background
fluorescence. Error bars represent the SEM of three independent experiments.
168
5.6 Cell growth
The balance between cell proliferation and cell death is fundamental in any
aspect of normal physiology and it is this balance that is disturbed in tumourigenesis
by activation of oncogenic processes and suppression of protective mechanisms.
Cancers arise by an evolutionary process whereby somatic cells mutate and escape
the restraints that normally guard them against uncontrolled expansion. Hence, the
aspect of cell growth is paramount in tumour biology, and any genes that are
implicated in the processes underlying this aspect are commonly the focus of intense
study.
Previous work had demonstrated that OPCML suppresses cell growth in
vitro, when expressed in SKOV-3 cells21. Although this phenotypic effect has been
described, what is not clear is why cells that express OPCML are growth-suppressed.
A possible explanation could be that these cells exhibit reduced proliferation;
alternatively, they could be subjected to increased cell death.
Before investigating the mechanism behind the growth suppression
phenotype of OPCML, the growth characteristics of SKOV-3 clones transfected with
OPCML were reassessed. Growth curves of the wild-type and mutant
OPCMZ-expressing SKOV-3 cells, as well as the parental cell line, are shown in
Figure 5.7. SKOV-3 OPCMLWT cells are strongly growth-suppressed relative to the
parental cells (p < 0.001). SKOV-3 OPCMLMut cells grow at a higher rate relative to
their wild-type counterpart (p < 0.001), even though they still lag behind the parental
cells (p = 0.001). In contrast, in HeLa Tet-On cells, OPCML does not have an effect
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Figure 5.7 The effect of OPCML on cell growth
Growth curves of SKOV-3 OPCML (A) and HeLa Tet-On OPCML (B) cell lines.
Error bars represent the SD of three replicates.
WT = wild type; Mut = mutant; Par = parent;




One explanation for the growth suppression effect of OPCML on SKOV-3
cells could be that cells expressing OPCML are less proliferative. As a consequence,
it would be expected that the cell cycle distribution and replicative capacity of
SKOV-3 OPCML cells be skewed towards a less proliferative profile in comparison
to the parental cells that do not express OPCML.
To test this hypothesis, proliferation was measured in SKOV-3 OPCML cells
by FACS-based proliferation assays. More specifically, the technique used was a
two-colour staining method for measuring cell proliferation by multiparameter
analysis of DNA replication and cellular DNA content / cell cycle position by flow
cytometry. This technique relies on the growth of cells in the presence of
5-bromo-2-deoxyuridine (BrdUrd), which is an accepted method for monitoring
DNA replication. This is coupled with staining with propidium iodide, in order to
acquire DNA cell cycle information.
As can be seen in Figure 5.8, OPCML did not have any significant effects on
either DNA replication or cell cycle distribution. In fact, both the wild-type and the



















Figure 5.8 Effect of OPCML on cell proliferation
DNA replication and cell cycle distribution analysis in the SKOV-3 OPCML cell lines
by flow cytometry. Error bars represent the SEM of three independent experiments;
in each, a total of 30,000 events were acquired.
WT = wild type; Mut = mutant; Par = parent;
PF = proliferative fraction (i.e. S + G2/M).
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5.8 Apoptosis
Another potential explanation for the growth suppression phenotype of
OPCML could be related to apoptotic death. Apoptosis is a form of cell death crucial
in the tumourigenic process, whereby a cell undergoes '"programmed" cell death,
triggered by a variety of intrinsic and extrinsic stimuli284.
Apoptosis is characterised by certain features, detection of which can be used
to identify it: DNA fragmentation, changes in cell size and granularity, changes in
plasma permeability, cell surface modifications and formation of apoptotic bodies.
An assay that is based on the detection of cell surface modifications is the annexin V
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assay . Annexin V is an anti-coagulant protein that preferentially binds negatively
charged phospholipids. Early in the apoptotic process, phospholipid asymmetry is
disrupted, leading to the exposure of phosphatidylserine (PS) on the outer leaflet of
the cell membrane. This event is thought to be important for macrophage recognition
of cells undergoing apoptosis. Annexin V binding to PS is calcium-dependent,
reversible and occurs with an affinity of approximately 5 x 10"10 M. As the event that
annexin V assays measure occurs early in the apoptotic process, these assays can
only accurately measure early apoptosis; late apoptosis cannot be distinguished from
necrotic death.
The two SKOV-3 OPCML-txpressing cell lines were analysed by the
annexin V method and compared to the non-expressing parental cell line, as can be
seen in Figure 5.9. Wild-type or mutant OPCML-qxpressing SKOV-3 cells
underwent significantly more (early) apoptosis than the parental cell line (p = 0.050
for the wild-type; p = 0.005 for the mutant). The overall cell death levels were also
elevated (p = 0.043 for the wild-type; p = 0.048 for the mutant). As the levels of
background apoptosis in a cell line under normal growing conditions are generally
low, in order to increase numbers and allow differences to be more distinctive, the
SKOV-3 cell lines were subjected to treatment with a cytotoxic drug, camptothecin.
After treatment with camptothecin, SKOV-3 OPCMLwl cells exhibited a three-fold
increase in early apoptosis compared to the parental cell line (p < 0.001). SKOV-3
OPCMLMut cells also showed an increase, albeit of a lower magnitude and not
statistically significant. In fact, they did not differ significantly to their wild-type
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counterpart. With respect to total cell death, both wild-type and mutant cell lines
exhibited a statistically significant increase relative to the parental cell line
(p < 0.001 for the wild-type; p = 0.011 for the mutant). Again, the effect of mutant
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Figure 5.9i The effect of OPCML on apoptosis
Annexin V analysis by flow cytometry. Representative dot plots of SKOV-3
OPCMLwt (A,B), SKOV-3 OPCMLMut (C,D) and SKOV-3 Par (E,F) cells, in the
presence or absence of treatment with 1 pM camptothecin (CPT) for 48 h. Each dot
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Figure 5.9ii The effect of OPCML on apoptosis (continued)
Annexin V analysis in the SKOV-3 OPCML cell lines by flow cytometry, measuring
steady-state levels of apoptosis (A), and after treatment with 1 pM camptothecin for
48 h (B). Error bars represent the SEM of three independent experiments; in each, a
total of 30,000 events were acquired.
*
p < 0.05, ** p < 0.01 compared to parental cell line by Student's t test.
WT = wild-type; Mut = mutant; Par = parent.
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5.9 Discussion
The functional characterisation of OPCML presented in this chapter was
aimed at identifying novel functions for this protein and also exploring further what
is currently known. In order to study the functions of OPCML, two alternative
expression systems were used: an ovarian SKOV-3 over-expression system,
expressing either wild-type or mutant OPCML, and a non-ovarian HeLa Tet-On
inducible system expressing wild-type OPCML at two different levels of expression.
A variety of phenotypic assays were used that focused on different aspects of cell
biology.
Initially, attention was drawn to the interactions of cells with the extracellular
matrix. It was found that wild-type OPCML increases significantly the adhesion of
SKOV-3 cells to fibronectin and vitronectin. The adhesion of cells to the ECM is
governed by receptor-mediated binding, involving surface receptors on cells and
ligands on ECM components. The RHO signalling pathway is often implicated in the
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attachment of cells to a matrix" . Cell surface receptors typically belong to the
integrin family, but can also be proteins such as CD44 and members of the
immunoglobulin subfamilily of cell-adhesion molecules. For example, in ovarian
cancer cells it has been shown that gonadotrophin stimulation of ovarian cancer MLS
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cells increases their adhesion to fibronectin due to CD44 and av integrins . More
recently, Li and colleagues demonstrated by the very sensitive method of quartz
crystal microbalance that strong ovarian cell adhesion to fibronectin and vitronectin
988
is mostly mediated by avP3 integrins . Hence, it can be postulated that the
differential binding of cells expressing wild-type OPCML to components of the ECM
could be attributed to an indirect effect via integrin signalling and/or the mere
presence of OPCML if this protein can function as a receptor. The fact that OPCML
is entirely extracellular makes the former postulation more likely.
Moreover, both wild-type and mutant OPCML were shown to significantly
decrease chemotactic migration in SKOV-3 cells, without influencing haptotactic
migration. Chemotactic cell migration is based on interactions between chemotactic
molecules, such as growth factors, and their respective receptors. Motility-inducing
9 8Q
cytokines and growth factors are known to signal via PI3K, RAC and RHO" . For
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example, tuberin, the TSC2 tumour suppressor gene product, decreases chemotactic
cell migration in leiomyoma ELT3 cells through RHO activation290. The fact that
OPCML has an effect on chemotactic, but not haptotactic cell migration is not
unusual: there are examples of proteins affecting only one of the two phenomena291
and even having an opposing effect" . In ovarian cancer, CXCR4 receptors are
thought to influence peritoneal spread by chemotactic migration29"*. In contrast,
integrin-mediated cell-ECM interactions are thought to be less important in
facilitating ovarian cancer cell implantation onto the peritoneal mesothelium294.
Interestingly, neurite outgrowth is closely related to cell migration and invasion, and
OPCML is reported to inhibit neurite outgrowth in association with another IgLON,
HNT37. It can be hypothesised that the effect of OPCML on chemotactic cell
migration is likely to be linked to the expression of specific receptors and signalling
through a pathway most probably associated with RHO. As OPCML affects cell
adhesion to fibronectin and vitronectin, but not cell migration to these ECM
components, it is important to note that in fact migration does not always correlate
with adhesion" ' . Interestingly, chemotaxis is also important in physiological
processes such as wound healing, which could be considered analogous to the
process of ovulation. OPCML is known to be down-regulated by the
proinflammatory cytokine interleukin-ip26.
In addition, OPCML was demonstrated to promote cell-cell adhesion in
SKOV-3 cells. The prototype homotypic epithelial cell-cell adhesion molecule
functioning through homophilic interactions is E-cadherin, which operates in
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adherens junctions" . The E-cadherin gene CDH1 is considered to be a tumour
suppressor gene and prevent cell invasion in most cancers of epithelial origin.
E-cadherin mediated cell-cell adhesion is lost concomitantly with progression
towards malignancy . This role of E-cadherin in epithelial tumourigenesis is
connected to its aiding the process of epithelial to mesenchymal transition, a
phenomenon characteristic of most epithelial tumours, whereby cancerous cells lose
some of their differentiation features. However, ovarian cancer is an exceptional type
of cancer in that respect: transformation of ovarian cells consists of their acquiring
differentiated features towards a more epithelial morphotype62. Hence, ovarian
cancer cells express E-cadherin, in contrast to OSE cells that express
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N-cadherin299'300. Because of this unconventional relationship between E-cadherin
and epithelial ovarian cancer, Sundfeldt argues that loss of normal cell-cell adhesion
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is a less important prerequisite in ovarian tumourigenesis" . However, this argument
undermines the importance of other cell-cell adhesion molecules. As OPCML
increases cell-cell adhesion when expressed in ovarian cancer cells, it could be part
of the mechanism that ensures functional cell-cell adhesion in the normal ovary.
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Tumour suppressor genes are often reported to promote cell-cell adhesion " . A
role in cell-cell adhesion could also involve cell signalling. For example, in
OVCAR-3 cells, an ovarian cancer cell line that expresses E-cadherin, cell-cell
adhesion is linked to the PI3K and EGFR pathways304. An interesting observation is
that cell-cell adhesion in SKOV-3 cells that express OPCML is of the same
magnitude as cell-cell adhesion between SKOV-3 cells that express OPCML and
parental cells that do not express it. This indicates that OPCML can promote cell-cell
adhesion by its presence on the surface of just one of the two interacting cell
populations. This observation suggests that OPCML participates in heterophilic
interactions; in the SKOV-3 parental cells its interacting partner is a protein other
than OPCML. It could in fact be another IgLON, supporting the postulation that
OPCML mainly functions through heterophilic interactions with other IgLONs37.
The possibility of homophilic interactions in OPCML-expressing SKOV-3 cells
cannot be excluded though. One apparent caveat in the cell-cell adhesion used was
that the observed adhesion between labelled SKOV-3 cells expressing wild-type
OPCML on an unlabelled monolayer of parental cells was not of the same magnitude
as of labelled parental cells to an unlabelled monolayer of cells expressing wild-type
OPCML. This could be accounted for by the nature of the particular type of cell-cell
adhesion assay, which allows the accurate measurement of the adhesion of only the
labelled cell population, which has been labelled using strictly defined conditions, as
opposed to the creation of the monolayers, which is subject to inherent variability.
Heterophilic interactions were examined with regard to cell-cell adhesion between
SKOV-3 cell lines that express different IgLON proteins; however, the observed
trends were inconclusive. It should be noted that the other IgLON expressing cell
lines have not been characterised to the same extent as SKOV-3 OPCML cells.
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Moreover, SKOV-3 cells already express high levels of LSAMP, so increasing its
expression by transfecting the gene might not have phenotypic consequences.
One of the most significant aspects of OPCML function in SKOV-3 cells is
growth suppression. OPCML expression in SKOV-3 cells causes marked growth
suppression and the mechanism underlying this effect was investigated. It was found
that OPCML significantly increases apoptosis, whereas it does not affect cell
proliferation. The importance of pro-apoptotic proteins in preventing tumourigenesis
is paramount and a variety of tumour suppressor genes play a role in apoptosis
(see chapter 1 for TSGs in ovarian cancer). Apart from the direct role of OPCML in
regulating cell growth by affecting apoptosis, it could also act as a deterrent for
migrating cells, which, upon leaving their natural environment, need to switch on
survival pathways in order to avoid anoikis. Furthermore, OPCML expression in
SKOV-3 cells renders them significantly more chemosensitive to camptothecin due
to elevated levels of apoptosis. Camptothecin is a cytotoxic drug that targets
topoisomerase I-dependent DNA replication by reversibly inducing single-strand
305breaks . Cell death by camptothecin requires an active S phase, a criterion that is
satisfied in the SKOV-3 cells that express OPCML. Camptothecin-derived drugs,
exemplified by topotecan and irinotecan, are widely used in clinical practice against
diverse types of neoplasia, including ovarian cancer. It is worth investigating in the
future whether the expression status of OPCML has an effect on the efficacy of these
treatments. The chemoresponsiveness of SKOV-3 OPCML cells to other cytotoxic
compounds also merits examination.
In SKOV-3 cells, the only clear-cut phenotypic difference between wild-type
and mutant OPCML expression identified is regarding adhesion to the ECM: whereas
wild-type OPCML expression increases adhesion to both fibronectin and vitronectin,
mutant OPCML expression does not. SKOV-3 OPCMLMut cells also grow somewhat
slower that the parental cell line, but they are not overtly growth-suppressed as their
wild-type counterpart. The difference with respect to cell-ECM adhesion could be
explained by a potential loss of function of the mutant that affects either integrin
signalling or the ability of the protein to act as a receptor for ECM ligands.
Biomolecular modelling of the P95R mutation has suggested a conformational
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change in the first immunoglobulin domain" ; this could in theory interfere with
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cell-ECM interactions. In the same report, the mutation abolishes the effect of
OPCML on cell-cell aggregation; in the present study, mutant OPCMZ-expressing
cells did not exhibit different cell-cell adhesion properties relative to the wild-type
OPCML-expressing cells. This probably is an indication of a difference in
methodology, with cell-cell adhesion assays being more accurate and quantitative
than aggregation assays. As far as the other phenotypic aspects of OPCML are
concerned, the P95R mutation does not modify the behaviour of cells.
OPCML expression in the inducible HeLa cell line did not recapitulate any
of the features identified in the SKOV-3 cells. In brief, in HeLa Tet-On cells
OPCML expression resulted in an increase in adhesion to collagen I, had no effect on
chemotactic migration or adhesion to the ECM and did not cause growth
suppression. This could reflect the different genetic backgrounds between the
cervical cancer HeLa cells and the ovarian cancer SKOV-3 cells. In fact,
glycosylation of OPCML is evidently different, as was shown in chapter 3, as is the
complement of IgLONs, as was shown in chapter 4. finally, in the HeLa Tet-On
system, all comparisons were made between the uninduced and the induced states.
The fact that OPCML "leaky" expression is detected and is probably at functional
levels could render some of these comparisons of questionable value. It can be
assumed, though, that in so far as a tumour suppressor gene in ovarian cancer is
being examined, the inferences based on the SKOV-3 cell lines are valid and more
likely to reflect physiologically relevant aspects ofOPCML biology.
There are two issues that might impose some caution in the interpretation of
all the above phenotypes: the fact that enzymatic dissociation was used and the
importance of the degree of cell-cell contact for a molecule like OPCML that might
function via interactions in trans. Trypsin, which was the dissociation agent
employed, has an effect on all cell surface molecules to varying degrees; however, it
is assumed that consistently minimal exposure to trypsin, as was used in all the
experiments described in this chapter, causes limited, if any, irreversible damage to
cell surface molecules like OPCML, which is also stabilised by the attachment of the
GPI anchor. Furthermore, the cells that were used in all the phenotypic assays had
been seeded at standard and optimised densities to allow the appropriate degree of
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confuency for each assay, but always more than 60% and less than 90%. Thus, lack
of cell-cell contact has not been an issue.
OPCML is characterised by two intriguing features: it is a GPI-anchored
protein (GPI-AP) and an immunoglobulin-like cell adhesion molecule (IgCAM).
GPI-APs participate in a wide range of functions, from catalysis to adhesion306.
Proteins tethered to the cell membrane by a GPI anchor are typically organised in
membrane domains termed lipid rafts, which are thought to orchestrate the sorting of
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associated proteins and act as platforms for cell signalling . There is a variety of
GPI-APs that are implicated in cancer, such as the urokinase-type plasminogen
activator receptor308, GML, encoded by a p53-responsive gene309 and HYAL2310.
Roles of GPI-APs in cell-cell and cell-ECM adhesion3", signal transduction312 and
invasion3'3 are well documented. GPI-APs are extracellular, thus as signalling
modulators they often interact in cis with transmembrane glycoproteins314'315.
Furthermore, recent advances in our understanding of IgCAM biology have linked
this important family of proteins with cell-cell and cell-matrix interactions, as well as
cell signalling316. IgCAMs are able to associate with various membrane components
in cis, such as growth factor receptors, integrins and cadherins. There also genes
encoding IgCAMs that are down-regulated in diverse types of cancer; examples are
NCAM1317, DCC318 and CEACAMli]9. All these aspects of GPI-AP and IgCAM
biology support the potential functions of OPCML identified in SKOV-3 cells and






The conception of this project, which was inspired by earlier studies that
identified OPCML as a novel tumour suppressor gene in epithelial ovarian cancer,
was based on two broad objectives: the expression profiling of OPCML and other
known members of the IgLON family in the mouse and human, and the functional
characterisation ofOPCML. Studies addressing both issues were designed in order to
complement and expand on current knowledge. Functional studies relied on the
creation and characterisation of suitable tools that would allow the examination of
phenotypes incurred by the expression of OPCML.
The first major part of this work concerned the expression profiling of
OPCML and the IgLON family in human cancer cell lines, in normal embryonic and
adult tissues in the mouse and human and in ovarian cancer. Expression studies can
be valuable in our understanding of the IgLON family, helping to further our
knowledge and provide suggestions of potential functions. This is particularly useful
with respect to a family that has been characterised in the brain mostly. So, what has
been learnt from these diverse expression studies? Firstly, it has become evident that
IgLON expression is not as restricted as previously thought. The IgLON genes might
be primarily expressed in the nervous system, but are also expressed in other organ
systems, an observation that suggests that they might have important functions
outside the brain. It is known that in the brain IgLONs are involved in cell-cell
recognition and cell adhesion, so it can be postulated that they could have similar
functions in other localities. Furthermore, all IgLONs were shown to be
developmentally regulated, a finding that reinforces previous knowledge and
suggests that this family might be important in both developmental regulation and
plasticity. Particularly pronounced was the developmental increase in expression of
Opcml and Negri in the mouse. With respect to Opcml specifically, this was also
reflected on histological expression patterns, especially in the mouse. As embryonic
development is longer in the human, the respective immunohistochemical detection
of OPCML in human embryos has not identified high expression of the protein. A
more thorough study of OPCML in human development is required, covering a
broader period of embryonic and foetal life, although this might be difficult to
achieve due to the restricted availability of human embryo sections. In addition, it
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has been demonstrated that IgLON family members have both over-lapping and
distinct expression patterns. At the level of the organ, there are examples wherein the
family is expressed as a whole, such as the heart and the lung, again stressing that
they must have important functions outside the brain. It is likely, however, that at a
more narrow level, as in the individual cell type level, more divergence occurs, as
has been previously reported. Moreover, this work has provided the first evidence of
transcriptional coordination within the IgLON family. It has been shown that
OPCML expression in three different ovarian cancer cell lines results in a decrease in
the expression of both LSAMP and NEGRI at the RNA level. Additionally, the
expressions of LSAMP and NEGRI exhibit a significant positive correlation, both in
OPCML-transfected cell lines, but more importantly in normal and tumour ovarian
samples. The significance of these trends is two-fold. They suggest that as a family,
the IgLONs might share cis and/or trans regulatory elements. It is worth
investigating in the future whether different transcription factors available in distinct
tissue types could alter the expression relationships of the IgLON family. All the
identified trends were in an ovarian context and they need to be investigated in other
tissue types as well. The second important implication of these observations lies at
the level of function: if IgLONs interact with each other then potential expression
inter-relationships will have an impact on the availability of partners for the
formation of functional complexes. Finally, we have established that in EOC it is not
just OPCML that might be of relevance, but also the rest of the family. Like OPCML,
LSAMP and NEGRI are down-regulated in sporadic EOC relative to the normal
ovary, whilst HNT is up-regulated. Specific IgLONs are associated with distinct
histological types of EOC. It is interesting to take a historical perspective of IgLON
biology. The IgLON family was identified and has been typically studied in the
brain. Subsequently, a study was reported that proposed OPCML as a TSG in
sporadic EOC, followed by a second study proposing LSAMP in another type of
cancer, clear cell renal cell carcinoma. Hence, it is becoming increasingly evident
that the IgLON family might play diverse roles and might be associated with
different types of cancer. OPCML in particular, was shown to be localised in the
OSE, the site of origin of EOC, the site where it exhibits its strongest expression in
the human ovary. This localisation is a prerequisite for the product of a TSG, which
185
is thought to be disrupted as an early event in ovarian tumourigenesis. Interestingly,
OPCML also exhibits strong epithelial staining in other tissue types, such as the
bladder.
Two distinct systems were used as means to study OPCML function. An
inducible system of OPCML expression, based on the cervical cancer HeLa cell line
was created and characterised so as to complement an over-expression system based
on the ovarian cancer SKOV-3 cell line. Together, they provided in vitro models of
gynaecological cancer from different perspectives. In developing the HeLa Tet-On
system, the aim was to establish a resource that allows the regulated expression of
OPCML exploiting the unparalleled advantages offered by inducible systems:
expression at a defined level and lack of clonal variation. Despite the fact that the
selected HeLa Tet-On OPCML clones had favourable inducibility profiles, as judged
at both RNA and protein levels, the overall evaluation of this approach was not very
promising. The clones were hampered by uninduced expression of OPCML, which
was at a level not much lower to its expression in the ovary, indicating that even
without induction functional protein was produced. In addition, differences between
the HeLa and SKOV-3 cell lines were identified, highlighting the importance of
context specificity. Disparity was evident both as expression of distinct OPCML
glycoprotein species, but also as divergence in phenotype. In addition, HeLa and
SKOV-3 cells differ in their complements of IgLONs. As a consequence, the
creation of an ovarian cancer in vitro model was imperative. The SKOV-3 cell line
was chosen as an obvious candidate, in view of its established use in the
over-expression system. An inducible SKOV-3 resource will offer invaluable
advantages in the study of genes associated with ovarian cancer, such as OPCML.
This system was developed towards the end of this work, and was therefore not used
in functional studies. Preliminary data suggest that the use of a second-generation
response plasmid results in tighter regulation of OPCML expression, so it is expected
that this system will lack the problems of uninduced expression that hampered the
use of the HeLa Tet-On system. Overall, the use of inducible systems does entail
counteracting numerous problems, mainly associated with "leakiness" and the
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necessity of extensive screening; nonetheless, once established, these systems offer
advantages that could not be offered by traditional over-expression in vitro models.
The second major part of this work was devoted in delineating the functions
of OPCML, as a potential novel tumour suppressor in ovarian cancer. These studies
were very important in thoroughly addressing for the first time the issue of OPCML
function in an ovarian cancer model in vitro. The functional characterisation of
OPCML has been very profitable. Several phenotypes were attributed to OPCML
expression in SKOV-3 cells including an inhibitory effect on chemotactic migration
and a stimulatory effect on adhesion to specific components of the extracellular
matrix. Moreover, OPCML was shown to promote cell-cell adhesion, most likely by
heterophilic interactions. The most significant finding, however, has been that
OPCML has pro-apoptotic properties, which underlie the growth suppression
phenotype that it incurs in vitro. Not only was OPCML found to play a pro-apoptotic
role, but also, in so doing, it renders cells more chemosensitive to the cytotoxic drug
camptothecin. If this effect were seen in response to additional drugs, then OPCML
expression status might have considerable impact on patient outcome after
chemotherapy in ovarian cancer. These identified functions reinforce the hypothesis
that it acts as a tumour suppressor in ovarian cancer. In view of relevant aspects of
GPI-AP and IgCAM biology as well as the biology of genes characterised by similar
phenotypic profiles, the functions of OPCML imply that it participates in one or
more signalling pathways; the identified phenotypes in adhesion, for example, have
highlighted RHO signalling as one potential pathway.
Based on the above evidence, how can we accommodate OPCML in a model
of ovarian tumourigenesis? It can be envisaged that in the normal ovary OPCML
plays an important role in restricting cell growth as well as maintaining tissue
architecture and confining OSE cells within their natural environment by cell-cell
and cell-matrix interactions. It might also participate in the tissue remodelling that
follows ovulation, as a response gene to pro-inflammatory cytokines such as IL-ip.
In sporadic epithelial ovarian cancer, these functions are disturbed as OPCML
expression is reduced or abolished, primarily by epigenetic silencing. Transformed
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cells become less constrained and more migratory. By being less responsive to
pro-apoptotic clues, they switch on survival pathways and can thus adapt to new
circumstances. Participation of OPCML in cell signalling pathways almost certainly
underlies these roles, which might be facilitated and/or stabilised by interactions with
other members of the IgLON family.
Very recent evidence suggests that the expression of OPCML is likely to be
influenced by hormones, such as oestrogen320. This new finding suggests that the link
between OPCML and ovarian physiology might not only lie in the maintenance of
tissue integrity, the regulation of cell growth, and the inflammatory response, but
also in hormonal regulation, which is an additional facet to ovulation. As stressed
previously, all these roles are likely to have a signalling component. This hypothesis
is supported by a recent report that OPCML methylation and therefore expression
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status is affected by oncogenic RAS in OSE cells . OPCML is a tumour suppressor
gene silenced by methylation early and very frequently in the development of EOC,
which makes it a good candidate marker, either alone or in combination with other
methylated genes. Finally, the possibility of using a small mimetic molecule and thus
replacing the lost functions of OPCML in ovarian cancer patients is very attractive as
therapeutic intervention for the future. It remains to be established whether the loss
of OPCML function occurs at a point of disease development that is reversible.
The observations and findings that this project has yielded pave the way that
will eventually lead to a fuller understanding of OPCML and the IgLON family in
normal physiology and cancer pathology. The work that was described and discussed
in this thesis should be appreciated as a starting-point rather than an end in itself, as it
has raised questions that need to be addressed in the future and has embraced only
certain aspects of IgLON biology. The identified functions of OPCML need to be
investigated further, in particular with respect to its specific involvement in apoptosis
and potential cell signalling pathways. In regard with apoptosis, it would be worth
examining the effect of OPCML using a different experimental approach, not based
on the particular aspect of apoptosis which annexin V assays measure. With respect
to cell signalling, potential pilot experiments could be designed focusing on
pathways that were suggested by OPCML's identified functions, including the RHO
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and PI3K pathways. Another promising approach to signalling studies could exploit
the fact that OPCML is detected in lipid rafts and can therefore be isolated alongside
other signalling molecules found in these domains. Proteomic identification of
binding partners could discover interacting proteins and more importantly receptors
that would be needed to convey signals intracellularly. Furthermore, an issue that has
not been addressed in this work is that of alternative isoforms. Certain IgLON
isoforms have been described in the literature; additionally, there is in silico evidence
for the existence ofmore. What is not known, however, is whether these isoforms are
differentially expressed in development and in adult tissues and more importantly if
they have diverse functions. Hence, a number of the studies described in the previous
chapters could be revisited in an isoform-specific manner. Moreover, a concept that
is likely to contribute signficantly in future studies of IgLON function is that of
interactions within the family. If IgLONs operate by forming heteromeric complexes,
then future studies will have to account for this and be designed accordingly. It will
become increasingly unfavourable to examine one family member in isolation,
assuming it functionally depends on other IgLONs. Experiments could be based on
in vitro models that either represent one particular IgLON only or a specific
combination of IgLONs. Inducible systems are particularly suited for these kinds of
experiments; a particular IgLON could be switched on at will against a defined
complement of other IgLONs. Finally, the role of the IgLON family in ovarian and
other types of human cancer needs to be addressed in a more thorough and
systematic way. Intensification in the pursuit of IgLON function is imperative in
order to assign the family roles in normal physiology and in cancer. More
specifically, in the context of the human ovary, there is a need to understand the roles
of OPCML and the other IgLONs, in adhesion, growth and any other aspect of their
functions, by carefully-designed experiments that address these issues as well as the
mechanisms underpinning them. If OPCML were confirmed to be a gene that is
responsive to inflammatory clues, could the link between this gene and ovarian
physiology lie in ovulation? The answers to this and the previous questions will
hopefully provide suggestions of how loss of OPCML, LSAMP and NEGRI
function and over-expression of HNT contribute to ovarian carcinogenesis.
Addressing all the aforementioned issues, of both expression and function, in
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physiology and pathology, will not be a trivial task, as it will require a combination
of approaches, but most importantly an increased awareness of the potential
significance of the IgLON family outside the brain. Hopefully, this thesis has
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Blocking solution (freshly-made & filter-sterilised)
15% (v/v) sheep serum, heat inactivated
2% (w/v) BSA




3x Denaturing sample buffer (stored at -20°C in aliquots)




1% (w/v) bromophenol blue
in deionised water
lOx Gel loading dye
0.25% (w/v) bromophenol blue
0.25% (w/v) xylene cyanol FF
30% (v/v) glycerol
in deionised water
Gel running buffer (protein)




Maleic acid buffer (autoclaved)
100 mM maleic acid





(100 mM Tris-HCl, pH 9.5)
PBS
Purchased as tablets from Oxoid. Dissolved as per the manufacturer's
instructions. Autoclaved. Optionally, DEPC-treated and re-autoclaved (for
WISH).
PBT (DEPC-treated & autoclaved)
PBS containing 0.1% (v/v) Tween-20
Post-hybridisation solution (filter-sterilised)
50% (v/v) deionised formamide
5x SSC, pH 4.5 (from a DEPC-treated & autoclaved 20x stock solution;
Sigma)
0.1% (v/v) Tween-20
0.5% CHAPS (from a 2% stock solution; Sigma)
Pre-hybridisation solution (filter-sterilised and stored at -20°C in aliquots)
50% (v/v) deionised formamide
5x SSC, pH 4.5 (from a DEPC-treated & autoclaved 20x stock solution;
Sigma)
2% (w/v) Blocking Reagent (Roche; heated to 65°C to dissolve)
0.1% (v/v) Tween-20
0.5% (w/v) CHAPS (from a 2% stock solution; Sigma)
50 pg/ml yeast tRNA (Sigma)
5 mM EDTA
50 pg/ml heparin (Sigma)
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Protein extraction buffer (freshly-made)
50 mM Tris, pH 7.5
5 mM EDTA, pH 8.5
150 mM sodium chloride
1% (v/v) Triton X-100
1 Complete Mini protease inhibitor cocktail tablet (Roche) per 10 ml buffer
in deionised water
Scott's tap water
42 mM sodium bicarbonate




0.5% (w/v) Bacto-yeast extract
0.1 M sodium chloride
2.5 mM potassium chloride
in deionised water
autoc laved
added 0.2 M Mg2+ and 0.2 M glucose prior to use and filter-sterilised
20x TAE
0.8 M trizma base
0.2 M EDTA
5.7% (v/v) glacial acetic acid
in deionised water
TBS
50 mM trizma base
150 mM sodium chloride
in deionised water
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TE buffer (DEPC-treated & autoclaved)
10 mM Tris





50 mM Tris-HCl, pH 7.5
in deionised water
Transfer buffer







PRIMER SEQUENCE (5' TO 3')
Human OPCML F1 TACCATAGATGACCGGGTAA
Human OPCML R CTATTAGGTGAACCCGGGAC
Human OPCML F2 CCACTGGTCTGGATGGAATG
pTRE2hyg R1 CCATTCTAAACAACACCCTG
Human OPCML F3 GCCCACTTCTTCATCAAGTT
pTRE2hyg R2 AAGGGACATCTTTCCCATTCT
pTRE-Tight R GGAGGTGTGGGAGGTTTT
Human HNT F TCTAGGGTCCACCTCATTGT
Human HNT R GGGAGAGATGTGTCTCCAAG
Human LSAMP F CGACAAGCTTCACTCAAATG
Human LSAMP R GTAGTTGCCGTAGTGCTCCT
Human NEGRIF TGTTACCAACGTGACACAGG
Human NEGRI R GCTCCCGGTAATTCCATACT
Human ACTB F CTACGTCGCCCTGGACTTCGAGC
Human ACTB R GATGGAGCCGCCGATCCACACGG
Human ACTG1 F ATGGCATCGTCACCAACTGG
Human ACTG1 R ATGACAATGCCAGTGGTGCG
Mouse Opcml F CCTCGAGTGATGATTTTGGTG
Mouse Opcml R CTGGTCAGTTTGATGTCTGA
Mouse Hnt F TCGTGTGGTCCTCCTGAGT
Mouse Hnt R TCCCGAGTGATGCCCTG
Mouse Lsamp F GACAACATCACCGTGAGACA
Mouse Lsamp R TGCAGACCAGGGTTACATTG
Mouse Negri F GGTGAGGAAAGGTGACACAG
Mouse Negri R CCAGTGGCCAAACAAGTAAG
Mouse Actb F CTATGTTGCCCTGGATTTTG
Mouse Actb R GGGGGAGCAATGATCTTAAT
NB F = forward primer




















































































The IgLON Family in Epithelial Ovarian Cancer: Expression
Profiles and Clinicopathologic Correlates
Evangelos Ntougkos,1 Robert Rush,1 Diane Scott,1 Tobias Frankenberg,1 Hani Gabra,2
John F. Smyth,1 and Grant C. Sellar1
Abstract Purpose: The IgLON family of cell adhesion molecules, comprising OPCML, HNT, LSAMP, and
NEGRI, has recently been linked to cancer, through two of its members being proposed as tumor
suppressors. We examined the expression profile of the family in human sporadic epithelial ovarian
cancer and the normal ovary.
Experimental Design: We determined the expression level of each Ig LON in a panel comprising
57 tumor and 11 normal ovarian samples by quantitative real-time reverse transcription-PCR.The
results were statistically tested for associations with clinicopathologic variables.
Results: OPCML, LSAMP and NEGRI exhibited reduced expression in the tumor samples rela¬
tive to the normal samples, whereas HNT expression was elevated. Statistically significant
changes were specific to histologic type. The expression levels of individual IgLONs were corre¬
lated, the most significant finding being a positive correlation between LSAMP and NEGRI.
LSAMP expression was also negatively correlated with overall survival and was found to be a
negative predictor of outcome.
Conclusions: The expression of the IgLON family is altered in sporadic epithelial ovarian tumors
in comparison to the normal ovary. In our small but representative cohort of patients, we have
found significant correlations and associations in expression and clinicopathology that suggest a
wider role of the family in ovarian cancer.
Ovarian cancer is the leading cause of gynecologic death in
both the U.S. and the U.K., in fact, it ranks fourth as a cause of
death from any cancer in women (Cancer Research UK statistics;
ref. I).3 The incidence of the disease increases with age, peaking
in around the seventh to eighth decade (2). Approximately 90%
of ovarian cancers are epithelial ovarian cancers (EOC), with 5%
to 10% being familial in origin (3, 4). Although, if diagnosed
early, it has a very good prognosis, with a 92% 5-year survival
rate, most cases (75%) are diagnosed at a late stage of
disseminated disease when the prognosis is much less favorable,
with only a 25% 5-year survival rate (5). Treatment of ovarian
cancer is usually based on surgical cytoreduction and platinum-
based chemotherapy (6). Although primarily a chemorespon-
sive disease, chemoresistance develops in most cases, resulting
in the high aforementioned mortality rate.
The IgLONs are an immunoglobulin subfamily of glyco-
sylphosphatidylinositol-anchored cell adhesion molecules
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comprising opioid binding protein/cell adhesion molecule -
like (OPCML/OBCAM; ref. 7), limbic system - associated
membrane prolein (LSAMP/LAMP, ref. 8), neurotrimin
(HNT; ref. 9), and neuronal growth regulator 1 (NEGRI/
Kilon; ref. 10). Our knowledge of the functions of these
proteins is limited and mainly derives from studies of chick
and rat brain, the tissue where they are primarily expressed.
Their patterns of expression in the brain are overlapping but
also distinct, with OPCML being mainly expressed in the gray
matter (11), HNT in the sensorimotor cortex and the
cerebellum (9), LSAMP in cortical and subcortical neurons
of the limbic system (8), and NEGRI in the cerebrum and
brain stem (10). In these studies, it is suggested that the
IgLONs could have an important role in cell adhesion and
cell-cell recognition, mediated by both homo- and hetero¬
phils interactions in cis and trans that are likely to be
stabilized by clustering of the proteins on the cell surface (12).
It has been recently suggested that IgLONs function mainly as
heterodimers termed Diglons (13).
OPCML has been shown to exhibit functional characteristics
of a tumor suppressor gene in an ovarian cancer cell line in vitro
and also in vivo when xenografted into nude mice (14).
Abrogated expression was found in 83% of sporadic EOC
samples examined. The mechanism underlying OPCML silenc¬
ing was shown to be CpG island hypermethylation. This first
report of an IgLON involvement in cancer was followed by a
further one, where the LSAMP promoter was shown to be
3 http://cancerresearchuk.org/aboutcancer/statistics/mortality.
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methylated in 26% of a panel of sporadic clear cell renal cell
carcinomas (15). Moreover, expression of LSAMP in clear cell
renal cell carcinoma lines inhibited cell proliferation.
We have investigated the expression of the four members of
the IgLON family in a panel of 11 normal human ovaries and 57
tumor samples from patients with EOC. Our primary objective
has been to observe each gene separately, as well as to attempt to
draw conclusions from the interrelationships of data that
emerge. In this extensive study, we report significant associa¬
tions between the expression levels of the IgLONs and various
clinicopathologic variables.
Materials and Methods
Patient samples. Primary human ovarian tumor material and
nonmalignant tissues were obtained from patients having undergone
gynecologic surgery in the Lothian University Hospitals National
Health Service Trust. Institutional ethical approval was granted for this
work by the Lothian University National Health Service Trust,
Medicine/Clinical Oncology Research Ethics Subcommittee. Tissue
samples were excised and stored in liquid nitrogen. Nonmalignant
tissue samples were derived from patients that underwent bilateral
oophorectomies for suspected malignancy, but were found to have
benign histologies; samples were collected from apparently normal
contralateral ovaries.
In this study, a panel comprising 57 sporadic ovarian tumors and 11
normal ovaries was used. The features of the panel are shown in Table 1.
Overall, our unselected cohort is very representative of the presentation
of 1,400 women from the Scottish community over 20 years to a single
center in a completely unselected fashion from primary care (16). Our
present cohort is exactly as expected for stage distribution in a Scottish
population; although it is skewed slightly towards a more adverse grade
distribution. The overrepresentation ofgrade 3 tumors may account for a
slightly shorter median survival of 2.25 years compared with 2.50 years.
























Median survival (y) 2.25
Abbreviation: FIGO, Federation Internationale des Gynaecologistes et Obstetristes.
RNA preparation. Total RNA was prepared from the ovarian tissues
and DNase I-treated using the Absolutely RNA reverse transcription-
PCR Miniprep Kit (Stratagene, La Jolla, CA), as per the manufacturer's
instructions.
Quantitative real-time reverse transcription-PCR. Quantitative
reverse transcription-PCR was done using Rotorgene 2000 and 3000
real-time thermal cyclers (Corbett Research, Australia). Fifteen-micro-
liter reactions were set up using 40 ng of DNase I-treated total RNA, 0.3
pmol/L each of forward and reverse primer and the Quantitect SYBR
Green one-step reverse transcription-PCR kit (Qiagen, Crawley, United
Kingdom), according to the manufacturer's guidelines. Primers were
designed using Primer 3 v0.2. Primer sequences are available upon
request. All reactions were carried out in triplicate for the standard curve
samples and in quadruplicate for the experimental samples and the
negative control (no template). Fluorescence was detected using the
FAM channel (source 470 mm, detector 510 nm). Analysis and
quantification was done using Rotorgene v4.6 and v5 software. The
relative quantification method was employed by extrapolation from a
standard curve and calculation of expression levels as ratios to (3-actin.
Cycling conditions were set as follows: reverse transcription at 50 °C
for 30 minutes, followed by a 15-minute polymerase activation at
95°C, and 40 cycles of denaturation at 94°C for 15 seconds, annealing
at 57°C for 30 seconds and extension at 72°C for 30 seconds; after a
final extension at 72°C for 1 minute, product melting was set across a
72°C to 99 °C temperature ramp, with 5-second steps of 1°C. Data were
corrected for inter-run variation using a "normalizer" sample that was
included in all runs.
Statistical analysis. All statistical analyses were conducted in SPSS
vl2 (SPSS Inc., Chicago, IL). Nonparametric comparisons between
unmatched samples were made using the Mann-Whitney (U) test for
two samples or the Kruskal-Wallis (x2) test for more than two samples.
Nonparametric correlations were tested using the Spearman rank (rs)
test. Regression models were made using linear regression analysis.
Survival curves were produced using the Kaplan-Meier method and
tested with the log-rank test. Survival models were estimated using Cox
proportional hazards regression analysis.
Results
IgLON expression levels differ between normal ovaries and
EOC. In order to evaluate the RNA expression levels of the four
IgLON family members in the panel that comprised 11 normal
human ovaries and 57 ovarian tumor samples, a real-time
quantitative reverse transcription-PCR approach was followed.
The results are shown in Fig. 1. For OPCML, LSAMP, and
NEGRI, the majority of tumors exhibit reduced expression as
compared with the normal ovary samples. In contrast, tumor
samples have increased HNT expression in relation to nonma¬
lignant ones. The distribution of values in all four genes is not
normal, hence, nonparametric approaches were chosen for
statistical analysis.
Associations of IgLON expression with EOC histologic types.
The expression data prompted us to take a closer look at each
gene separately in the different histologic types and make
comparisons to expression in the normal ovaries. In all four
IgLONs, there are statistically significant differences between
normal ovaries and tumor subgroups (Fig. 2). More specifically,
OPCML expression is reduced in clear cell carcinomas (LI = 19,
P = 0.039); LSAMP expression is reduced in endometrioid
tumors (U = 28, P = 0.012); and NEGRI expression is reduced
in serous (If = 59, P = 0.014), clear cell (If = 9, P = 0.009), and
endometrioid (If = 7, P = 0.001) tumors. In contrast, HNT
expression is elevated in serous carcinomas as compared with
normal ovaries (If = 113, P = 0.008).
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Correlations in expression between IgLONs. As all the four
genes that constitute the focus of this study are structurally and
functionally related, a question that arises is whether their
individual expression levels are interlinked. The following
statistically significant correlations of expression between
IgLONs were found: LSAMP and NEGRI (rs = 0.553, P <
0.001); OPCML and NEGRI (rs = 0.389, P = 0.001); OPCML
and LSAMP (rs = 0.356, P = 0.003). In all these cases, the
correlations are positive.
Associations between IgLON expression and clinicopathologic
variables. In an attempt to establish whether expression of
IgLON family members could be a function of age as a
continuous variable, the expression of each gene was tested
against age. However, evidence to support associations was not
found, either by correlation testing or by regression analysis.
Neither was stage found to differentiate IgLON expression;
nonetheless, there is a statistically significant difference in
LSAMP expression among tumors of different grades (x2 =
6.73, P = 0.035). In fact, as can be seen in Fig. 3, this difference is
even more significant when comparing grade 3 tumors with
grades 1 and 2 tumors: undifferentiated carcinomas have lower
levels of LSAMP than moderately or well-differentiated ones
(U = 148, P = 0.017). In comparison to the large study of Clark
et al. (16), grade 1 tumors are underrepresented in our relatively
small sample cohort. The low number of grade 1 cases in our
cohort has prevented us from comparing expression in these
samples against grades 2 or 3, which is a more customary
comparison.
IgLON expression and survival. The impact of IgLON
expression levels on the survival of the patients was tested at
two levels. Firstly, correlation between expression of each gene
and overall survival was investigated. This highlighted LSAMP
as having a negative correlation (rs = -0.296, P = 0.025).
Patients were then divided into high and low expressers for
each gene, using the median values of the normal samples as
cutoff points. Survival curves were plotted and high expressers
were compared with low expressers (data not shown).
However, we were not able to show statistical significance for
any of the four genes on this division.
To address whether the expression level of an IgLON gene
can predict clinical outcome, we tested the expression variables,
as well as the clinicopathologic ones, for prognostic value by
Cox regression analysis. As can be seen in Table 2, in univariate
analyses, log-transformed LSAMP expression, as well as stage,
were found to be negative predictors of overall survival. Both
variables were still found to be significant predictors of overall
survival when tested together by multivariate analysis.
Discussion
When the link between a member of the IgLON family,
OPCML, and EOC was put forward (14), questions were raised
regarding the role of this gene in ovarian physiology and ovarian
cancer pathology. The realization that the family as a whole
might be associated with ovarian or other types of cancer also
Fig. 1. IgLON expression in EOC and normal ovaries.The relative expression levels
of the four IgLON genes. OPCML (A), HNT (B), LSAMP (C). and NEGRI (D)
were investigated in a panel of EOC samples and normal human ovaries using a
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Serous Clear cell Mucinous Endometrioid Normal
Clear cell Mucinous Endometrioid Normal
Mucinous Endometrioid Normal
Fig. 2. IgLON expression according to histologic type.The EOC sample panel was
categorized by histologic type, i.e., into serous, clear cell, mucinous, and
endometrioid tumors.The median relative expression levels of OPCML (A), HNT
(,B), LSAMP (C), and NEGRI (D) are shown for these subgroups as compared with
normal ovary samples. *, P < 0.05; *\ P < 0.01.
emerged. This probability was subsequently strengthened by the
finding of another IgLON, LSAMP, being associated with clear
cell renal cell carcinomas as a putative tumor-suppressor gene
(15). Could there be a case for the IgLON family being of
importance in cancer?
To answer this question, one needs a powerful global
approach that examines the family as a whole. This study has
been based on a well-characterized panel of ovarian tumors and
normal ovaries, which has come under scrutiny for the
expression of each IgLON separately, but also for expression
patterns and associations deduced in a statistically sound
manner.
Here we present evidence that, at least with respect to EOC, it
is not just OPCML, but the other members as well, which may
be of relevance. We have shown that the expression of all the
IgLONs differs significantly between normal ovaries and EOC
at the RNA level. The expression levels of OPCML, LSAMP, and
NEGRI are all reduced in EOC, whereas that of HNT is
increased. Confirmation of these trends at the protein level will
merit investigating whether, apart from OPCML, there could be
a case for LSAMP and NEGRI acting as tumor suppressors in
sporadic EOC. It has been shown that the cause of the
reduction in expression in the case ofOPCML in EOC is mainly
epigenetic (14), and there is evidence that the same applies for
LSAMP in clear cell renal cell carcinomas (15). Thus, it seems
likely that the reduction in LSAMP and NEGRI expression in
EOC may be attributed to epigenetic mechanisms. In addition,
we have found a significant positive correlation, the strongest in
this study, between the expression of LSAMP and that of
NEGRI. Consequently, it could be hypothesized that both
genes need not be genetically or epigenetically silenced in EOC;
the reduction in expression of the one could result in a
reduction in expression of the other, potentially through a
mechanism of coordinated transcriptional regulation. Although
epigenetic modification is an age-related variable which affects
gene expression, we have not found an association between
altered IgLON expression and age in this study.
We have shown that in EOC, the importance of each IgLON
might be specific to histologic type. OPCML expression is
significantly reduced in clear cell carcinomas, LSAMP in
endometrioid, and NEGRI, exhibiting the most striking reduc¬
tion in expression, in serous, clear cell, and endometrioid
tumors. In contrast, HNT is significantly elevated in serous
carcinomas. With regard to mucinous carcinomas, it should be
noted that the lack of statistical significance could be accounted
for by the under-representation of this type of tumor in the panel.
Malignant transformation in ovarian cancer is characterized












Fig. 3. LSAMP expression according to differentiation status. The EOC sample
panel was divided into tumors of poor differentiation, i.e., of grade 3 histology, and
tumors that are moderately or well-differentiated, i.e., of grades 1 or 2 histology.
Columns, median relative expression of LSAMP in each of these tumor subgroups.
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Table 2. Survival models
Variable Odds ratio 95% Confidence interval Significance
Lower Upper
OPCML * 0.84 0.50 1.41 0.506
HNT" 1.15 0.84 1.57 0.376
LSAMP• 1.63 1.10 2.41 0.015
NEGRI * 1.30 0.86 1.96 0.221
stage' 8.86 2.10 37.32 0.003
grade* 22.06 0.0 4 13126 0.343
age at diagnosis 1.03 1.00 1.06 0.020
age last recorded 1.01 0.98 1.04 0.400
LSAMP' 1.85 1.14 3.02 0.013
stage* 10.21 2.40 43.77 0.002
Univariate
Multivariate
NOTE: The expression and clinical variables were tested by univariate regression analysis. The two variables that were found to be statistically significant were further tested
by multivariate analysis.
'Log-transformed.
TEarly (i.e., stages I and II) versus late (i.e., stages III and IV).
•High (i.e., grade 3) versus rest (i.e., grades 1 and 2).
types, where the converse occurs (17). Normal ovarian
epithelium is not fully differentiated, retaining certain mesen¬
chymal characteristics; upon transformation, differentiation
drives the epithelium toward certain histologic morphologies,
depending on the type of the tumor. Because IgLONs have
partially distinct patterns of histologic subtype expression, they
could be part of a different pathway that guides this
differentiation process.
Interestingly, LSAMP expression is significantly higher in
moderately and well-differentiated tumors. This indicates that
the level of LSAMP expression is likely to be a biological
function of differentiation. It could be speculated that the
significance of reduction of LSAMP expression in the process
of malignant transformation of the ovarian surface epithelium
could lie in the cells acquiring a less differentiated phenotype,
which is considered to be of higher malignant potential.
Furthermore, LSAMP was found to be a negative prognostic
factor in both univariate and multivariate models of EOC in
addition to being negatively correlated with overall survival. In
both cases, the impact ofLSAMP on survival is not high. This link
may seem paradoxical, given that its overall tumor levels are
significantly lower than in normal ovaries. However, the role of
residual LSAMP in the tumors might be antithetical to its original
functions in the normal ovary. In terms of the multifactorial
output described as survival, ovarian tumors could be disadvan¬
taged by not expressing LSAMP and losing its novel functions.
The true reason behind this paradoxical finding remains as yet
undetermined.
The analysis of the present study, albeit deriving from a
relatively small cohort and requiring confirmation in a larger
study, has pointed to a very interesting and novel association of
the IgLON family with ovarian cancer. In order to integrate
OPCML and its relatives into models of ovarian carcinogenesis,
we need to establish their functions in the normal ovary, their
localization within the ovarian environment and the pathway
that links them to ovarian cancer. In addition, the functional
importance of homo- and heterodimers needs to be addressed.
Finally, profiling the expression of the IgLONs in other types of
neoplasia might reveal that this hitherto mysterious family has
a wider importance in cancer.
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